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Abstract 
 Phenylalanine Hydroxylase (PheH, EC: 1.14.16.1) is a non-heme iron 
monooxygenase that converts L-Phe to L-Tyr using a tetrahydrobiopterin 
coenzyme and dioxygen. PheH is allosterically regulated by its substrate L-Phe. 
Binding of L-Phe to the allosteric site causes PheH to convert from a low-activity 
T-state to a high-activity R-state. Upon the T to R conversion, PheH experiences 
an increase in hydrophobicity, a shift in fluorescence emission peak maximum, 
increased hydrodynamic radius, and elongation of its quaternary structure. 
While PheH has been well characterized in terms of these global changes that 
occur upon allosteric activation, less is known about how the active site 
properties change upon this process. Herein, we report the use of cw-EPR and 
pulsed-EPR techniques (electron spin echo envelope modulation (ESEEM) and 
v 
 
hyperfine sublevel correlation (HYSCORE) methods) to probe the properties of 
the active site of PheH with respect to the primary coordination sphere of the 
non-heme iron center and the orientation of pterin coenzyme and substrate L-
Phe.  
 A suit of cw-EPR experiments using 17O enriched water and 1H-HYSCORE 
approaches were used to probe the water coordination of the iron center across 
mechanistic states of PheH and select mutants. The ESEEM technique was 
combined with 2H labelled L-Phe and H4pterin coenzyme to examine how the 
binding orientation of both L-Phe and H4pterin change upon allosteric activation. 
These results demonstrate that L-Phe allosteric activation causes the pterin 
coenzyme to move ~1.8 Å closer to the iron center. Furthermore, 2H-ESEEM 
samples prepared at non-activating concentrations of L-Phe suggest that its 
binding in the active site alone is not sufficient to induce the movement of the 
pterin coenzyme. 2H-ESEEM studies using site specifically deuterated L-Phe 
demonstrate that allosteric activation and binding of pterin cause the 
reorientation of L-Phe such that both the meta and ortho positions are similarly 
close to the iron center. Lastly, steady state kinetic measurements of pterin 
oxidation within the active site of apo-wtPheH and apo-PheH118-452 were 
vi 
measured to understand how the active site influences the reactivity of pterin 
with O2. These results will be explained in the context of the regulatory 
properties of PheH as well as the catalytic mechanism. 
vii 
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Chapter 1 Regulation of the Aromatic Amino Acid Hydroxylases 
 
Introduction 
The proper regulation of enzymatic activity is essential for maintaining 
homeostasis for living organisms. Consequently, Nature has found many ways 
to regulate the activity of enzymes. These mechanisms include production of 
isoenzymes, reversible covalent modification (e.g. phosphorylation, 
ubiquitination, and acetylation), proteolytic activation, and allosteric regulation 
(both positive and negative). Of these, allosteric regulation provides one of the 
more acute methods to provide instantaneous regulation of the enzymatic 
activity. Many of these methods are used in concert with each other to allow an 
organism to respond to many of the environmental changes it might experience. 
Therefore, the understanding of these regulatory mechanisms is important for 
understanding the physiological roles of enzymes. 
The aromatic amino acid hydroxylases (AAAHs) are a group of 
enzymes that have complex regulatory mechanisms. This group of enzymes 
includes Phenylalanine Hydroxylase (PheH, E.C. 1.14.16.1), Tyrosine 
Hydroxylase (TyrH, E.C. 1.14.16.2), and Tryptophan Hydroxylase (TrpH, E.C. 
1.14.16.4). The AAAHs all have a non-heme iron center and use 
2 
tetrahydrobiopterin (BH4) and dioxygen to hydroxylate their respective amino 
acid substrate (Figure 1.1). These enzymes are involved in the biosynthesis of the 
neurotransmitters dopamine, adrenaline, norepinephrine, and serotonin. Both 
TyrH and TrpH are localized in neuronal tissues.  In contrast, PheH is localized 
in the liver where it comprises 0.1% of soluble protein.1 The high abundance of 
PheH in the liver and the relative ease of purification2 has historically allowed for 
the early progression of the study into this enzyme relative to TyrH and TrpH. 
The study into PheH has also been incentivized by its link to the disease 
Phenylketonuria (PKU). Inability to clear L-Phe from the bloodstream causes 
hyperphenylalaninemia (HPA) and in more severe cases PKU. These diseases are 
associated with abnormal brain development leading to severe mental 
retardation and other cognitive deficiencies. For these reasons, understanding 
how these enzymes are able regulate the physiological concentrations of their 
respective amino acids have become important in understanding these diseases.  
PheH is the central enzyme involved in controlling both physiological L-
Phe concentrations and L-Tyr biosynthesis. The activity of PheH must be tightly 
controlled as both high and low levels of L-Phe can impair human development. 
At high concentrations of L-Phe, Tyrosine amino transferase (TAT) can convert 
L-Phe to the neurotoxic phenylpyruvate. Additionally, high concentrations of L-
 




Phe also prevent the transport of L-Tyr and L-Trp into the brain resulting in a 
decrease in cerebral concentration of dopamine and serotonin.3 Thus, L-Phe must 
be readily cleared from the bloodstream. However, if all the PheH in the liver 
were fully active, all the L-Phe would be converted to L-Tyr in a matter of 
minutes.4 In contrast, low levels of L-Phe impair proper growth and 
development. Therefore, PheH must be regulated to prevent the accumulation of 
toxic levels of L-Phe, yet not completely depleting the body’s supply of L-Phe.  
 




 Allosteric activation is the main regulatory mechanism that controls the 
activity of PheH. In addition to its role as a substrate, L-Phe acts as an allosteric 
effector to convert PheH from a low activity T-state to a high-activity R-state 
(using Monod-Wyman-Changeux nomenclature5). The T→R transition can be 
modulated by presence of L-Phe, BH4, and phosphorylation. This chapter will 
 
 












cover the known regulatory properties of liver PheH with emphasis on 
development of a structure-function relationship for its regulatory behaviors and 
its relationship to both TyrH and TrpH.        
   Structural Characterization 
Each monomer of PheH consists of three domains—an N-terminal 
regulatory domain (residues 1-117), a catalytic domain (residues 118-410) 
containing the iron site, and a C-terminal tetramerization domain (residues 411-
452) (Figure 1.2, Figure 1.3). Biophysical and mechanistic data show that PheH 
constructs lacking the regulatory domain behave as though they are kinetically 
competent, i.e. these constructs do not require preincubation with L-Phe for full 
activity. This observation has led to the conclusion that the regulatory domain 
plays a fundamental role in the allosteric activation process. When the N-
terminus of PheH is cleaved by chymotrypsin, PheH has an increase in reactivity 
towards both DL-methionine, norleucine, and tryptophan,6 leading to the 
conclusion that the regulatory domain is also involved in substrate specificity. 
Additionally, the regulatory domain has been proposed to be involved in gating 
access to the active site7 (vide infra). The catalytic domain consists of an α helical 
basket that binds both the substrate and coenzyme as well as the non-heme iron 
center responsible for catalysis. The iron center is in the hydrophobic active site ~ 
 




10 Å from the surface of the protein. Lastly, the tetramerization domain of all the 
AAAHs consist of a leucine zipper or coil-coil motif.8 This motif allows for the 
oligomerization of individual subunits into different dimers and tetramers. PheH 
has high sequence homology with the other AAAHs with respect to the catalytic 
and tetramerization domain but diverge most with regards to its regulatory 
domain (Figure 1.2)  Consequently, there is a high structural homology for 
AAAHs constructs lacking the regulatory domain.  
  
 








TyrH        MPTPDATTPQAKGFRRAVSELDAKQAEAIMVRGQGAPGPSLTGSPWPGTAAPAASYTPTP 60 
PheH        ------------------------------------------------------------ 0 
TrpH-2      -----------------------MQPAMM----------MFSSKYWARRGF--------- 18 
                                                                         
 
TyrH        RSPRFIGRRQSLIEDARKEREAAVAAAAAAVPSEPGDPLEAVAF--------EEKEGKAV 112 
PheH        -----------------------MST---AVLENPGLGRKLSDFGQETSYIEDNCNQNGA 34 
TrpH-2      -----------SLDSAVPEEHQLLGS---STLNKPNSGK-NDDKGNKGSSKREAATESGK 63 
                                   :.:   :. .:*.                :    ..  
 
TyrH        LNLLFSPRATKPSALSRAVKVFETFEAKIHHLETRPAQRPRAGGPHLEYFVRLEVRRGD- 171 
PheH        ISLIFSLK-EEVGALAKVLRLFEENDVNLTHIESRPSRLK---KDEYEFFTHLDKRSLPA 90 
TrpH-2      TAVVFSLK-NEVGGLVKALRLFQEKRVNMVHIESRKSRRR---SSEVEIFVDCECGKT-E 118 
              ::** :  : ..* :.:::*:   .:: *:*:* ::       . * *.  :       
 
TyrH        LAALLSGVR----------QVSEDVRSPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDLD 221 
PheH        LTNIIKILRHD-----IGATVHELSRDKKKDTVPWFPRTIQELDRFANQILSYGAELDAD 145 
TrpH-2      FNELIQLLKFQTTIVTLNPPENIWTEEEELEDVPWFPRKISELDKCSHRVLMYGSELDAD 178 
            :  ::. ::                ..     ******.:.***:  : :  :. :** * 
 
TyrH        HPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLKGLYATHACGE 281 
PheH        HPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYMEEEKKTWGTVFKTLKSLYKTHACYE 205 
TrpH-2      HPGFKDNVYRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACRE 238 
            ****.* *** *** :.::*  *::*:*******  **  **  *:  *. ** **** * 
 
TyrH        HLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQC 341 
PheH        YNHIFPLLEKYCGFHEDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSRDFLGGLAFRVFHC 265 
TrpH-2      YLKNFPLLTKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHC 298 
            : . * ** ::.*::***:******* **:  :** :***** ** ****..**:***:* 
 
TyrH        TQYIRHASSPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASDEEIEKLSTLY 401 
PheH        TQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQEIGLASLGAPDEYIEKLATIY 325 
TrpH-2      TQYIRHGSDPLYTPEPDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCY 358 
            ******.*.*:::**** *********:::* .******:******** ** ::**:* * 
 
TyrH        WFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQPYQDQTYQSV 461 
PheH        WFTVEFGLCKQGDSIKAYGAGLLSSFGELQYCLSEKPKLLPLELEKTAIQNYTVTEFQPL 385 
TrpH-2      FFTIEFGLCKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQECLITTFQEA 418 
            :**:******* ..::********* *** :.**::  :  :: : :.:*      :*   
 
TyrH        YFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLEGVQDELDTLA 521 
PheH        YYVAESFNDAKEKVRNFAATIPRPFSVRYDPYTQRIEVLDNTQQLKILADSINSEIGILC 445 
TrpH-2      YFVSESFEEAKEKMRDFAKSITRPFSVYFNPYTQSIEILKDTRSIENVVQDLRSDLNTVC 478 
            *:*:***.:**:*:*.:*  * ***** ::***  *::*.. : :.   :.:..::. :. 
 
TyrH        HALSAIG----- 528 
PheH        SALQKIK----- 452 
TrpH-2      DALNKMNQYLGI 490 
             **. :       
 
Figure 1.2: Sequence alignment for the AAAHs with the regulatory domain (green), 
catalytic domain (blue), and tetramerization domain (red) highlighted. A “*” 
represents a singly conserved residue, “:” represents conserved residues with strongly 
similar properties, “.” Represents conserved residues with weakly similar properties 
 





While PheH is the most characterized of the AAAH enzymes, a detailed 
structure-function understanding of its allosteric activation process is still 
challenged by the absence of relevant crystal structures. There are currently only 
three full-length crystal structures of PheH,9,10 two of  the ligand-free wtPheHT[ ]a 
9,10 state and one of the iron free wtPheHT[BH4].11 Truncated constructs lacking 
both the regulatory and tetramerization domain have been used to facilitate 
 
a Empty brackets indicate lack of substrate and coenzyme  
Figure 1.3: Full-length crystal structure of PheH using 5DEN.pdb. The regulatory 
domain (residues 1-117) is shown in green, the catalytic domain(residues 118-410) is 
shown in blue, and the tetramerization (residues 411-452) domain is shown in red. 
Residues with no electron density is shown by dashed line 
 




crystallization of binary (BH4 and BH2) and ternary (with both substrate analogs 
and BH4 states). These crystal structures report a variety of protein domain 
conformations and primary coordination spheres of the iron center including 
variations in the iron geometry, the number of water molecules coordinated to 
the iron center, and the denticity of the primary sphere ligand E330 (vide infra). 
However, it is not clear whether these variations are a result of 
substrate/coenzyme binding, represent structural plasticity that arises from 
truncation of the enzyme, or a consequence of challenging refinement issues. 
Furthermore, the absence of crystal structures with the natural substrate (L-Phe) 
bound preclude a detailed characterization of any structural changes induced by 
L-Phe binding and global allosteric activation. In place of L-Phe, studies have 
used analogs such as L-thienylalanine (L-THA) and L-norleucine (L-NLE). These 
compounds are not reported to induce allosteric activation under the reported 
crystal growing conditions. Therefore, it remains unclear if the active site 
structural changes induced by L-Phe also occur using these substrates. Finally, it 
is important that the reported iron geometry from crystallographic studies agree 
with both spectroscopic (i.e. XAS12, VTVH MCD13,14, Mössbauer15, EPR 
spectroscopy16) and biochemical studies. The crystallographic characterization of 
PheH with regards to the variations in the protein fold and primary iron 
 




coordination observed across the mechanistic states of PheH and the degree to 
which these data support or differ from spectroscopic and biochemical studies 
will be discussed below.     
PheHT[ ] 
 PheHT[ ] is the only mechanistic state for which full-length crystal 
structures exist.9,10 Prior to the full-length crystal structure, a chimeric model17 
(based on previous truncated crystal structures 1PHZ.pdb (PheH1-429[ ])bc and 
2PAH.pdb (PheH118-452[ ])) was used to develop a structure-function relationship 
for the interpretation of PKU mutants. The full-length crystal structure allowed 
for verification of predicted effects of various PKU mutants.17 Later, Meisburger 
et al. reported an attempt to crystalize full-length PheH[L-Phe] (PheH with L-Phe 
bound in the active and allosteric site).10 However, despite the presence of 1 mM 
L-Phe in the crystallization buffer, no electron density was reported for L-Phe in 
either the active or any potential allosteric site,10 suggesting this structure is 
reflective of the PheHT[ ] state. The lack of identifiable electron density for bound 
L-Phe led the authors to suggest that a currently undefined conformational 
change in the active site must occur before L-Phe can bind. In contrast, both EPR 
 
b The T and R designation are not use for the truncated constructs as these do not undergo the same 
allosteric activation mechanism as full-length PheH 
c The number in superscript represents the residues comprising the PheH construct 
 




(Chapter 3) and MCD/XAS14 studies suggest that substrate can bind in the 
absence of allosteric activation. However, given the resolution of the crystal 
structure (3.6 Å), this discussion will focus on the earlier full-length structure of 
PheHT[ ] and the higher resolution truncated PheH variants.  
 The full-length PheHT[ ] crystal structure contains a homo-tetramer 
consisting of a dimer of homo-dimers (Figure 1.4). While all the subunits interact 
with one another through a leucine zipper motif in the tetramerization domain, 
there are several salt bridge interactions between the tetramerization domain of 
the subunits of a single dimer that contribute to the dimerization of individual 
monomers (Figure 1.4). These salt-bridge interactions are not present between 
adjacent subunits that do not form a dimer.  Additionally, the interface surface 
area between the subunits of one dimer (~2800 Å2) is approximately four times 
larger than adjacent subunits in a tetramer that do not form a dimer (~ 700 Å) 
(Figure 1.4).d The N-terminal regulatory domain has a βαββαβ structural fold 
characteristic of an ACT domain (see ACT domain section). The ACT domain is 
structural motif found in many allosteric enzymes involved in amino acid and 
purine biosynthesis.18 Interestingly, the ACT domain on each subunit is pointed 
 
d Values calculated using PISA (Protein, Interfaces, Structures, and Assemblies) 
(https://www.ebi.ac.uk/pdbe/pisa/) 
 




away from each ACT domain on an adjacent subunit (see Figure 1.5). In contrast, 
the ACT domain in other enzymes (e.g. aspartate kinase19, prephenate 
dehydratase20 ) dimerize in the absence of allosteric effector to form the effector 
binding site. However, the ACT domains in Thermotoga maritima 3-Deoxy-D-
arabino-heptulosonate-7-phosphate Synthase (DAH7PS), which is involved in 
the biosynthesis of the aromatic amino acids in the shikimate pathway, do not 
interact in the absence of the effectors L-Phe and L-Tyr.21 While the ACT domain 
has been implicated in the allosteric activation mechanism of PheH, its relevancy 

















Figure 1.4: Full-length crystal structure (5DEN.pdb) showing A) The full 
tetrameric crystal structure. The dimer that the tetramer dissociates into is shown 
in the box. B) The intra-dimer domain interactions between subunits(left) and 
inter-dimer domain interactions(right) C) Surface model of the interactions 
between subunits that form a dimer (left) and subunits that are adjacent to each 
other in the tetramer but do not form a dimer (right). The interface between the 
subunits is shown in red. The interface was found using the Clash/Contact 
















Figure 1.5: ACT domain shown in A) PheHT[ ] where the ACT domain on each subunit 
is separated from each other ACT domain(5DEN.pdb) B) DAH7PS open conformation 
(1RZM.pdb) (Left) and the closed conformation with bound L-Tyr(3PG9.pdb) (Right)  
C) 3-PGD in the open conformation (1YBA.pdb)(left) and closed conformation 
(1PSD.pdb)(right) D) Prephenate Dehydrogenase in the L-Phe unbound 
(2QMW.pdb)(left) and L-Phe bound conformation (2QMX.pdb)(right)   
 




N-terminal “autoregulatory” region 
   Both PheHT[ ] structures that include the regulatory domain (full-length-
wtPheH (5DEN.pdb)9 and PheH1-429[ ] (1PHZ.pdb)7) have an N-terminal 
“autoregulatory” region. This autoregulatory region comprises the first ~ 33 N-
terminal residues and extends over the active site where it has been proposed to 
regulate PheH activity by gating access to the active site7 similar to other ACT 
domain containing enzymes.22 However, no crystal structure containing the 
regulatory domain had electron density for the first ~20 residues in the 
autoregulatory region suggesting this sequence is highly flexibly and/or 
disordered.7,10,11  The flexible nature of the autoregulatory region was further 
supported by an NMR study on phosphorylated PheH1-428.23 The 1H-1H TOCSY 
spectrum for phosphorylated PheH contained cross-peaks corresponding to 
approximately 25 spin systems in the NH to aliphatic region. The authors were 
able to assign about half (residues 2-7,9-10, and 16) of the 25 spin systems. In 
contrast, the 1H-1H TOCSY spectrum PheH30-428 lacking autoinhibitory region 
contained no cross-peaks in the NH to aliphatic region.23 Therefore, the sharp 
resonances observed in the 1H-1H TOCSY were attributed to this N-terminal 
autoinhibitory region. Addition of L-Phe decreased the intensity of these 
resonances suggesting a decrease in mobility for this region upon binding of L-
 




Phe23 (assuming the level of aggregation remained unchanged).  The authors 
proposed that the decrease of mobility could be associated with folding of the 
autoinhibitory region with the folded core of the PheH upon allosteric activation. 
However, other explanations such as decrease in dynamics or oligomerization of 
this region are also possible. Additionally, it should be noted that the authors 
reported that L-Phe was added to 200 mM—a concentration the exceeds the 
solubility of L-Phe in water. Therefore, it is difficult to define a definitive role of 
the effect of L-Phe binding on the auto-inhibitory region.   
Active site lid 
  In addition to the autoinhibitory region, a partially disordered active site 
lid/loop (residues 130-150) has been hypothesized to govern access to the active 
site.9 All crystal structures have an “open” active site lid except for those 
containing both L-Phe analog and BH4 (Figure 1.6). However, since there are no 
crystal structures containing just L-Phe (or L-Phe analog) it not clear whether 
binding of L-Phe (or L-Phe analog) alone can induce the “closed” confirmation.  
The conformation of the active site lid is proposed to be dependent on the 
positioning of F131 where F131 acts as a hinge for the active site lid allowing for 
the “open” and “closed” conformation. In the full-length crystal structure, F131 
makes cation-π interactions with R111 to stabilize the open conformation (Figure 
 




1.7).9 None, of the current ternary structures of PheH contain electron density for 
R111. Presumably, a closed confirmation of the active site lid would prevent an 
unwanted molecule (e.g. water) from entering the active during the catalytic 
reaction that might intercept a reactive intermediate. However, how the “closed” 
conformation directly relates to an increase in activity is not yet understood. 
Having an “open” confirmation in the absence of L-Phe and pterin coenzyme 
appears counter to the proposed regulatory role of the auto-inhibitory region, 
which is thought to block access to the active site in the absence of L-Phe. 
Therefore, it currently remains difficult to define the biochemical roles of these 
regions given the inherent difficulty of discerning structural details of these 
dynamic regions from static crystal structures.                 
     
A B C D 
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Figure 1.6 : Active site lid conformation for selected PheH crystal structures. The active site lid is shown in teal. All crystal structures have 
an open conformation unless both substrate analog and pterin coenzyme are in the active site. A) full-length PheH 5DEN.pdb B) PheH [ ]103-
4271J8T.pdb C) PheH [ ]118-4241PAH.pdb D)phosphorylated  PheH [ ]19-429 1PHZ.pdb E) PheH [ ]19-429 2PHM.pdb F) PheH[ ]118-452 2PAH.pdb G) 
PheH118-424[BH2] 1DMW.pdb H) PheH118-424[BH4] 1J8U.pdb I) PheH103-427[BH2] 1LRM.pdb J) PheH103-427[L-THA,BH4] 1KW0.pdb K) PheH103-









Iron Coordination Sphere   
 There is currently no consistent description of the primary iron 
coordination sphere based on the available crystal structures (Figure 1.8). Early 
biochemical studies demonstrated two His residues (H285 and H290) were 
required for iron binding.24 The full-length tetrameric crystal structure of PheHT[ 
] had variations among the individual subunits regarding the primary 
coordination sphere of the iron center. Three of the four subunit had a trigonal 
bipyramidal geometry with H285, H290, E330, and two waters with the fourth 
subunit having a tetrahedral arrangement with H285, H290, E330, and one water 
Figure 1.7:  Position of F131 in the open (5DEN.pdb) (white) and closed 








as ligands. The use of Tris buffer, which can bind to the iron center25 in the 
crystallization buffer further complicates interpretation of the electron density 
around the iron atom. Two other crystal structures containing both the 
regulatory and catalytic domain (phosphorylated and unphosphorylated PheH1-
429 Fe3+[ ]) differ in their coordination environment. PheH1-429 Fe3+[ ] 
phosphorylated at S16 had an iron coordination of H295, H290, E330, and one 
water molecule, while unphosphorylated PheH103-427 showed H285, H290, E330, 
and three water molecules. The remaining truncated PheH[ ] crystal structures 
also vary with regards to the primary coordination environment of the iron 
center (Figure 1.8). These variations in the primary coordination sphere may 
result from variations in crystallization conditions and use of truncated 
constructs. While it is tempting to assign PheH the same 2-His 1-carboxylate 
motif seen in other non-heme iron oxygenases,26 an accurate determination of the 



























Bidentate 2.9 9 







PheH [ ]103-427 1J8T Octahedral One Monodentate 1.7 28 
PheH [ ]118-424 1PAH Octahedral Three Monodentate 2.0 261 
Pi -PheH [ ]19-
429 
1PHZ Octahedral One Monodentate 2.2 7 
PheH [ ]19-429 2PHM Octahedral One/Three Monodentate 2.6 7 
PheH[ ]118-452 2PAH Tetrahedral Zero Monodentate 3.1 262 
PheH14-452 6HPO Pentagonal 
Bipyramidal 
Three Bidentate 1.7 11 
       
 
 






































PheH            
Chain A 5DEN 2.1 2.2 2.2 2.3 2.3 N/A 109.5 88.7 71.1 16.9 
Chain C 5DEN 2.1 2.2 2.3 2.3 2.4 N/A 111.3 83.1 80.3 18.8 
fl-PheHT[ ] 5FGJ           
PheH [ ]103-427 1J8T 2.3 2.1 2.1 2.6 N/A N/A 97.3 88.5 102.9 9.9 
PheH [ ]118-424 1PAH 2.1 2.2 2.2 2.3 2.3 2.3 84.8 111.9 93.7 13 
Pi -PheH [ ]19-429 1PHZ 2.7 2.6 2.4 2.8 N/A N/A 88.8 105.1 82.6 9.7 
PheH [ ]19-429 2PHM 2.2 2.1 2.1 2.8 N/A N/A 82.7 91.7 84.5 5.3 
PheH[ ]118-452  2PAH 2.1 2.1 2.0 -- -- -- 103.1 125.9 90.4 15.1 
Chain A 2PAH 2.1 2.1 2.0 N/A N/A N/A 103.1 125.9 90.4 15 
Chain B 2PAH 2.0 2.2 2.4 N/A N/A N/A 102.6 113.2 79.1 18.1 
PheH14-452[ ] 6HPO 2.7 
2.2 





a root mean squared deviation for the ligand-metal-ligand compared to idealized values. Values were determined 










































Figure 1.8: Active sites of crystal structures of containing neither substrate nor 
coenzyme analog. A) Full-length wtPheHT[ ] (5DEN.pdb)(Chain A) B) PheH103-427 [ ] 
(1J8T.pdb) C) PheH103-427 [ ] (1PAH.pdb) D) phosphorylated PheH1-429 [ ](1PHZ.pdb) 
E) dephosphorylated PheH1-429 [ ] (2PHM.pdb) F) PheH118-452 [ ] (2PAH.pdb)G)PheH14-
452[  ] 6HPO.pdb 
 




PheH[BH4 and BH2]  
There is one full-length binary crystal structure of PheH (6HYC.pdb) 11 
and three truncated binary crystal structures of PheH(Fe3+Phe118-424 [BH2] 
(1DMW.pdb),27 Fe3+ PheH103-427 [BH2] (1LRM.pdb) ,Fe2+ PheH103-427 [BH4] 
(1J8U.pdb)28. The full-length crystal structure contained two different 
tetramers—one with BH4 bound and one with BH4 unbound. Neither tetramer 
was modeled with an iron bound to the 2-His 1-Glu facial triad. However, it 
should be noted that there was unmodeled electron density where the iron 
would be expected (Figure 1.9A). Additionally, Y325 and BH4 are both moved 
closer towards the 2-His 1-Glu facial triad compared to other binary crystal 
structures with BH4 making close contract with the area expected for the iron 
center. However, both spectroscopic and crystallographic studies suggest that 
BH4 does not directly coordinate to the iron center. Lastly, there appears to be 
little electron density for BH4 (Figure 1.9B) and also steric clash between the BH4 
coenzyme and F254. One interpretation of both the poor modeling of the electron 
density for BH4 and the steric clash with F254 is that the electron density 
modeled for BH4 might instead by the Bis-Tris propane buffer used in the 
crystallization process. Previous reports have demonstrated that Tris buffer can 
 




coordinate to non-heme iron centers.29,30 For these reasons, it is not clear if this 
structure is truly representative of fl-wtPheH[BH4] state. 
 The three other binary crystal structures are of constructs lacking both the 
regulatory and tetramerization domain. The first two structures were crystallized 
using 7,8-dihydrobiopterin (7,8-BH2),27 which has a significantly reduced binding 
affinity for the active site (Kd 1.1 ±0.2 mM).31 Consequently, the occupancy for 
Fe3+Phe118-424 [BH2] (1DMW.pdb) is 0.5 consistent with the 1 mM concentration of 
BH2 used in the crystallization solution.27  A later study grew crystals in 10 mM 
BH4—the catalytically relevant form the reduced pterin coenzyme.28 It is 
important to note that BH4 reacts relatively quickly with oxygen (0.6 M-1s-1).32  
Figure 1.9:  A)Fo-Fc map contoured to 3 σ for fL-PheH[BH4] 6HYC.pdb. There is a region 
of unmodeled electron density around the 2His-1Glu facial triad where an iron atom 
would be expected B) 2Fo-Fc  map for BH4 in fL-PheH[BH4] 6HYC.pdb  contoured to 1 σ. 
There is poor electron density for the BH4 coenzyme. 
A B 
 




Although the crystals for Fe2+ PheH103-427 [BH4] (1J8U.pdb) were grown in an N2 
atmosphere with 150 mM DTT (which can reduce both Fe(II) and oxidized 
dihydropterin), given the long crystallization times (four days)28  used in these 
studies, BH4 could easily oxidize during the course of the crystallization process.   
The crystal structures of both Fe2+PheH[BH4] and Fe3+PheH [BH2] suggest 
binding of the pterin coenzyme does not significantly alter the global folds or 
primary coordination sphere of PheH. The tetrahydrobiopterin binds at an 
internal active site loop formed by residues 247-251(1J8U.pdb) (Figure 1.10).28 
BH4 mainly makes contacts with the peptide backbone (G247, L249, S251, and 
A322) of this loop with the notable exception of π-stacking interactions made 
with F254. Additionally, E286 has been proposed to be an important residue in 
pterin binding through a water mediated hydrogen bond.27,33 Binding of BH4 
causes this loop to move closer to the iron center with a maximum displacement 
of 1.5 Å closer to the iron center for G247 Cα. 28 The primary coordination sphere 
likewise remains relatively unaltered upon binding of pterin coenzyme. BH4 
does not coordinate to the iron center in agreement with both biochemical31 and 
spectroscopic studies.12 All crystal structures show a 6 coordinate octahedral 
geometry with the iron coordinated to H285, H290, E330 and three water 
molecules (Figure 1.11, Table 1.3, Table 1.4 ). E330 takes on a new conformation 
 




with Cγ moving ~1.4 Å upon pterin binding. These crystallographic data are 
consistent with MCD/XAS studies which showed minimal changes to the 
electronic properties of the iron center upon binding of pterin coenzyme and a 
six-coordinate geometry.12,13 The MCD were indicative a 6 coordinate octahedral 
(∆5Eg=1,600 cm-1, 10Dq=9,300 cm-1) coordination and were essential identical to 
PheHT[ ] state ((∆5Eg=1,600 cm-1, 10Dq=9,400 cm-1) suggesting no net change to the 





























Table 1.4 Properties of the non-heme iron center for binary pterin bound crystal structures of PheH 





















PheH118-424 [BH2] 1DMW 2.0 2.1 2.2 2.3 2.6 2.2 6.1 88.3 113.3 96.0 12.9 
PheH118-424 [BH4] 1J8U 2.1 2.1 2.1 2.1 2.4 2.4 5.9 97.1 92.6 98.7 7.5 
PheH103-427 [BH2] 1LRM 2.2 2.3 2.2 2.4 2.5 2.3 6.0 76.9 110.5 104.9 12.5 
fL-PheH [BH4]a 6HYC            
a The crystal structure for fL-PheH[BH4] contained no modeled electron density for the iron center. 
 














PheH118-424 [BH2] 1DMW Octahedral Three Monodentate 6.06 2.0 32 
PheH118-424 [BH4] 1J8U Octahedral Three Monodentate 5.92 1.5 27 
PheH103-427 [BH2] 1LRM Octahedral Three Monodentate 5.96 2.1 N/A 









PheH[ L-Phe analog, pterin] 
There are currently no PheH crystal structures that contain the natural 
substrate, L-Phe, bound in the active site. Attempts to soak in L-Phe into PheH103-
427 [BH4] structures caused the crystal to disentigrate.34 Therefore, in place of L-
Phe, two substrate analogs, L- THA and L-NLE, have been used to generate the 
ternary structure of PheH. While L-THA has been proposed to activate PheH at 













Figure 1.11: Active sites of binary crystal structures of PheH containing coenzyme. A) 
Fe3+ PheH118-424 [7,8-BH2] 1DMW.pdb B) Fe3+ PheH103-427 [ 7,8-BH2] 1LRM.pdb C)  Fe2+ 














deformed/disintegrated when exposed to L-Phe  the structural change induced 
by L-THA might not be the same ones induced by L-Phe.34 Additionally, all 
current ternary structures lack both the regulatory and tetramerization domain. 
Therefore, any interdomain interaction induced by binding of substrate would be 
absent in these crystal structures. While the exact location of the allosteric site 
remains controversial (see Location of the allosteric site), all proposed sites 
somehow involve the regulatory domain. As these crystal structures lack the 
regulatory domain, the observed structural changes are a result of substrate 
binding to the active site. Therefore, structural changes as a direct result of 
allosteric activation cannot be made based on current crystal structures.   
 




The binding of substrate analogs induces changes in both the global folds 
and primary coordination sphere of PheH. In contrast to PheH[ ] and PheH 
[pterin] crystal structures, the ternary crystal structures have a closed active site 
conformation (Figure 1.6).  Additionally, there is a large movement of Y138 
(Figure 1.12). Here, the hydroxyl group of Y138 moves 20.7 Å from a loop 
(residues 134-139) on the surface to a partially buried position in the active site to 
form a hydrogen bond interaction with the pterin coenzyme.34 Consequently, the 
position of BH4 has a shortened Fe-C4a distance (4.4 Å vs 5.9 Å in the binary 








Figure 1.12: Movement of the flexible loop (residues 134-139) upon addition of L-THA PheH103-
427 [BH4] crystals.  The hydroxyl group on Y138 moves 20.7 Å towards the iron center. PheH 103-
427[BH4] 1J8U.pdb shown in white and PheH103-427 [L-THA, BH4]  
 




pterin adduct more favorable (see Catalytic Mechanism). However, there is a 
water molecule between the tetrahydrobiopterin and the iron center in one of the 
ternary crystal structures (PheH103-427 [L-THA, BH4] 1MMK.pdb). This water 
molecule is inconsistent with the proposed catalytic mechanism where this site is 
vacant to allow for formation of the Fe-OO-adduct. The exact role of Y138 
remains elusive. 6-MPH4, which does inhibit allosteric activation, can act 
substitute BH4 in the catalytic mechanism with comparable catalytic rates with 
tight coupling of product formation to 6-MPH4 oxidation. Therefore, the 
hydrogen bonding to the O1` hydroxyl group is not necessary for proper 
positioning of the pterin coenzyme and the exact role of the movement of Y138 is 
not yet understood. 
Binding of substrate analog also triggers a change in the primary 
coordination sphere of the iron center. E330 changes from a monodentate 
conformation in the PheH [ ] and PheH [pterin] structures to a bidentate 
conformation in all the ternary state crystal structures (Figure 1.13). However, 
the crystal structures are ambiguous to the geometry and number waters 
coordinated to the iron center (Figure 1.13, Table 1.5 and Table 1.6). Two 
structures, PheH103-427 [ L-THA, BH4] 1KW0.pdb34 and PheH103-427[L-NLE, BH4] 
1MMT.pdb,38 do show this five-coordinate complex albeit with poor electron 
 




density for a water molecule. While another structure of the ternary complex 
using L-THA, PheH103-427[ L-THA, BH4] 1MMK.pdb, 38 showed a four coordinate 
iron center with no electron density for a water molecule. It is important to note 
that MCD/XAS studies of the wtPheHR[L-Phe, pterin] unambiguously show a 
five-coordinate square pyramidal geometry.12,13 Similar to the crystal structures 
for PheH[ ], there are variation in the iron coordination environment for the 
ternary crystal structures that could result from variations in crystallization 

















Table 1.5 Active site properties of the ternary crystal structures of PheH 










PheH103-427[L-THA,BH4] 1KW0 Tetrahedral One Bidentate 4.45 2.5 34 
PheH103-427[L-THA,BH4] 1MMK Trigonal 
bipyramidal 
Zero Bidentate 4.42 2.0 38 
PheH103-427[L-NLE,BH4] 1MMT Tetrahedral One Bidentate 4.60 2.0 38 
 
Table 1.6 Properties of the non-heme iron center in ternary crystal structures of PheH 
























































The nature of this reorganization seen upon substrate binding is not yet 
understood. Since there are no crystal structures with just L-Phe (or L-Phe 
analog) it is not clear whether these structural changes require both substrate and 
coenzyme or if substrate alone is enough. Additionally, the binary and ternary 
crystal structures lack both the regulatory and tetramerization domain.  
Therefore, it is not known if these changes are a result of truncation of the 
enzyme or if they are relevant to full-length wtPheH. Interestingly, ternary 
crystal structures L-THA and L-NLE are only observed to bind in the active site, 
therefore the structural changes seen are a result of binding to the active site and 
not the allosteric site.  How these results are understood in the context of the 
allosteric activation process in wtPheH is not yet certain.  One interpretation is 
that the allosteric activation brings PheH into a state that can undergo the 
rearrangement upon substrate binding in the active site.39 Truncation of the 
regulatory and tetramerization domain bring PheH into a state like that of the 
activated R-state allowing for the reorganization to occur when substrate binds 
in the active site.  
 Both spectroscopic and biochemical studies have been used to further 
elucidate the primary coordination environment of the iron center. MCD/XAS 
studies show that the Fe2+wtPheHT[ ] adopts a six-coordinate octahedral 
 




geometry.12,14 The iron center of wtPheH remains six-coordinate until both 
substrate and coenzyme are loaded in the active and allosteric activation has 
occurred.13,14 Additionally, XAS studies on Fe3+wtPheHT[ ] suggest the iron center 
is octahedral regardless of the oxidation state.12 Other studies from the 
Caradonna lab have used stopped-flow NO binding studies to further probe the 
primary coordination environment of both wtPheH and PheH118-452. These studies 
measured the associative and dissociative rates of NO binding to the iron 
center.39 Both associative and dissociative rates the NO binding to the iron center 
were best fit to a single exponential suggesting a single labile ligand site for 
wtPheH. Further, wtPheH was unable to bind NO after inactivation of the iron 
center which leads to a loss of a coordination site on the iron center also 
suggestive of a single labile ligand site (presumably water).12 In contrast, 
associative and dissociative rates of NO binding to PheH118-452 [ ]  were best fit to a 
two-exponential and PheH118-452 [ ]  was able to bind NO even after inactivation 
and thus subsequent loss of labile ligand site. These results suggest, that PheH118-
452 [ ] and removal of the regulatory domain alter the primary coordination sphere 
of PheH.   Therefore, any interpretation of the crystal structures must also 
consider these spectroscopic and biochemical data.  
 
 




Relationship to TyrH and TrpH  
TyrH                                                                                                                                                                                  
TyrH is less well characterized crystallographically compared to PheH. 
There are no full-length crystal structures of TyrH, and no crystal structures exist 
with substrate bound. Only structures of Fe3+TyrH156-498[ ]40 (TyrH containing 
residues 156-498) and Fe3+TyrH160-498[BH2]41 (TyrH containing 160-498 with BH2 
bound in the active site) exist. Overall, the structure of Fe3+TyrH156-498 is similar to 
the equivalent PheH construct also lacking the regulatory domain (PheH118-452 
2PAH.pdb) (Figure 1.14). The high structural homology is unsurprising given 
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Figure 1.13: Active sites of ternary crystal structures of PheH containing both substrate analog 
and tetrahydrobiopterin. A) PheH103-427 [NLE, BH4] 1MMT.pdb B) PheH103-427 [L-THA, BH4] 
1MMK.pdb C) PheH103-427 [L-THA, BH4] 1KW0.pdb 
 




the high sequence homology (75-80%)6,42 of the catalytic and tetramerization 
domain between all three AAAHs. Like PheH, the crystal structure for 
Fe3+TyrH156-498 exhibits a 2His-1Glu motif with the iron center coordinated by 
H331, H336, E276, and two waters (Table 1.7 and Table 1.8). However, in 
contrast to PheH crystal structures where E330 is monodentate, E276 adopts a 
bidentate conformation in the absence of both substrate and coenzyme. 
However, it is not clear if the change in denticity is a result relevant differences 
in PheH and TyrH or a result of the plasticity of the truncated variants and 














Table 1.7 Active site properties of TyrH and TrpH crystal structures 











TyrH        
TyrH156-498 1TOH Octahedral One Bidentate N/A 2.3 40 
TyrH160-498[BH2] 2TOH Octahedral Two Bidentate 5.57 2.3 41 
        











TrpH        
TrpH102-402 [BH2] 1MLW Octahedral Three Bidentate 5.74 1.71 50 
TrpH101-414[L-Trp] 3E2T Tetrahedral Zero Bidentate N/A 1.90 51 
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Like PheH, binding of pterin coenzyme does not alter the global folds of 
TyrH. The Fe3+ TyrH160-498[7,8-BH2] structure is isomorphous with ligand-free 
Fe3+TyrH156-498 [ ] structure with an RMSD of 0.18 Å.41 Interestingly, F300 appears 
to be hydroxylated in the meta position of this crystal structure and makes π-
stacking interactions with 7,8-BH2. F300 is not hydroxylated in the ligand free 
crystal structure nor is the corresponding residue (F254) hydroxylated in any of 
the PheH crystal structures. The authors suggested that the hydroxylation was a 
result of post-translational modification involving F300, O2, and the iron center. 
However, other groups were not able to reproduce hydroxylated F300.43 Only 
upon incubation with excess ferrous ammonium sulfate and DTT was the 
hydroxylated F300 observed.43 Therefore, the post-translation modification may 
be the result of Fenton-like chemistry44 that arose as a result of crystallization 
conditions.  In the binary Fe3+ TyrH160-498[7,8-BH2], the pterin coenzyme is rotated 
approximately 180° around the C4a-C8a axis compared to the position in 
PheH103-427[BH4] and TrpH [7,8-BH2] (Figure 1.15). The significance of the 
difference in orientation is uncertain.  The electron density is relatively poor for 
the 7,8-BH2. The 2Fo-FC map contoured 1.5σ show little electron density for the 
7,8-BH2 (Figure 1.15). Therefore, modeling of the electron density for the 7,8-
dihydrobiopterin is challenging.  Given that the pterin binding site is highly 
 




conserved across all AAAHs45,46 it is expected that the tetrahydrobiopterin 
coenzyme would bind in similar orientations. The difference in orientation could 
be a result of differences in crystallization conditions or the apparent 
hydroxylation of F300.  
 
Spectroscopic characterization of TyrH 
 MCD/XAS studies on TyrH indicate that TyrH adopts a six-coordinate 
octahedral geometry until both L-Tyr and pterin coenzyme are bound in the 
        A       B 
Figure 1.14: Comparison of the overall folds PheH (white), TyrH (pink), and TrpH (teal) 
subunits. A) ligand-free variants Fe3+PheH118-452 [ ] (2PAH.pdb) and Δ1-155 Fe3+TyrH [ ] 
(1TOH.pdb) lacking the N-terminal regulatory domain B) binary constructs with bound 
pterin coenzyme, PheH103-427 [BH4] (1J8U.pdb), Δ1-155 TyrH [7,8-BH2](2TOH.pdb), and 
TrpH102-402 [7,8-BH2] (1MLW.pdb). The pterin cofactor has been omitted for clarity. 
 




active site whereupon the iron center becomes a five-coordinate square 
pyramidal site.47 Additionally, an ESEEM study was able determine the distance 
and orientation of the deuterons for both  3,5-2H-L-Tyr and 6,7-2H-6-MPH4 with 
respect to the Fe-NO adduct.48 The 2H-ESEEM spectrum for TyrH[6,7-2H-6-
MPH4] suggested the closest deuteron was >5.9 Å away. However, upon binding 
of L-Tyr, the effective dipole-dipole distance was 4.4±0.2 Å. These results 
suggested that binding of L-Tyr causes the pterin coenzyme to move closer to the 
iron center. In contrast, binding of 6-MPH4, causes the effective dipole-dipole 
interaction between the Fe-NO adduct and 3,5-2H-L-Tyr to increase from 4.1±0.1 
Å to 4.7±0.2 Å. 
TrpH 
There are two crystal structures of TrpH--one reported with 7,8-BH2 
(1MLW.pdb) and one reported with L-Trp modeled in the active site (3E2T.pdb). 
The overall fold for TrpH102-402[7,8-BH2] is similar to that of both PheH103-427 [7,8-
BH2] and TyrH160-498[7,8-BH2] (Figure 1.14) with 7,8-BH2 orientated in a similar 
position to PheH103-427 [7,8-BH2] (Figure 1.15). While the pterin coenzyme appears 
to bind in a similar orientation in TrpH compared to PheH and TyrH, the 
coenzyme makes different interactions with the protein scaffold. The 7,8-BH2 
makes π-stacking interactions with Y235. In both PheH and TyrH, this residue is 
 




a leucine. When Y235 is mutated to a leucine residue, the specific activity of 
dropped to ~5% of wtTrpH.49 Additionally, in PheH S251 makes hydrogen bond 
interactions with the eryhtro tail of BH4. The analogous residue in TrpH is a P238 
and is 3.6 Å away from the 1’-OH group of the L-erythro tail.50 These differences 
could possibly be related to the role of BH4 as a negative allosteric effector in 
PheH but not TrpH. The primary coordination sphere of the iron center has a 
canonical 2His-1Glu motif with the iron center is coordinated by H273, H278, 
E319, and three water molecules. This is a similar coordination environment seen 
in the binary coenzyme bound crystal structures of PheH. 
 




 To our knowledge, TrpH is the only AAAH that has been reported to have 
been crystallized with its natural substrate. The TrpH101-414[L-Trp] structure has 
several similarities with the ternary complexes of PheH. The TrpH101-414[L-Trp] 
crystal structure is isomorphous to the PheH103-427[ L-THA, BH4] with an RMSD of 
0.9 Å.51 TrpH101-414[L-Trp] structures is more compact compared to TrpH102-402[7,8-
          





















Figure 1.15: Primary coordination environment of the iron center based on 
crystallographic studies for different AAAHS A) PheH103-427 [BH4] (1J8U.pdb) B) 
TyrH156-498[7,8-BH2] (2TOH.pdb) C) TrpH102-402 [ 7,8-BH2] (1MLW.pdb) D) Electron 
density of the active site for TyrH156-498[7,8-BH2](2TOH.pdb). The electron density 








BH2] and its active site access is more similar to that of  the “closed” 
conformation of the PheH ternary state crystal structures (Figure 1.6, Figure 
1.16B).  It would be intriguing to find out if substrate binding alone might trigger 
the closed conformation in PheH. While these the global folds of TrpH101-414[L-
Trp] are like the ternary PheH structures there are some subtle differences. As 
mentioned above, Y138 moves 20.7 Å inwards upon substrate binding (Figure 
1.12). However, this dramatic movement of Y126(the corresponding residue in 
TrpH) does not occur in TrpH101-414[L-Trp] in comparison to TrpH101-414[BH2]. Y236 
and I367 are positioned where Y126 would be expected to move. However, 
whether simultaneous binding of L-Trp and BH4 might reposition Y236 and I367 
to allow for the movement of Y126 is not yet known. In the TrpH101-414[L-Trp] 
crystal structure, the iron is coordinated by H273, H278, a partially bidentate 
E318, and an imidazole (Figure 1.16, Table 1.7, and Table 1.8). The imidazole 
could potentially be displacing an endogenous ligand or alter the resting primary 
coordination sphere of TrpH. Finally, it is important to note the there was no L-
Trp included in the crystallization buffer nor was there any added to the 
purification buffers. Therefore, modeling of the electron density of that region as 
L-Trp is uncertain and therefore may not be reflective of the substrate bound 
form. 
 




  A crystallographic characterization of the AAAHs is important for 
under- standing their functionality and regulatory properties. Unfortunately, the 
paucity of crystal structures has hindered our understanding of their properties. 
The AAAHs diverge most in their regulatory domain and currently only crystal 
structures of PheH exist with the regulatory domain intact. Therefore, 
understanding the differences in the regulatory behavior for these enzymes is 
difficult. Additionally, a crystallographic understanding of the T and R state is 
important for determining the structure-function relationship of PheH and its 
allosteric activation process. However, the relevancy of the current crystal 
structures has yet to be determined. Interdomain contacts likely play an 
important role in the allosteric activation process, but all binary and ternary 
crystal structures only contain the catalytic domain. Therefore, any domain 
movements caused by the regulatory and tetramerization domain would not be 
present. Additionally, allostery has evolved to recognize the importance of 
dynamics and flexibility to the allosteric process. Therefore, static crystal 
structure can only be so informative of the allosteric activation process.  
Nonetheless, these crystal structure do contribute to our understanding of the 
important changes that occur upon the T →R state transition.  
  
 






The catalytic mechanism of PheH remains poorly understood in terms 
of both the activation of O2 and subsequent hydroxylation of product by Fe 
(IV)=O. While it is well established that reduction of the iron center29 and 
allosteric activation52 must occur to achieve a catalytically competent state, there 
is not yet a consensus as to how O2 is activated in the catalytic mechanism. 
Further, the intimate details of how the hydroxylation occurs and proposed 
mechanisms for certain mechanistic features (e.g. NIH shift) remains 
controversial. While it is often assumed that the AAAHS all share the same 
A            B 
Figure 1.16: A) Primary iron coordination sphere for TrpH101-414[L-Trp] (3E2T.pdb) B) 










intimate details with regards their catalytic mechanism, these enzymes appear to 
vary in terms of their reported kinetic mechanism and specific mechanistic 
features (e.g. the NIH shift). The current understanding of the intimate details to 
the catalytic mechanism of PheH and the relationship to TyrH and TrpH will be 
discussed below. 
Kinetic Mechanism 
There have been multiple reports for the kinetic mechanism for PheH. 
Initial studies into the kinetic binding mechanism used Chromobacterium 
Violaceum (cvPheH), a monomeric form of PheH. cvPheH lacks the regulatory 
domain observed mammalian PheH and therefore does not have the same 
regulatory properties as mammalian PheH (i.e. allosteric activation by L-Phe and 
negative allosteric inhibition by BH4). Pember et al.53 first reported that in cvPheH 
the kinetic mechanism involved O2  binding first followed by random order 
binding of 6,7-DMPH4  and L-Phe when using. 53 A later study, also using 
cvPheH, found the order of substrate binding was 6,7-DMPH4 followed by L-Phe 
and lastly O2.54 The differences in the reported kinetic mechanism likely arise 
from reconstitution of cvPheH with Cu2+ by Pember et al., but Fe2+ by Volner et 
al.54 Given that there is an absolute requirement for Fe2+ for cvPheH,55 the results 
 




seen by Pember et al are might not reflective of the actual kinetic binding 
mechanism of cvPheH.  
Activation O2 and formation of the iron-oxo 
It is generally agreed that Fe (IV)=O is the hydroxylating intermediate 
and is formed by the heterolytic cleavage of Fe-OO-BH2 adduct. However, how 
the Fe-OO-BH2 adduct is formed and the intimate details of how PheH initially 
activate O2 remain controversial. Evidence has been given for the initial 
activation of O2 by either the BH4 coenzyme, ferrous center,56 or a concerted two-
electron oxidation involving both BH4 and the ferrous center.47  
The first proposed mechanism for O2 activation involves the reaction of 
O2 with BH4 coenzyme to form a c4a-peroxy-BH4 adduct. While the reaction of 
triplet O2 (S=1) with BH4 (S=0) is formally spin forbidden, pterins are known to 
react with oxygen32,57,58 and many have proposed that initial attack of O2 occurs at 
the c4a position of the pterin coenzyme(Figure 1.17a).55 Evidence for activation of 
O2 by BH4 comes from studies demonstrating that the rates of oxidation of the 
ferrous center by O2 is not to be kinetically competent with catalytic activity.39 
These studies from the Caradonna lab used reduced Fe2+PheH118-452 and measured 
the rate reactivity of oxidation of the ferrous center by the formation of the 
histidine-to-Fe3+ LMCT at 330 nm in the absence (0.23 M-1s-1) and presence (0.55 
 




M-1s-1) of both L-Phe and 5-deaza-6-MPH4. These rates were slower than the rate 
of catalysis (10-20 s-1) and agreed well with another studied which measured rate 
of ferrous oxidation by O2 (~0.024 min-1) in the absence of substrate and 
coenzyme using the ferric chelator 2,3-dihydroxynaphthalene for wtPheH.59  It 
should be noted that the ferrous center is expected  to have a five-coordinate 
square pyramidal coordination in wtPheHR[L-Phe,5-deaza-6-MPH4].12,13 The six 
→ five-coordinate coordination change has been proposed to allow for a 
“vacant” site for O2 to bind.60 Therefore, even when the iron has a vacant 
coordination site to interact with O2 the rate of oxidation (0.55 M-1s-1) is not 
kinetically competent with catalytic turnover and O2 (10-20 s-1). Based on these 
studies O2 must react with the pterin coenzyme first in the catalytic mechanism.39 
Additionally, an enhanced rate of both BH4 and 6-MPH4 occurs in the apo-
wtPheH and apo-PheH118-452 (Chapter 5) in the presence of L-Phe suggesting that 
the presence of ferrous center is not required for O2 activation. 
Others have used DFT calculations to probe a mechanism where O2 first 
reacts with the ferrous center to form an iron superoxide Fe3+O2- which could 
then react with BH4 to form a Fe-OO-BH2 adduct(Figure 1.17c).56 This study 
suggested that O2 must bind to the primary coordination sphere of the ferrous 
 




center before it can be reduced by BH4. However, this computational study used 
binary crystal structures of PheH118-424[BH2]. As discussed above, the binding of 
the substrate analog induces several changes to the active site of PheH, including 
movement of the BH4 coenzyme closer to the iron center, a coordination change 
from a six- (octahedral) to a five-coordinate square pyramidal site, and alteration 
of the primary coordination sphere of the iron center to adopt a bidentate E330 
binding mode.  Additionally, pulsed EPR-studies (Chapter 2) suggest that the 
BH4 coenzyme moves ~1.8 Å closer to the iron center upon allosteric activation. 
Neither the change in BH4 position nor the primary coordination sphere change 
appear to be accounted for in this DFT study. Therefore, the conclusions drawn 
from this study may not be relevant to the activated form of PheH as catalytically 
relevant crystal structures were not used.  
Some have suggested the possibility of a concerted electron transfer to 
both the ferrous center and BH4(Figure 1.17b).61 Support for this proposal comes 
from a study using TyrH,  which proposed a concerted two-electron reduction of 
O2 to H2O2 by the reactions Fe2+→Fe3+ and 6-MPH4→6-MPH3· that was favored 
over individual one-electron reactions.47 This study used stopped-flow 
spectrometry to examine singe-turnover kinetics for the reaction of O2 with both 
pterin and ferrous center of TyrH. By monitoring the absorbance changes at 246 
 




and 350 nm upon mixing TyrH[6-MPH4] with O2, this study determined that the 
rate of the ferrous and pterin oxidation across the various mechanistic states of 
TyrH. The rate of oxidation of the ferrous center in TyrH[6-MPH4] (0.16 s-1) was 
5-fold faster compared to TyrH[5-deaza-6-MPH4] (no reaction) or TyrH[6-MPH2] 
(0.032 s-1). The authors also argue that a concerted mechanism is favored based 
on the redox potentials of the individual species. For the one electron oxidation, 
they assumed the estimated the redox potential of TyrH using a study that 
reported redox potential for PheH. The one electron oxidation of the ferrous 
center by O2 (Fe2++O2→Fe3++O2-•) had an E0=-537 mV and uphill 12.5 kcal/mol 
while 6MPH4+O2→6MPH3•H+ + O2-•) was E0=-600 mV and uphill by 14 kcal/mol.  
Though the rate of oxidation in TyrH[6-MPH4] is not kinetically competent, the 
two-electron transfer reaction could be facilitated by i) the six → five 
coordination change that occurs upon binding of both L-Tyr and pterin 
coenzyme,47 and ii) the movement of pterin coenzyme closer to the iron center 
upon binding of substrate.48  While the AAAHs are expected to have similar O2 
activation methods the relevancy to PheH is yet to be determined.  
  
 





Regardless of the route of formation the Fe-OO-pterin adduct, it is 
generally agreed that once the Fe-OO-pterin adducts forms,  heterolytic cleavage 
of the peroxy bond occurs to yield a Fe(IV)=O and a C4a-hydroxy-BH2.62 The iron-
oxo has been characterized by Mössbauer spectroscopy15 in cvPheH, a 
monomeric form of the enzyme containing just the catalytic domain.15 This rapid 
freeze-quench Mössbauer study indicated a species with maximum intensity at 
20 msec with a peak at 0.9 mm/s with δ=0.28 mm/s and ΔEQ=1.26 mm/s indicative 
 









of a high spin Fe(IV)=O species.63 It is predicted that mammalian PheH and 
cvPheH follow similar, if not identical, catalytic mechanisms. The Fe(IV)=O 
species has also been characterized in TyrH.64 The other product of heterolytic 
cleavage, c4a-hydroxy-BH2, can be dehydrated by 4α-carbinolamine dehydratase 
(formerly known as phenylalanine hydroxylase stimulator (PHS)) to form the 
quininoid-BH2 (q-BH2). The q-BH2 tautomerizes to 7,8-dihydrobiopterin (BH2) 
which can be enzymatically reduced to BH4 by dihydrofolate reductase. The 
heterolytic cleavage of the Fe-OO-pterin is thought to be driven by the pKa of the 
c4a-hydroxy-BH2 product. 
It has also been reported that the iron-oxo can be generated through a 
peroxide shunt65, similar to what is seen in P450 enzymes. This report measured 
the ability for TyrH to hydroxylate L-Phe using H2O2 in place of BH4 and O2. The 
hydroxylation reaction results in the formation of both L-Tyr and 3-hydroxy-L-
phenylalanine. Loss of specificity was attributed to the absence of pterin in the 
active site. However, the high concentration of ferrous ammonium sulfate (400 
µM) and H2O2 (10 mM) are conducive to Fenton chemistry (oxidation by the 
generation of hydroxide radicals).44 Therefore, the hydroxylation observed could 
be attributed to the formation of hydroxide radicals rather than a formal 
enzymatic reaction. Lastly, while L-Tyr was formed under these conditions, L-
 




DOPA was not an observed product when using TyrH. While the authors 
indicate that L-DOPA decomposes under these conditions, it is not clear if L-Tyr 
was an effective substrate under their conditions. 
Hydroxylation of substrate 
Within the PheH system, Fe(IV)=O can perform a variety of reactions 
on both aliphatic and aromatic substrates (Table 1.8). An important mechanistic 
feature in the catalytic mechanism is the migration of the para-substituent to the 
meta position in a so called NIH shift.66 The NIH shift is observed in other 
enzymatic (e.g. P450s)67 in and non-enzymatic reactions(trifluoroperacetic acid).68 
However, enzymatic reactions show greater retention of the migratory 
substituent than their non-enzymatic counter parts. While the origin of the 
increase in migration is unknown, one possibility is the stabilization a resulting 
carbocation by the enzyme active site allows for the carbocation intermediate to 
live longer enough for the migration to occur. In PheH, the NIH shift is observed 
with a variety of substituents in the para position including Cl,69 Br,69, 2H,66 3H,66 
and -CH3.64,70 Many proposal have been made to link the observation of the NIH 
to the O atom transfer mechanism by Fe(IV)=O that either involve the formation 
of an ionic intermediate66,70,71 or the formation of an arene epoxide.72,73 However, 
 














The first proposal to explain the NIH shift was initially proposed upon 
observation of the NIH shift in PheH by Guroff et al.66 They proposed a direct 
hydroxylation of the para position with subsequent migration of the para-
Substrate Product  Reference 
 



























Table 1.8: Representative sample of alternative substrates for Fe(IV)=O 
within the PheH system 
 
 58 
The first proposal to explain the NIH shift was initially proposed upon 
observation of the NIH shift in PheH by Guroff et al.66  They proposed a direct 
hydroxylation of the para position with subsequent migration of the para-
substituent (Figure 1.18a). This mechanism was later supported by a study using 
para-methyl-L-Phe.70 In this study, when using purified PheH, the sole products 
were para-hydroxymethylphenylalanine and 3-methyltyrosine. In contrast, in an 
earlier study, the hydroxylation products were para-
hydroxymethylphenylalanine, 3-methyltyrosine, and 3-hydroxy-4-
methylphenylalanine.64  Siegmund and Kaufman attribute the discrepancy to the 
use of a crude enzyme fraction in the initial report70 (which possibly contained a 
microsomal hydroxylase that could perform the ortho hydroxylation). However, 
while the hydroxylation products were never determined, it was reported that 3-
hydroxy-4-methylphenylalanine can also serve as a substrate for PheH.70 
Therefore, another explanation could that 3-hydroxy-4-methylphenylalanine was 
formed, but never detected because it had been oxidized again. The authors 
proposed that the observation that no detectable amounts of 3-hydroxy-4- 
methylphenylalanine was observed supported a mechanism involving direct 
attack of the para position to form a carbonium ion. However, substrate binding 
to the active site of PheH can trigger changes active site properties (Chapter 2) 
 




therefore binding of para-methylphenylalanine might not trigger the same 
changes as the natural L-Phe substrate.  
 
Miller and Benkovic proposed O atom transfer leads to an arene oxide 
intermediate over the 3,4 π-bond to form a 3,4-epoxide (Figure 1.18b, Table 
1.8).72 This pathway has been supported by a study using the [2,5-H2]-L-Phe.72  
This substrate can form the putative epoxide but lacks the ability to re-aromatize 
that would allow for collapse of the epoxide. When used as a substrate the sole 
product was a 3,4-epoxide and not allylic oxidation, supporting the formation of 
an epoxide intermediate. However, others have noted that the observation of the 
3,4-epoxide when using [2,5-H2]-L-Phe does not establish the arene oxide as an 
 
 









obligatory intermediate.79 The observation of the 3,4-epoxide could simply be a 
result of the altered substrate used.  Additionally, the 2H-ESEEM studies 
(Chapter 3) demonstrated that the meta position is closer to the iron center than 
the para position consistent with addition of O over the 3,4 π-bond. However, 
once aspect of this mechanism that is not yet explained is why ring opening of 
the epoxide leads to only L-Tyr without any m-L-Tyr formed. PheH only 
produces L-Tyr and formation of m-L-Tyr does not occur under normal activity 
condition.80  
PheH performs the hydroxylation reaction using a non-heme iron center and 
a tetrahydropterin coenzyme to activate oxygen. Tetrahydropterins are similar in 
structure to dihydroflavins with the exception that pterin lack the third fused 
benzene ring seen in dihydroflavins. Because of third aromatic ring, 
dihydroflavins react more quickly with O2 (~250 M-1s-1)81 than tetrahydropterin (~ 
0.6 M-1s-1) 82  because flavins can stabilize resulting radical. The differences in the 
structure of the coenzyme result in differences in the hydroxylation mechanism 
between pterin dependent monooxygenases and the flavin dependent 
monooxygenases. Flavin dependent monooxygenases typically have the 
dihydroflavin act as the hydroxylating species and have non-aromatic or 
activated substrates, in contrast, pterin dependent monooxygenases use the 
 




tetrahydrobiopterin coenzyme to form high-valent metal center to hydroxylate 
unactivated substrates. In flavin dependent monooxygenases, O2 reacts with 
dihydroflavin to form a C4a-hydroperoxyflavin that can then hydroxylate the 
substrate.  Depending on the FDH, the protein scaffold can provide considerable 
stability the resulting C4a-hydroperoxyflavin (e.g. t1/2~300 s for cyclohexanone 
monoxygenase83, at pH 7.2,4°C  t1/2 ~1400 for ActVA(an enzyme involved in the 
biosynthesis of the antibiotic actinorhodin) 84, pH 7.4, 4°C). In contrast, the c4a-
hydroperoxytetrahydropterin has been proposed but never observed putatively 
because of its relative instability and resulting short t1/2. In summary, 
dihydroflavin differ from the tetrahydrobiopterin in terms of the substrates they 
act on and the hydroxylating intermediate used. Both TyrH and TrpH are 
proposed to follow a similar mechanism.85 
TyrH and TrpH 
TyrH 
 TyrH appears to differ from PheH in its catalytic mechanism in terms of 
the kinetic mechanism, activation of O2, and hydroxylation by Fe (IV)=O. As 
opposed to PheH, the kinetic mechanism appears to be binding of 6-MPH4 
followed by O2 and then L-Tyr.86Additionally binding of L-Tyr to TyrH, is 
reported to form a dead-end complex.86  The initial activation by O2 also appears 
to differ from PheH. Evidence has been given to support a concerted two-
 




electron transfer reaction from both Fe(II) and 6-MPH4 to reduce O247 based on 
both the kinetics of the oxidation of the ferrous center by O2 and the reduction 
potentials of the ferrous center and 6-MPH4. The absorption traces at 246 nm and 
350 nm for the reaction of TyrH[6-MPH4] (corresponding to the formation q-
6MPH4) with O2 were best fit to a concerted two-electron transfer reaction. 
However, 2H-ESEEM studies suggest that when using 6,7-2H-6-MPH4 the closest 
deuteron to the Fe-NO center is >5.9 Å away.48 Additionally, the crystal structure 
for TyrH[BH2] has a C4a-Fe distance of 5.6 Å (2TOH.pdb).41  Therefore, a 
concerted reaction between O2 and 6-MPH4 and Fe(II) might be unlikely given 
the distance between iron center and 6-MPH4.  
 TyrH also appears to differ from PheH in terms of the actual 
hydroxylation mechanism. Studies examining the partitioning of deuterated L-
Phe substrates by TyrH argue against a mechanism involving an epoxide.79 
When using L-Phe as a substrate for TyrH, both L-Tyr and 3-hydroxy-L-Phe are 
observed as products.  If an arene oxide were an intermediate, an increase in the 
rate of formation of L-Tyr should lead to a concomitant decrease in the formation 
of 3-hydroxy-L-Phe. In this study, KIE effects were only observed for product 
that was deuterated at the site of hydroxylation e.g. there was a KIE for the 
formation L-Tyr when using para-2H-L-Phe but not for 3,5-2H-L-Phe. Because 
 




there was not a concomitant decrease observed for the non-deuterated substrate 
the authors concluded that an arene oxide could not be an intermediate for TyrH. 
However, it should be noted that this study did not attempt to measure the 
potential for subsequent hydroxylation of either L-Tyr or 3-hydroxy-L-Phe by 
TyrH. Therefore, reported rates of formation of both these products could have 
been underestimated.  
Further studies on various para-substituted L-Phe substrates have suggested 
that the steric bulk on the para-position influences the distribution of products 
for the hydroxylation of L-Phe by TyrH.87 However, it is not clear if the natural 
substrates for each of the AAAHs use the same hydroxylation method as natural 
substrates especially given the large uncoupling (~25% coupled reaction) seen 
when using these substrates.  Additionally, since in TyrH , L-Tyr binding induces 
a structural rearrangement of the active site,48  it is not certain if L-Phe induces 
the same structural arrangements that would lead to comparative active site 
properties. Regardless of the mechanism of the NIH shift, the para substituent 
migration remains an important mechanistic marker the enzyme catalyzed 
hydroxylation of L-Phe. Presence of NIH shift allows for the differentiation 
between hydroxylation by the enzyme as opposed to hydroxylation occurring 
independent of the enzyme (e.g. Fenton chemistry).44 
 




Lastly, in contrast to PheH, TyrH does not exhibit retention of the substituent 
at the site of hydroxylation. For 3,5-ditritiotyrosine, where a tritium is 
incorporated at the site of hydroxylation, tritium is released as 3H2O.66 The reason 
for the release of tritium might arise from the ability to form an o-quinonoid 
through resonance. 
TrpH 
 To our knowledge, the kinetic mechanism for TrpH has not been well-
studied aside from two early studies which reported a sequential mechanism.88,89  
However, a study using TrpH102-416(the catalytic core of TrpH) reported substrate 
inhibition (by both 6-MPH4 and BH4) when using L-Trp, but not L-Phe .90 A later 
study also reported substrate Inhibition by BH4 was reported for TPH-1 
(expressed in the pineal gland and the periphery nervous system) and to a small 
extent TPH-2.91 While the PheH and TyrH do not appear to exhibit the same 
substrate inhibition that was demonstrated in the study on TrpH102-416, one NMR 
study suggested that BH2 bound in a different conformation in TrpH compared 
to PheH or TyrH.92 Additionally, crystal structures of TrpH102-402 [ 7,8-BH2] reveal 
that Y235 makes π-stacking interactions with the BH2 (1MLW.pdb).50 In PheH 
and TyrH, the analogous residue is a leucine. Therefore, TrpH might interact 
different with the pterin coenzyme. One study that examined the catalytic core of 
 




TrpH102-416, found a tight coupling between BH4/6-MPH4 oxidation when using 
either L-Trp or L-Phe as a substrate (0.99-1.12 hydroxylated product/pterin 
oxidation)90  with 5-hydroxy-L-Trp and L-Tyr as the only products. However, 
when using L-Tyr as a substrate and BH4 there was very little coupling 
(0.0122±0.0008 hydroxylated product/BH4 oxidized).90 
 While the Fe (IV)=O intermediate has not yet been observed in TrpH, it is 
generally accepted that it is an intermediate in all AAAHs.  A single-turnover 
kinetics study on TrpH measured the change in absorbance at a variety of 
wavelengths upon mixing various mechanistic states of TrpH with O2. Upon 
mixing TrpH[L-Trp,6-MPH4] with O2, the authors observed an intermediate with 
a λmax=420 nm with rate of formation of 65 s-1. This intermediate formed before 
the formation of the Fe (IV)=O and the decay of the intermediate was 
commensurate the formation of the c4a-OH-6-MPH4. While never suggested in 
the study, one possible identity for this intermediate is c4a-hydroperoxy-6MPH4. 
The possibility of this species would explain why no change in the Mössbauer 
was observed when rapid freeze-quench Mössbauer was performed to 
characterize the intermediate.  When 5-3H- L-Trp is used as a substrate >85% of 
the 3H label is retained.66 However, other groups have reported lower 3H 
retention (65%).93  
 




 A single-turnover kinetics study of TrpH, found an unidentified 
intermediate with a λmax=400 nm which built up maximally at 100 msec form 
upon mixing TrpH, 6-MPH4, and L-Trp with O2 in the active site. This 
intermediate occurred after binding of all substrates but before formation of the 
Fe (IV)=O species. One possibility for this intermediate is a c4a-peroxy-6-MPH2. 
Such a species would explain why no change in the Mössbauer spectrum was 
observed upon mixing TrpH, 6-MPH4, and L-Trp with O2. 
 Like PheH, TrpH also undergoes an NIH shift. In TrpH, the substituent in 
the 5-position migrates to the 4-position.93,94 One study suggested direct 
electrophilic aromatic substitution to form a cation on the 4 position was most 
likely given the pattern of the kinetic isotope effect.93 If a cation is formed, there 
should be an inverse KIE for an isotopic substitution on the site of oxygen 
addition ( 5 position) but not at adjacent positions ( 4 or 6 position). In contrast, if 
an arene oxide were formed, there should be an inverse KIE for isotopic 
substitution at the 4- or 5-position. A later study was only able to observe a small 
inverse KIE for 2H-5-L-Trp (0.93) and small KIE for 2H-4-L-Trp (1.03) suggesting 
that direct formation of the cation was favored over the epoxide formation.  
 





 Variations in activity assay methods has led to challenges in developing a 
cohesive understanding of the PheH system. The activity of PheH can be affected 
by several factors including the order addition of substrates, types of pterin 
coenzyme used, buffer used, pH (which can affect both the catalytic step and the 
T→R transition), and temperature. This section will review the standard assays 
used to measure the activity of PheH and the features associated with each 
method. 
 There have been three main activity assays used to measure the activity of 
PheH. The first method spectrophotometrically measures the formation of the q-
BH2 or q-6-MPH2 (Figure 1.19) at the isosbestic point (330 and 334 nm 
respectively). While this assay provides a straight-forward method for 
determining the activity, this method has a high background resulting from the 
oxidation of the reduced pterin by ambient O2. Additionally, the rate of 
dehydration of c4a-hydroxy-6-MPH2 is pH dependent. Therefore, the pH 
dependence must be carefully considered when measuring the activity using this 
assay. The q-6-MPH4 species is not the immediate product of the catalytic 
reaction. Instead, the formation of q-6-MPH4 relies on the dehydration of c4a-
OH-6-MPH2. At high pH values (> 8.5), the c4a-OH-6-MPH2 is stabilized and 
 




must be considered when performing activity assays under these pH conditions. 
Lastly, this assay has a high background due to the autoxidation of reduced 
pterin by O2  and the pterin oxidase capabilities of PheH.95 Both of these reaction 
can cause lead to an artificially high measured rate unless careful controlled for. 
 The second assay method couples the reduction of q-6-MPH2 catalytic 
reaction to 6-MPH4 using NAD(P)H and dihydropterin reductase (DHPR). The 
absorbance  of the oxidation of NAD(P)H is measured at 340 nm.37,96 This reaction 
is often initiated by the addition unactivated PheH to an otherwise complete 
reaction mixture. Therefore, the measurement of activity when using BH4 (a 
negative allosteric effector), is complicated by the competing roles of L-Phe 
inducing the T→R transition and BH4 inhibiting the transition. This assay will 
underestimate the actual catalytic rate until q-6-MPH4 builds up to a steady state 
level. Like the previous assay, this assay suffers from a high background because 
of the auto-oxidation of 6-MPH4 and the pH dependence of the dehydration of 
c4a-hydroxy-6-MPH2 to q-6-MPH2.  
  
 




 The third activity assay directly measures the  formation of L-Tyr by the 
change in absorbance at 275 nm (Δε = 1700 M-1cm-1).97 The Δε takes into account 
the differential extinction coefficient of L-Phe and L-Tyr as well as the oxidation 
of DTT. In this assay, the reaction is first pre-incubated with L-Phe, catalase, and 
DTT for 3 minutes at 25°C. The reaction is then initiated by the addition of 6-
MPH4. Incubation with L-Phe is necessary to fully activate PheH and 6-MPH4 is 
used to obviate any negative allosteric effects that are normally associated with 
BH4. Catalase is added to remove H2O2 generated by the oxidation of reduced 
pterins by O2. H2O2 can inactivate PheH and react with exogenous iron to 
perform Fenton chemistry. This Fenton chemistry side reaction can hydroxylate 
 
Figure 1.19: Scheme representing the various intermediates formed in the catalytic 
cycle of PheH.  
 
 




L-Phe in the para, meta, and ortho position artificially increasing the apparent 
measured activity of PheH. Lastly DTT is included to regenerate 6-MPH4 from q-
6-MPH2. This assay is the most frequently used as it is a continuous assay that 
directly measures the formation of product. Because this assay is performed on 
fully activated PheH, there are not complicating factors associated with the T→R 
conversion like in the previously discussed assays. However, it should be noted 
that this assay is not able to distinguish the formation of L-Tyr from m-L-Tyr or 
o-L-Tyr which are all the products of Fenton chemistry.  
 Lastly, it is important to note the choice of buffer is important when 
performing activity assays. While both phosphate and Tris buffer are commonly 
used in activity assays, Tris buffer acts as a competitive inhibitor of 6-MPH4 with 
respect to catalysis and reduction.29 This observation is particularly important for 
studies examining the Km and binding affinities of various reduced pterin 
analogs. 
TyrH 
 The most common assays for TyrH activity measures the release of tritium 
from [3,5-3H]tyrosine as 3H2O using a fixed time assay98 and the colorimetric 
determination of DOPA.99 Ferrous ammonium sulfate is typically added to 
“stimulate” TyrH activity. However, Fe2+ can decompose H2O2 to form OH·. 
 




Therefore, H2O2 that arises from the autoxidation of reduced pterin could react 
with Fe2+ to form OH·. These OH· could then react with L-Tyr to form L-DOPA or 
other hydroxylation products. Consequently, some of reported that ferrous 
ammonium sulfate does not stimulate TyrH in the presence of catalase or 
peroxidase.100 It is important to note that Fe2+ is typically added immediately 
before the activity assay is initiated. Therefore, reports of Fe2+ incorporation are 
rarely measured. One study examined the increase in specific activity and the 
extent of dopamine binding for TyrH at varying ferrous ammonium sulfate 
concentrations.101 TyrH (0.4 Fe/subunit) was incubated at 10 µM ferrous 
ammonium sulfate (the concentration typically used in activity assay).  Excess 
ferrous ammonium sulfate and dopamine were subsequently removed by gel 
filtration. After removal of excess ferrous ammonium sulfate, there was only a 
30% increase in activity and a 50% increase in dopamine binding.  In contrast, if 
there were full iron incorporation into TyrH, a 2.5-fold increase in both activity 
and dopamine binding would be expected given the initial 0.4 Fe/subunit 
metalation. Therefore, Fe2+ may not be readily incorporated into full-length TyrH.  
TrpH 
 The activity of TrpH is measured fluorometrically by the detection of 5-
hydroxytryptophan using an excitation wavelength of 295 nm and an emission 
 




wavelength of 540 nm102,103 or excitation at 270 nm and an emission wavelength of 
310 nm.104 Similar to TyrH, Fe2+ is typically added to stimulate the activity. 
Therefore, like TyrH, addition of Fe2+ to reduced pterins could likewise induce 
the formation of OH· artificially increasing the apparent activity for TrpH. 
Additionally, the fluorometric measurements are typically performed using 
fixed-time assays. The use of fixed time assay may obscure any lag or burst in 
activity that may occur in early time periods of the assay. Current studies 
underway by Cynthia Ibarra in the Caradonna lab are being done to develop a 
continuous assay by using the differential extinction coefficient between 5-HTP 
and L-Trp. 
Allosteric Activation 
First reports that PheH undergoes allosteric activation by L-Phe came in the 
late 1960s.105,106 These studies revealed a short lag period for the activity of PheH 
when performing an activity assay.105,106 This lag period could be abolished by 
pre-incubation with L-Phe prior to the addition of pterin coenzyme suggesting 
that L-Phe acts as a positive allosteric effector. Later studies showed L-Phe 
activates PheH in a cooperative manner (Hill coefficient=2.3-2.6).25,52,76,107,108  In the 
absence of allosteric activation, wtPheH has <1% of the activity of fully activated 
PheH.52 However, it is not clear whether this residual activity is intrinsic to the T-
 




state of PheH, a result of a high background associated with the assay used, or a 
result of a small population of the enzyme present in the R-state. In addition to 
the increase in specific activity, PheH allosteric activation induces a 
conformational change that increase the tetrameric hydrophobicity,2 a 
bathochromic shift (8-10 nm) in the fluorescence peak maximum,25,109 an increase 
in hydrodynamic radius,25 alteration in the exposed surface dependent 
hydrogen-deuterium exchange profile,110 and a shift in the dimer-tetramer 
equilibrium to favor a tetramer structure.106,111 However, despite several decades 
of investigation into the allosteric nature of PheH, a consistent activation 
mechanism as well as the intimate details for the chemical basis for the increase 
in activity remain elusive.  
This section will present a current summary of our understanding of the 
allosteric activation process with regards to i) the potential relationship of the 
ACT-like domain found in PheH with analogous domains found in other 
enzymes that has guided many initial studies of the PheH regulatory behavior, 
ii) the structural location and functional implications of the allosteric site on the 
activation process, iii) the various models put forth to describe the regulatory 
behavior of PheH, and iv) the commitment to catalysis the explains the chemical 
basis for the regulation of catalytic activity upon allosteric activation. 
 




Relationship to ACT domain containing enzymes 
The regulatory domain of PheH contains a canonical βαββαβ fold (residues 
35-110) characteristic of an ACT domain.112 The presence of this ACT domain is 
one of the characteristics that has guided many of the recent studies into the 
observed regulatory properties of PheH. The ACT domain is a protein fold often 
found in many enzymes involved in amino acid and purine biosynthetic 
pathways.18 Enzymes containing ACT domains exhibit complex allosteric 
regulatory processes that are allosterically controlled by amino acids. 
Consequently, PheH is presumed to behave in a manner analogous manner to 
ACT domain containing enzymes 3-deoxy-D-arabino-heptulosonate 7-phosphate 
synthase (DAH7PS), porphobilinogen synthase (PBGS), or phosphoglycerate 
dehydrogenase (PGDH). Active site access (and therefore activity) of these 
enzymes is proposed to be modulated by allosteric regulation with the allosteric 
effector binding occurring at the dimeric interface of two ACT domains.22,113   
 DAH7PS is an ACT domain containing enzyme that is allosterically 
controlled by the negative allosteric effector L-Tyr. The crystal structure of the 
DAH7PS L-Tyr free state is shown in Figure 1.5. In the L-Tyr free structure, there 
is open access to the active site. However, in the L-Tyr bound DAH7PS, the 
regulatory domain is rotated ~110° occluding access to the active. Therefore, it 
 




has been proposed that main function of allosteric activation is to regulate 
substrate access. In analogy to DAH7PS, allosteric activation in PheH is proposed 
to result in a 90° rotation of the regulatory domain and subsequent movement N-
terminal auto-inhibitory region away from the active site entrance.9,114,115  The 
current lack of a full-length crystal structure with well-defined electron density 
for the autoinhibitory region (residues 1-17) in both the T-state and R-state of 
PheH make assessment of the structural similarities of the regulatory role of the 
ACT domain challenging. However, early studies suggested that the regulatory 
domain is involved in controlling substrate specificity.37,116 DAH7PS catalyzes the 
first step in the shikimate pathway for aromatic amino acids. L-Tyr acts as an 
allosteric effector and binds at the dimeric interface between two ACT domains. 
The bound form of DAH7PS adopts a closed active site conformation thought to 
restrict active site access and therefore inhibit the enzyme. 
Despite apparent similarities of the N-terminal ACT domain of PheH to other 
ACT domain containing enzymes, there remain notable differences with respect 
to the ACT domain positioning and potential regulatory behavior. The effector 
binding site in other ACT domain containing enzymes occurs at the interface of 
two ACT domains(but in different binding motif),18 which typically are located at 
the C-terminal position (Figure 1.5) of the protein. In contrast, the ACT domain 
 




of PheH comprises the N-terminal regulatory domain of the enzyme.  
Furthermore, the effector induces a negative allosteric response whereas L-Phe 
behaves as a positive allosteric effector in PheH.7  These differences in behavior 
between PheH and the other ACT domain containing enzymes suggest that the 
ACT domain might behave differently in PheH compared to other enzymes of 
the ACT domain family. TyrH and TrpH, whose activities are not currently 
reported to be regulated by an allosteric activation mechanism, have also been 
reported to contain an ACT domain fold.16 The presence of an ACT domain fold 
in regulatory domain of all three AAAHs is interesting given the little sequence 
homology seen in the N-terminal regulatory domain and differences in their 
regulatory behavior (e.g. Only PheH has been reported to be allosterically 
activated by its substrate). However, the role of the ACT domain in the AAAHs 
is not yet fully understood and whether it behaves in an analogous manner to 
other ACT domain enzymes remains under investigation. 
Location of the allosteric site 
 The exact location of the allosteric binding site in PheH remains a topic of 
intense interest and debate.  The absence of any reported structural data of the L-
Phe activated form of PheH has left investigators to use indirect biochemical and 
computational methods to determine the location of the allosteric site.  
 




Consequently, evidence was presented and interpreted to support a variety of 
proposed locations for the allosteric sites of PheH (Figure 1.20). First reports of 
an L-Phe binding site distinct and non-overlapping from the active site came 
from gel filtration studies117 and  14C pulse-chase118. An early gel-filtration study 
found that in the presence 3.3 mM tryptophan(which binds to the active site, but 
not allosteric site) 75 PheH was still able to bind 1 mole of [14C]phenylalanine per 
subunit of The 14C pulse-chase showed that when PheH is first incubated in [14C]-
phenylalanine, an amount of [14C]-phenylalanine equal to the concentration of 
PheH remained unavailable for hydroxylation under standard activity assay 
conditions.  These studies indicated that there is one allosteric site/subunit of 
PheH. However, another study which measured the binding of L-Phe to PheH by 
deposition ultrafiltration suggest 1.5 molecules of PheH bound/subunit of 
PheH.119 Here, a two-site model was used to explain the non-integral 
stoichiometry whereby one L-Phe binds to each active site of a monomer (as 
substrate) and two monomers of a dimeric structure, formed from dissociation of 
the tetrameric form PheH associate to form a single allosteric binding sites before 
reforming the homotetrameric quaternary form of the enzyme.120 Identification of 
the allosteric site location has remained elusive because of a lack of full-length 
crystal structures containing L-Phe.  Attempts to crystallize full-length wtPheH 
 




in the presence of L-Phe resulted in no observed electron density for bound L-




Figure 1.20 Proposed locations for the allosteric site A) Interface of the regulatory and 
catalytic domains at residues 42-47 B)Residues 44,47,48 and 62,64,and 65, C) Residues 
110-120 and 312-317 
 




 Multiple groups have proposed a range of allosteric site locations. One of 
the first proposed locations for the allosteric site came from analysis of a crystal 
structure of PheH containing the regulatory domain. Kobe et al. suggested that 
the allosteric occurs at the interface between the regulatory and catalytic domain 
based on the crystal structure of PheH1-429 .7 This site was suggested based on the 
similarity between the regulatory domain of PheH1-429 and the corresponding 
regulatory domain in the ACT domain containing enzyme phosphoglycerate 
dehydrogenase (PGDH) which is allosterically regulated by serine  (Figure 1.21). 
Figure 1.21: Alignment of part of the regulatory domain of PheH ( 2phm.pdb shown in 
grey) with part of the regulatory domain of PGDH (1PSD.pdb shown in orange). The 
structural homology between the two domains led Kobe et al. to propose that the 
allosteric site effector site of PheH occurs in this region 
 




 A series of studies have suggested that PheH binds at the dimer interface 
between two ACT domains on adjacent PheH subunits (Figure 1.20B).10,115,121–123 
Given the presence and defined mechanism of action of the ACT domain 
reported for other enzymes, it was believed PheH would follow a similar 
mechanism. Using this rationale, the ACT domains on adjacent subunits would 
reorganize to allow for dimerization and formation of the putative allosteric 
binding site. Towards this end, a series of studies were performed with PheH1-117 
and PheH25-117, a construct of PheH containing just the regulatory domain minus 
the first 24 apparently non-structured residues. This study used analytical 
ultracentrifugation (AUC) to measure the sedimentation coefficient as a function 
of both PheH1-117 concentration and L-Phe concentration. This study suggested 
isolated regulatory domains exist in monomer-dimer. This study suggested that 
the Kd of L-Phe for binding to the dimer was 8.3 µM (assuming equal affinity for 
each L-Phe molecule for the dimer).123 The reported binding constants for the two 
L-Phe are ~80 times smaller than the reported Kd of L-Phe in the allosteric site for 
wtPheH determined by SAW and ~15 times smaller than the reported affinities 
reported by other methods. Another study which measured the [L-Phe]-
dependent change in mid-q scattering for R70K, a mutant unable to bind L-Phe 
in the active site found a midpoint of transition at an L-Phe concentration of 370 
 




± 35 μM.10 Another study using E280K measured the change in fluorescence as a 
function of L-Phe and determined a Kd of 320±20 µM. The large discrepancy 
between the reported Kd values could be interpreted as either the binding site in 
the regulatory domain takes on an altered conformation in wtPheH resulting in 
altered affinity of the regulatory domain for L-Phe or that the binding of L-Phe to 
the isolated regulatory domains is not relevant as L-Phe could bind to an 
alternate site on PheH.  Regardless, this was the first study to demonstrate the 
ability for the isolated regulatory domain to both dimerize and bind L-Phe. 
 A later study from the same laboratory used 1H−15N HSQC, AUC, and 
fluorescence studies to probe the specificity of amino acids binding to the 
isolated regulatory domain of PheH.121 This study assigned resonances in the 
1H−15N HSQC associated with the formation PheH25-117 dimers by looking at the 
spectral changes that occur at increasing concentration of PheH25-117 dimers. The 
authors then examined the changes that occur in the 1H−15N HSQC spectrum 
upon the addition of various amino acids. The authors also determined if these 
amino acids were able to bring about the same changes in sedimentation 
behavior, activation in activity, and change in fluorescence in wtPheH as L-Phe 
did. They found amino acid specificity for the stabilization of regulatory domain 
dimers correlated with the activation in activity and change in fluorescence that 
 




are indicated of allosteric activation in wtPheH. Several things should be noted 
about this study. The authors attempted to compare change in fluorescence upon 
L-Phe binding to that of other amino acids as a probe for activation. However, 
the change in fluorescence is a result of L-Phe binding to both the active and 
allosteric site.124 Additionally, as other have demonstrated using [2,5-H2]-L-Phe, 
certain compounds can induce a change in fluorescence without the concomitant 
increase in activity.72 Lastly, the change is fluorescence does not correlate well 
with the fold-increase in activation. For example, D-Phe causes same fold-
activation (7-fold increase) at 10 mM as does L-Phe (6-fold increase) at 1 mM. 
However, D-Phe only induces about half the maximal change in fluorescence at 
10 mM as L-Phe does at 1 mM.121 Therefore, there is not necessarily a relationship 
between amino acids that can stabilize the regulatory domain dimers and those 
that activate PheH. 
 NOESY-HSQC NMR experiments with PheH25-117  identified E44, A47, L48, 
L62, H64, and I65 as residues involved in binding of L-Phe in PheH25-117 (and 
presumably full-length wtPheH).122 A crystal structure of a regulatory domain 
homo-dimer corroborated these findings .115 The authors were not able to 
crystallizePheH1-118. Instead a tryptic digest was used to flexible regions to 
facilitate crystallization to yield PheH19-118 that were grown in 10 mM L-Phe. The 
 




dimer interface contained hydrogen bond interactions between regions E43-L48 
and N61-S67. This crystal structure suggested that the L-Phe binding site is 
composed of ExVxAL (residues 43-48) and YxF (residues 77-79) on one subunit 
and NLTIxS (residues 61-66) on another subunit.    
 In contrast, hydrogen-deuterium exchange (HDX) mass spectrometry 
experiments showed an increase in hydrogen-deuterium exchange for this region 
(residues 39-59)upon addition of L-Phe to wtPheH,110 counter to what might be 
expected as dimerization of domains should decrease the solvent accessibility of 
the interface and thus the hydrogen-deuterium exchange. An additional 
challenge arises from attempts to reconcile the proposed allosteric site with full-
length crystal structures where the regulatory domain for wtPheHT[ ] state must 
be rotated 90° in order to form this putative allosteric site. Here, the dimers rotate 
such that two of the subunits interact to form an allosteric site that can bind two 
molecules of L-Phe. However, this model also proposes that the remaining two 
subunits are not able to form an allosteric site that can bind L-Phe.  This type of 
allosteric mechanism appears to be inconsistent the behavior of other ACT 
domain containing enzymes that typically bind their effector molecule in a one to 
one ratio of effector to enzyme subunit (Figure 1.5). 
 




 Studies from the Caradonna lab have suggested L-Phe binds at residues 
110-120 and 312-317 (Figure 1.20C).124 This site was determined using a 
combination of ligand docking simulations and mass spectrometry analysis 
using photo crosslinking studies with 2-azido-3-phenylpropanoate (azido-L-
Phe).  FTMap protein mapping algorithm was used on monomeric PheH to 
identify three potential sites. Of these sites, one site containing residue 113-119 
was chosen for further study based on sequence conservation across different 
mammalian PheH and number of associated probe clusters. To further define the 
putative allosteric site, azido-L-Phe was used to allosterically activate PheH. UV-
light was used to photo-activate a Cα-based nitrene radical that would covalently 
crosslink to nearby residues. PheH was then digested with α-chymotrypsin and 
mass spectrometry analysis. Mass spectrometry results revealed a fragment 
(residues 110-120 (SRDKEKNTVPW) with a mass/charge of 1361.1 m/z) 
corresponding with photo-crosslinked azido-L-Phe supporting assignment of 
these residues as being involved in forming the allosteric site. This site occurs at 
a hinge region thought to be important for the allosteric activation. In this case, 
each subunit is able to bind one L-Phe effector molecule consistent with previous 
studies suggesting that there are four activation sites in a PheH tetramer.117,118  
 




Allosteric Activation Models 
Despite several decades of research, there is no consensus model for the 
allosteric activation mechanism for PheH. How L-Phe binding interacts with 
PheH remains controversial in terms of the stoichiometry of L-Phe effector 
molecules to PheH subunits and whether the cooperative unit of PheH is a dimer 
or tetramer. Additionally, there is no consensus as to whether binding of L-Phe 
triggers the T→R transition or if L-Phe binds to the R-state of PheH and 
consequent stabilizes the activated form.  The differing models of allosteric 
activation with respect to these questions will be discussed below. 
Shiman Model 
An initial model proposed by Shiman et al. that considers both the allosteric 
role of L-Phe and the inhibitory role of BH4 is shown in (Figure 1.22). In this 
model, binding of L-Phe to the T-state triggers the T→R transition and stabilizes 
the R-State whereas binding of BH4 stabilizes the T-state. This model is based on 
an assumption that each protomer of PheH contains both an active site and an 
allosteric site that is distinct from the active site.107,117 In this model, binding of L-
Phe to the allosteric site induces the T→R transition to kinetically trap PheH in 
the R-state i.e. L-Phe decreases the rate of the R→T conversion118,124,125. This type 
of behavior is characteristic of a hysteric protein126 such as DAH7PS127.  This 
kinetic trapping phenomenon of R-state PheH was supported by Surface 
 




Acoustic Wave (SAW) biosensing studies from the Caradonna lab. Here, there 
was a shallower dose-response curve under de-escalating L-Phe concentration 
compared to escalating L-Phe concentrations.124 Additionally, Shiman et al. 
studied the rates of R→T conversion by measuring the change of fluorescence 
upon diluting wtPheHR[L-Phe] in varying L-Phe concentration. Upon the T→R 
conversion, PheH experiences a shift in fluorescence emission to longer 
wavelengths. The authors examined the change in fluorescence upon diluting 
wtPheHR[L-Phe] low concentrations of phenylalanine. As wtPheHR[L-Phe] is 
diluted into lower concentration of L-Phe, L-Phe is released from the allosteric 
site inducing the R→T conversion resulting in an increase in fluorescence 
emission at 313 nm. The authors then modeled the increase in fluorescence vs 
time to either a dimer-concerted, dimer-sequential, tetramer-sequential, or a 
general-concerted kinetic model. They were able to demonstrate that the T→R 
conversion involves cooperativity between all four subunits and that the 
cooperative unit of PheH is the tetramer.118 However, it should be noted that the 
dimer-tetramer equilibrium for PheH was not taken into account when modeling 
the fluorescence data. Reported Hill Coefficient of 2.4-2.61,25,124  based on SAW 
biosensing measurements, changes in fluorescence peaks maxima, and specific 
 




activity also support a model that involves the interaction of more than two 
subunit.e  
 
While the Shiman model proposes the cooperative unit is a tetramer, the data 
has not allowed the differentiation between a concerted (MWC) and a sequential 
model (KNF). In a concerted model, PheH would be in rapid equilibrium 
between a state where all the site are activatable and a state which none of the 
 
e The Hill coefficient represents the degree of cooperativity and the minimum estimate of ligand 
binding sites259 and it is important to note the Hill coefficient only represents the number of 




Figure 1.22 Shiman model for the allosteric activation of PheH by both L-Phe and BH4 
 




sites are activatable.1 In a sequential mechanism, binding of the first L-Phe 
molecule to PheH causes the subsequent binding of L-Phe to the other protomer 
to occur more quickly.1 The kinetic trapping of the R-state as described by this 
model would increase the efficiency of PheH by decreasing the rate of 
inactivation without affecting the apparent Kd.118 This type of behavior is 
consistent with the role of PheH as a clearance enzyme. It should be noted that in 
both the SAW biosensing and fluorescence studies that measured the 
conversation for the T→R and R→T transition were done in the absence of BH4 a 
negative allosteric effector (unlike the commonly used 6-MPH4 coenzyme). 
Under physiological conditions, BH4 is thought to always be present in the active 
site.125,128 Thus, it would be interesting to examine the role of BH4 on the kinetic 
trapping of PheH.   
Morpheein Model ACT model 
More recently, a morpheein model114 was proposed in which PheH exists as 
in inactive tetramer that is unable to perform catalysis because of the auto-
inhibitory region (first ~30 N-terminal residues ) of PheH blocking access to the 
active site.9,114 This model proposes that the fundamental difference between the 
T-state and the R-state lies in active site access.114 A proposed 90° rotation 
between the regulatory and catalytic domains allows for the formation of the 
 




allosteric site. This rotation also displaces the autoinhibitory region so that it no 
longer occludes the active site. The rotation is achieved by dissociation of the 
inactive tetramer to form inactive dimers that then undergo a conformational 
change to form active dimers, which associate to form an active tetramer. 
Dimerization of the ACT domain and subsequent formation of the active 
tetramer induces formation of the allosteric site. Finally, binding of L-Phe at 
newly formed allosteric site stabilizes the active tetrameric form. The observation 
of two distinct bands in a native PAGE gel that correspond to a tetramer have 
been used to support this model.114 However, the two bands are of 
approximately equal intensity suggesting that in the absence of L-Phe the T-state 
and R-state exist in equal populations. However, it is generally agreed that in the 
absence of L-Phe, PheH remains >99% in the T-state. Another rationale for this 
model is based on the presence of the ACT domain.114 Specifically, PheH has 
been proposed to follow a similar allosteric regulatory mechanism as 3-deoxy-D-
arabino-heptulosonate 7-phosphate synthase (DAH7PS) (see above).  In short, 
binding of L-Phe stabilizes a PheH tetramer that has open access to the active 
site. As such, this model proposes that fundamental cause for the increase in 
activity is largely driven by substrate access to the active site and not any change 
in the active site properties per se.114   
 




While the morpheein model has been mainly supported by structural 
homology with other ACT domain enzymes, the morpheein model is 
inconsistent with several spectroscopic and biochemical studies. The morpheein 
model suggest that in the T-state, the autoinhibitory region occludes access the 
active site. However, both wtPheHT[5-deaza-6-MPH4] and wtPheHT[L-Phe] show 
distinct MCD/XAS12,13 and EPR spectrum (Chapter 3) from wtPheHT[ ] 
suggesting binding of substrate and coenzyme to the T-state. Also, Surface 
Acoustic Wave (SAW) biosensing and fluorescence studies form the Caradonna 
Lab observed two binding events for L-Phe—one occurred ~150 µM( the Km for 
L-Phe) and the second occurred ~850 µM).124 These results suggest L-Phe binds in 
the active site before binding to the allosteric site. Additionally, several chelators 
are known to bind to the ferrous and ferric iron center of the T-state of PheH 
including o-phenanthroline129,catechol39, dopa,59 2,3-dihydroxynaphthalene 
(DHN),31 bathophenanthroline,31 acetylacetone,59 acetohydroxamate,59 
benzohydroxamate59 and a non-chelator linoleic hydroperoxide has also been 
shown to bind to the active site of the T-state of PheH.130 Association rate 
constants for DHN (4.3x 105 M-1s-1) and bathophenanthroline (0.7x108 M-1s-1) are 
very rapid (and in the case of bathophenanthroline, diffusion controlled) 
suggesting that access to the active site of wtPheHT[ ] is not hindered.59 However, 
 




one study examined the binding of catecholamines to wtPheH, PheH118-452 and 
R280K by measuring the change in absorbance at 700 nm reported. 131 This study 
a ~2-3 fold enhanced rate of catecholamine binding to PheH118-452 compared to 
wtPheH.131 The authors suggest that enhancement is a result of removing the 
autoinhibitory region blocking the active site. However, an alternate 
interpretation is that removal of the regulatory domain alters the primary 
coordination sphere of PheH and make the iron center more labile.  These 
spectroscopic and biochemical studies suggest access to the iron center is not 
inhibited in the T-state of PheH. 
Non-dissociative ACT model 
Another closely related model to the Morpheein model was proposed by 
Fitzpatrick et al. Like the Morpheein model, this model proposes that L-Phe 
binds at the dimeric interface between ACT dimers which form the allosteric 
binding site. This dimerization of the ACT domain allows for enhanced substrate 
access to the active site as well as allow for the movement of Y138 to form the 
active site. This model proposes that the T→R conversion occurs by rotation of 
the ACT domain to undock the N-terminal autoregulatory region from occluding 
the active site. However, using 1H-1H TOCSY, Horne et al. demonstrated that the 
peaks associated with the N-terminal region decreased upon L-Phe binding 
 




suggesting that this region becomes less mobile upon allosteric activation.23 The 
main difference between this model and the Morpheein model is that while the 
Morpheein model requires the dissociation of tetrameric PheH dimers to 
facilitate the dimerization of the ACT domain, this model requires no such 
dissociation mechanism.  This model proposes a non-dissociative pathway in 
which PheH adopts an expanded conformation in the tetrameric state that allows 
for the domain rearrangement required for activation. SAXS studies have shown 
that no dimeric intermediate present in the allosteric transition process.10 
Additionally, this model proposes two molecules of L-Phe bind per tetramer in 
the allosteric site. Here, the ACT domain on two PheH subunits of a tetramer 
dimerize to form an allosteric binding site capable of binding two L-Phe 
molecule. However, the remaining two subunits do not form an ACT 
homodimer in way to bind L-Phe (based on the current reported structures). 
Another study which modeled the change in fluorescence upon binding of L-Phe 
to E270K (a mutant unable to bind L-Phe in the active site) using stop-flow 
spectrometry.132 The authors claim the fluorescence traces were best fit a model 
where E270K undergoes a conformational change followed by binding of two L-
Phe molecules. However, the L-Phe induced change in fluorescence is 
complicated process involving the three tryptophan residues. Specifically, 
 




binding of L-Phe in the allosteric site causes changes in fluorescence of W187 and 
W326. The changes in the fluorescence of multiple tryptophan residues does not 
appear to be considered in any of the model proposed in this study. 
 This proposal is inconsistent with both gel filtration and 14C pulse chase 
experiments which demonstrated PheH binds four molecules of L-Phe per 
tetramer in the allosteric site.  This allosteric model is also inconsistent with other 
ACT domain containing enzymes which can bind their effect molecule in a 1:1 
ratio of effector molecule: subunit.  Additionally, both 14C-L-Phe gel filtration and 
pulse-chase experiments have demonstrated one L-Phe molecule binds/subunit. 
Lastly, one study using unphosphorylated and phosphorylated E270K PheH, a 
mutant the cannot bind L-Phe in the active site, after the conformation change 
based on examining the change in fluorescence as a function of time upon mixing 
E270K with varying concentrations of L-Phe .132  
There are two key differences between the model proposed by Shiman et al. 
and similar Morpheein model and that proposed by Fitzpatrick et al. Shiman et 
al.  proposes binding of L-Phe induces a conformation change from the T→R 
state. However, the non-dissociative ACT model proposes that PheH exist in a 
dynamic equilibrium and L-Phe can only bind to the allosteric site after the T→R 
 




transition has already occurred. Second, the Shiman model proposes four 
molecule of L-Phe binds/ tetramer in the allosteric site115 while the non-
dissociative ACT model suggest 2 molecules of L-Phe bind per tetramer in the 
allosteric site. Support was given for two molecules binding in the allosteric site 
per tetramer using a reported Hill coefficient of 2. However, the number of 
ligand bindings sites is only equal to the Hill coefficient when dealing with a 
system that has infinite positive cooperativity. The Shiman model is supported 
by both gel filtration117 and 14C pulse chase studies.107 A study using deposition 
ultrafiltration suggested 1.5 L-Phe molecule bound per subunit119 which would 
be consistent with the previously described model. as it would suggest a total of 
6 molecules of L-Phe can bind to one tetramer of PheH (four in the active site and 
two in the allosteric site).  
 Lastly, others have proposed that PheH is not allosterically activated but 
instead is regulated by homotropic binding of L-Phe at the catalytic site133–135 and 
that L-Phe does not bind to the regulatory domain.133 DSC studies which 
examined the thermal denaturation of PheH were used to come to this 
conclusion. 133 These studies showed two irreversible processes that the authors 
interpreted as corresponding to the unfolding of the four regulatory domains 
and two of the four catalytic domains. The authors concluded that L-Phe was not 
 




released upon denaturation of the regulatory domain and therefore did not bind 
to the regulatory domain. However, the DSC studies used an irreversible process 
(i.e. denaturation) to probe equilibrium thermodynamics. However, it is 
generally accepted that DSC can only make meaningful measurement for 
reversible process.136,137 Therefore, the results these DSC studies are difficult to 
interpret. Another study reported cooperative homotropic binding to the active 
site by examining the binding of noradrenaline to the active site using 
microdialysis and ultrafiltration methods.138 Noradrenaline binds to the active 
site but not the allosteric site, therefore the resulting cooperative homotropic 
interaction was solely a result of noradrenaline binding to the active site. 
However, noradrenaline binds by coordinating to the iron center directly in a 
bidentate manner (like catechol) whereas L-Phe binds in the active site by 
intermolecular interactions with the PheH scaffold (Figure 1.13). Therefore, 
direct comparisons between the binding behaviors of noradrenaline and L-Phe 
are difficult to make. Another study that examined the binding of dopa to PheH 
found no cooperativity in the binding isotherm.59 Additionally, cooperative 
homotropic binding of L-Phe to the active site would require that BH4 and L-Phe 
act as competitive inhibitors.139 However, this type of behavior has never been 
demonstrated in PheH. Lastly, multiple studies have suggested more than one L-
 




Phe binds per subunit.117–119,124 Therefore PheH is likely not regulated by 
homotropic binding of L-Phe to the active site, but rather allosteric binding of L-
Phe to the allosteric site   
Commitment to catalysis 
Allosteric activation by L-Phe is the central physiologically relevant 
regulatory mechanism for PheH. The most important consequence of the T→R 
transition is the increase in enzyme specific activity.52,105 Other changes include 
an increase in hydrophobicity2, a shift in fluorescence peak maximum with the 
dominant fluorescence shifts occurs from Trp120, which is substrate binding in 
active site,25,109 increase in hydrodynamic radius,25 and alteration in the extent of 
hydrogen-deuterium exchange indicative of structural changes induced by 
activation.110 While these structural change are characteristic of allosteric 
activation, PheH can experience some of these structural changes (e.g. increase in 
fluorescence peak maximum) without experiencing a concomitant increase in 
activity such as  what is seen when using [2,5-H2]-L-Phe.72 Therefore, evidence of 
these features is not necessarily indicative of an activated state. Importantly, 
none of these changes can directly explain why the T-state in inactive and the R-
state active.  Thus, one of the central questions regarding the allosteric activation 
 




process is understanding the chemical basis of the increase in activity and how 
these structural changes relate to the allosteric activation process.  
Studies from the Caradonna lab have proposed two reasons for this increase 
in specific activity that act in concert to increase the catalytic activity.  The first 
involves the repositioning or reorienting of the tetrahydrobiopterin coenzyme to 
a position that fully supports coupled oxidation of L-Phe to L-Tyr via a high 
valent iron-oxo reactive intermediate with coenzyme utilization.  A second 
potential reason involves an observed increase in the accessibility of gaseous 
molecules to the iron center.  Physiological oxidation state of Fe is not fully 
defined, but if pterin is present, then should be Fe (II) necessary for catalysis.  
PheH cycles ≈ 250-300 times before Fe (II) adventitiously oxidizes to Fe (III) and 
requires reduction to proceed.  NIH shift consistent with oxygen atom transfer 
chemistry from Fe (IV)=O, state other evidence here.  When physiological levels 
of L-Phe are lowered, loss of allosteric site binding and conversion of R-state 
back to inactive T-state, shutting down L-Phe conversion to L-Tyr allowing for 
baseline levels of L-Phe required for protein synthesis. Pulsed EPR studies using 
a deuterated non-redox active coenzyme analog (Chapter 2) and stopped-flow 
studies measuring the rate of pterin oxidation (Chapter 5) in the protein scaffold 
of PheH. 2H-ESEEM studies using 5-deaza-6-MPH4 have demonstrated that upon 
 




allosteric activation, the C5 proton moves 1.8 Å closer to the iron center. The 
repositioning of the pterin coenzyme closer to the iron center would make the 
formation of the Fe-OO-pterin adduct. Additionally, the new position might 
cause the pterin coenzyme to experience a change in dipole field altering its 
reactivity with O2.  Given that the rate of catalysis (10-20 s-1) is much faster than 
the buffer rate of tetrahydropterin and O2 (0.6 ±0.03 M-1s-1)32, the active might alter 
the reactivity of the C4a positioning through hydrogen bonding network with 
N5 position of the pyrazine ring. Studies examining both the rate of 6-MPH4 
oxidation and oxygen consumption indicate a parallel increase in both values 
when using wtPheH activated by lysolecithin in the absence of substrate. These 
studies suggest the active site modulate the reactivity of the pterin coenzyme 
with O2. 
An increase in gaseous accessibility has also been implicated in influencing 
the catalytic activity of PheH. Stopped-flow studies examining the formation of 
an Fe-NO adduct showed that the kobs for the rate of Fe-NO increased ~25-fold 
upon allosteric activation suggesting increased accessibility to the active site.39 
However, similar NO binding studies on PheH118-428, which lacks the regulatory 
domain and autoinhibitory region show slow rates of NO binding (kobs= 32±1.5 s-
1) in the absence of substrate. However, upon substrate binding there is a large 
 




increase in the rate of NO binding (285 ±20 s-1).39 As mentioned previously, 
enhanced access to the active site has been proposed to allow for the increase in 
activity seen upon the T→R.9,10,114 The enhanced substrate access is thought to 
occur by movement of the autoinhibitory region of PheH away from the active 
site. Given that PheH118-452 (which lacks the autoinhibitory region) exhibits slow 
NO binding until substrate is bound, it is unlikely that the autoinhibitory region 
blocks substrate access. Instead, allosteric activation could induce formation of a 
gas channel facilitating access of O2 into the active site.   
The chemical basis for the increase in specific activity upon the T→R 
conversion likely has many components. The presence of the ACT domain raises 
the possibility chemical basis for the increase in activity might be analogous to 
other ACT domain contain enzymes i.e. substrate access drives the change in 
specific activity.  However, there is no direct evidence to support this conclusion 
or that the PheH behaves analogously to other ACT domain containing enzymes. 
To our knowledge, there have been no direct measurements of the binding of L-
Phe or BH4 to the active site in either the T- or R-state. In fact, metal chelators 
bathophenanthroline and DHN can bind to the iron center at or near a diffusion 
controlled manner59, suggesting unhindered access to the active site. However, 
studies from our lab have been able to directly measure the change in orientation 
 




of the pterin coenzyme (Chapter 2), reactivity of the pterin coenzyme (Chapter 5) 
and gaseous accessibility to the iron center upon the T→R suggesting that these 
components likely play an important role for explaining the chemical basis for 
the increase in catalysis upon allosteric activation.  
BH4 
 The natural coenzyme for PheH (and also TyrH and TrpH) is (6R)-
erythro-2,3-dihydroxypropyl tetrahydropterin (BH4).140,141 Several other pterin 
coenzymes are able to be substituted for BH4 including 6-MPH4 and 6,7-DMPH4 
in catalysis and reduction of the AAAHs (  Figure 1.23). The coenzyme has three 
roles—i) reduction of oxidized PheH to its catalytically active reduced form ii) 
coenzyme in the catalytic reaction iii) as a negative allosteric effector for the 
enzyme.125 Each of these roles will be discussed below. 
 





  Figure 1.23 Different Reduced pterins commonly used in the study of PheH 
Role as a reductant 
As isolated, PheH remains in the oxidized state with a ferric iron center and 
must be reduced to achieve a catalytically active state.29,142 The pterin coenzyme 
can serve as a reductant, however, the stoichiometry of pterin enzyme is O2 
dependent. One study determined that under aerobic conditions, 0.95±0.1 
equivalents of 6-MPH4 is oxidized per PheH subunit by measuring the change in 
fluorescence of PheHT that occurs upon reduction by 6-MPH4.29 However, under 
anaerobic condition 0.5 equivalents of 6-MPH4 was oxidized per PheH subunit.143 
An early study reported that under anaerobic conditions, the rate of 6-MPH4 
oxidation was <5% than under aerobic condition when coupling 6-MPH4 to 
 




NADH oxidation using DHPR.29 The authors interpreted these results to suggest 
that O2 is somehow involved and necessary in the reduction step. However, 
studies from the Caradonna lab measured that the increase in fluorescence upon 
PheH reduction by 6-MPH4 under anaerobic conditions.143 Under these 
conditions it found that the stoichiometry was 0.66 reducing equivalence/subunit 
when using PheH containing 0.75 Fe/subunit. Therefore, O2 is not required in the 
reduction of PheH. 
Reduced pterins act as two-electron donors. While one of these electrons 
reduces the Fe(III) center to Fe(II), the fate of the second equivalent remains 
controversial. H2O2 was not detected in the reduction of PheH by 6-MPH4,29,130 
suggesting that O2 does not accept the electrons from 6-MPH4. Some have 
proposed the second electron equivalent reduces a disulfide bond.143 Support for 
this proposal comes from studies demonstrating the number of reactive thiols 
changes upon addition of 6-MPH4.143 However, the specific cysteine residues 
involved in the putative disulfide are not yet known. Identification of the 
electron acceptor is important for the understanding of the mechanism of 
reduction for PheH. 
 




Role as an allosteric inhibitor 
The second role of BH4 is that of an inhibitor for the allosteric activation 
process. When L-Phe is added last to an otherwise complete standard activity 
reaction mixture using BH4 as a coenzyme, there is 3-4 minute delay before the 
activity reaches a steady state.125 In contrast, when 6-MPH4 is used instead, the 
lag is only several seconds. Consequently, the erythro tail seems to be required 
for the inhibitor effects since 6-MPH4 does not inhibit the T→R conversion.125 The 
erythro tail likely interacts with the autoinhibitory region of PheH since 
constructs lacking this region (PheH30-428)  do not experience inhibition by BH4.144 
This finding was further supported by a study that determined that the specific 
activity when using 6-MPH4 was 1.4 times greater than when using BH4 when 
assayed with PheH27-452.145 Because BH4, but not 6-MPH4, inhibits the activation of 
PheH, 6-MPH4/BH4  activity ratio is often used to express the extent of apparent 
activation of PheH. A 6-MPH4/BH4 ratio of 1.4 suggest that PheH27-452 does not 
experience allosteric inhibition by BH4. In contrast, wtPheH had a 6-MPH4/BH4 
ratio of 27.8145 suggesting that the N-terminal residues are involved in the 
interaction with BH4 to bring about allosteric inhibition 
In addition to inhibiting the T→R conversion, BH4 also appears to affect the 
activation of PheH by alternate activators as well as influence the 
 




phosphorylation/dephosphorylation behavior of PheH. Treatment with 
lysolecithin activates PheH to a functionally identical state as activation by L-Phe 
(vide infra). Similar to allosteric activation, BH4, but not 6-MPH4, also appears to 
inhibit the ability lysolecithin to activate PheH.52 On studied found that 30 µM 
BH4 decreases the rate of activation by lysolecithin 10-fold.52 The fact that BH4 can 
inhibit activation by both L-Phe and lysolecithin is interesting given that L-Phe 
and lysolecithin are structurally dissimilar and likely do not bind to the same site 
on PheH. Binding of BH4 also prevents the proteolytic cleavage of PheH by 
chymotrypsin.146 Additionally, BH4 also inhibits the phosphorylation ( by CAMP-
dependent protein kinase) and dephosphorylation( by phosphoprotein 
phosphatase) of PheH.147 Phillips and Kaufman showed that BH4 inhibited the 
phosphorylation of PheH by ~80%. Neither DMPH4 nor 6-MPH4 inhibit the rate 
of phosphorylation, while (6S)-erythro-2,3-dihydroxypropyl tetrahydrobiopterin 
inhibited the phosphorylation to a smaller extent than the natural R-
diastereomer. These results further emphasize the importance of the erythro tail 
on the inhibitor properties of BH4.  
One proposal has been given for the regulatory role for BH4 and its relation to 
L-Phe binding.125 Here, the physiological role of BH4 as a negative allosteric 
effector is to prevent depletion of L-Phe and to sequester BH4.The reported Kd of 
 




BH4 for the active site is 0.09 µM31 and the concentration of BH4 in the liver is 8-9 
µM. The high affinity for BH4 also allows PheH to sequester BH4 in the active site. 
Therefore, BH4 is likely to also be present in the active site of PheH. Because the 
Kd for the R-State is 14 µM, the 150>fold decrease in affinity could facilitate 
release of product. This sequestration process could prevent the unwanted 
reaction of BH4 and O2 which would create H2O2.  
Role as a coenzyme 
While both 6-MPH4 and DMPH4 can act as coenzyme in the catalytic reaction, 
BH4 has several distinguishing properties with regards to its role in the catalytic 
reaction with regards to observed KIE and inhibition behavior (Table 1.9) . When 
using per-2H5-L-Phe as a substrate, a KIE is observed for 6-MPH4 but not BH4.146 
While, both VH/VD and KH,L-Phe/KD,L-Phe were ~1 for BH4, when assayed with 6-
MPH4, these values were 1.45-1.50 when using either wtPheH, chymotrypsin 
treated PheH, or PheHlysolecithin.  Additionally, when another study used BH4 with 
para-methylphenylalanine as a substrate, more product was produced than 
NADH oxidized (0.75 moles NADH oxidized/mole of hydroxylated product) 
when using dihydropteridine reductase to regenerate the BH4 coenzyme.70  
However, the <1 NADH oxidized/mole of L-Tyr formed could be a result of the 
ability of DHPR to regenerate BH4 than an intrinsic property of PheH. Lastly, p-
 




CL-Phe will inhibit (KI 30µM) PheH when using BH4 as an coenzyme, but not 
when using 6,7-DMPH4.148 The reason for these differences is unclear since the 
pterin coenzyme does not directly interact with L-Phe substrate. One possible 
explanation is that binding of pterin coenzyme causes a subtle reorganization of 
the active site that influences the L-Phe position or interaction with PheH 










  Table 1.9 Kinetic constants for the AAAHs with respect to the specific pterin coenzyme 










(µmol product min-1 
mg-1) 
Coupling 
PheH (R)-BH4 23±2263,a 200 75,b 11.1145,c 1.0264c 
 6-MPH4 6125,d 17025,d 8-141,25d 0.98265d 
 DMPH4 101±14263,a 830±50263,a (17% of BH4)222a --- 
TyrH (R)-BH4 46101,e ----- 2.7266f -- 
 6-MPH4 37267g 42267h 250 min-1 g 1.0-1.111gh  
 DMPH4 ------ ------  1.75100i 
TrpH-1 (R)-BH4 3991j 22.891j 0.646 ± 0.04391j  88268,k 
 6-MPH4 56269 53197 ,7.3269  89268,k 
 7(R,S)-BH4 -- --  18268,k 
TrpH-2 BH4 
 
20.291j 77197 ,40.391j 0.194 ±0.007291j ------ 
 6-MPH4 119199 802197k 0.05178l ------ 
 DMPH4 130103 290103  ------- 
a Assay used 100 mM Tri-Cl(an competitive inhibitor for 6-MPH4)29 and measured the 
activity by spectrophotometrically by the measuring the A330 using ε=4350 cm-1M-1 
b Coupled assay using DHPR-NADH system. Initiated reaction by adding unactivated 
PheH to an otherwise complete reaction mixture 
c Coupled assay using DHPR-NADH system. Measured on PheH that had been 
preincubated with L-Phe 
d Activity measured by monitoring absorbance at 275 nm. 6-MPH4 was added last to an 
otherwise complete reaction mixture 
e Activity measured by the release of 3H2O, no ferrous ammonium sulfate was added 
f Activity measured by the release of 3H2O, 10 µM ferrous ammonium sulfate was added 
or by the colorimetric determination of DOPA 
g Activity was measured by colorimetric determination of DOPA, 10 µM ferrous 
ammonium sulfate was included in assay 
h Activity was measured by the 6-MPH4 oxidation, 10 µM ferrous ammonium sulfate was 
included in assay 
i Activity was measured by colorimetric determination of DOPA, no ferrous ammonium 
sulfate was added 
j Activity was measured fluorometrically by HPLC, 250 µM ferrous ammonium sulfate 
was included in the assay 
k Activity assay performed on crude COS7 lysates, with a final concentration of 20 µM 
ferrous ammonium sulfate. 5-hydroxy-L-Trp was determined by reversed phase HPLC 
using UV-Vis detection 
l Estimated from bar graph in reference 178 
 




Lastly, one study suggested BH4 binds to PheH in a cooperative manner.149 
However, this behavior was not seen in other studies that examined binding of 
BH4 to the active site.31,150–153 Interestingly, in the study reporting cooperative 
behavior, the putative cooperative binding of BH4 is seen even in PheH101-427 
which lacks the residues thought to interact with the erythro tail of BH4.  It 
should be noted that the fluorescence emission spectrum reported in the study 
was shifted towards longer wavelength (340 nm for T-State 351 nm for R-state) 
compared to previous reported fluorescence emission spectrum (335 for T-state 
and 343 for R-state).124 One possible explanation for the unusual binding 
behavior of BH4 and the fluorescence spectra is the use of maltose binding 
protein that was fused to the N-terminus. The maltose binding protein was used 
for purification and never removed from PheH in this study.149 
Relationship to TyrH and TrpH 
TyrH 
TyrH behaves differently to alteration in the pterin coenzyme structure 
compared to PheH. While PheH, has a higher specific activity when using 6-
MPH4 or DMPH4 compared to BH4, the activity of TyrH is equal to or greater 
when using BH4 compared to 6-MPH4 or DMPH4 (Table 1.9). Like PheH,154 TyrH 
appears to be sensitive to substitution of the 7 position of the pterin coenzyme. 
When using DMPH4, TyrH experiences uncoupling of the hydroxylation reaction  
 




with 1.75±0.15 mole of dihydropterin formed to moles of DOPA formed and 
1.60±0.05 when using 7-MPH4(Table 1.9).155 However, PheH can readily use 6,7-
DMPH4 without significant uncoupling of product formation to DMPH4 
oxidation. 
TyrH exhibits substrate inhibition with regards to L-Tyr however, the identity 
of the coenzyme also appears to play a role in the extent substrate inhibition by 
L-Tyr.156  Bailey et al. examined the kinetic of TyrH using a variety of mono and 
di-substituted pterins that were substituted at the 6 and 7 position.156 Of the 
pterin analogs used, only the two with hydroxyl group on a substituent on the 6 
position (R)-BH4 and 6-hydroxymethyl-PH4) showed substrate inhibition. When 
phosphorylated TyrH is assayed with 50 µM (R)-BH4 there is substrate inhibition 
> 20 µM L-Tyr. 156 Additionally, substrate inhibition is observed with 200 µM 6-
hydroxymethyl-PH4 at concentration of L-Tyr >100 µM. However, substrate 
inhibition was not seen using 6-MPH4, 6-ethyl-PH4, 6-Phenyl-PH4, 6,6-dimethyl-
PH4,6-ethyl-6-methyl-PH4, or 6-phenyl-6-methyl-PH4 for either phosphorylated 
or unphosphorylated TyrH.156 Another study using unphosphorylated TyrH 
reported substrate inhibition above 50-100 µM L-Tyr when using 1 mM (R)-BH4. 
Some have proposed that the role of substrate inhibition in TyrH serves to 
stabilize the TyrH reaction velocity and the dopamine stores in the brain.157 
 




Lastly, it is important to note that TyrH purified from bovine adrenal glands 
or PC12 cells can contain stoichiometric amounts of catecholamines.158 
Catecholamines are competitive inhibitors with respect to BH4 for all the 
AAAHs. Many of the earlier studies into these enzymes which used TyrH 
purified from natural sources reported Km for BH4 much higher than those for 
TyrH recombinant expressed in bacterial systems.  Since TyrH and TrpH are 
localized in brain where there are high concentrations of catecholamines, their 
inhibitory effect is physiologically relevant for TyrH and TrpH. Many earlier 
studies of TyrH were complicated by the presence of catecholamines that co-
purified with TyrH. 158 The dominantly used coenzyme for TyrH and TrpH 
studies seems to be 6-MPH4 therefore the role of the erthro tail is not fully 
understood.  
TrpH 
   Like all the AAAHs, variations in coenzyme structure appear to affect 
the interactions of both TrpH-1 and TrpH-2 with the amino acid substrate and 
the extent of inhibition by the amino acid substrate. However, TrpH-1 and TrpH-
2 appear to be more sensitive to the pterin coenzyme structure compared to 
PheH (Table 1.9). TrpH from hindbrain (TrpH-2) seems to be sensitive to 
substitution 7 position of the pterin coenzyme.120 In contrast,  BH4 behaves 
 




similarly to 6-MPH4 in terms of its kinetics properties. The Km for DMPH4 and for 
L-Trp when using DMPH4 as a substrate are 4-5 times higher compared to that of 
BH4. However, the reaction when using DMPH4 is slight less coupled (90%)159 
compared to using 6-MPH4. Additionally, when using BH4, TrpH  (from rabbit 
hindbrain) can hydroxylate L-Trp and L-Phe at comparable rates (10.8 and 9.3 
nmol/30 min) using 0.3 U of enzyme).159 However, when using 6-MPH4, the TrpH 
(from hindbrain) can only hydroxylate L-Phe at ~ 44% the rate of L-Trp and 
only.159 
 One study that examined the catalytic core of TrpH102-416, found a tight 
coupling between BH4/6-MPH4 oxidation when using either L-Trp or L-Phe as a 
substrate (0.99-1.12 hydroxylated product/pterin oxidation)90 with 5-hydroxy-L-
Trp and L-Tyr, respectively, as the only products. However, when using L-Tyr as 
a substrate and BH4 there was very little coupling (0.0122±0.0008 hydroxylated 
product. BH4 oxidized).90 
 Human TrpH from the brain exhibited L-Trp inhibition (>130 µM) using  
BH4 as the coenzyme but not 6-MPH4.160 Another study found substrate 
inhibition for both TrpH-1 and Trp-2 above 100 µM with KI of 385 ±70 µM and 
970 ±328 µM respectively when using 250 µM BH4.91 Therefore, similar to TyrH 
 




and PheH, TrpH-1 and TrpH-2 exhibit substrate inhibition with regards to its 
amino acid when using BH4 as a coenzyme. 
Phosphorylation 
Phosphorylation of PheH occurs at S16,161 with the overall effect of increasing 
the Vmax,4 making the T→R transition more facile52 and alleviating the inhibitory 
role of BH4. 36,147 One of the first studies to provide evidence for the 
phosphorylation of PheH came in 1972.162 This study demonstrated PheH 
isolated from rat liver had three peaks when eluted through a calcium 
phosphate/cellulose gel suggestive of varying states of phosphorylation.162 A 
later study demonstrated PheH isolated from rat liver was partially 
phosphorylated and could be further phosphorylated.163 This study 
demonstrated a 0.7 [32P]phosphate per subunit incorporation when attempting to 
phosphorylate rat liver PheH using [γ-32P]ATP and protein kinase.163 The sub-
stoichiometric incorporation was shown to be a result of PheH that had already 
been phosphorylated with 0.3 phosphate per subunit.163 Finally, Shiman et al. 
demonstrated when rats are injected with glucagon, PheH containing 1 
phosphate/ subunit can be isolated4, suggestive of a physiological role of 
phosphorylation. The observation that PheH is isolated from rat liver is partially 
phosphorylated suggest the effects of phosphorylation might be underestimated 
 




in these studies. In contrast to PheH that has been isolated from rat liver, PheH 
expressed using E. coli is completely unphosphorylated. Therefore, direct 
comparisons between studies using PheH isolated from rat liver and 
recombinantly expressed PheH can be challenging to make. 
Both L-Phe and BH4 modulate the ability of protein kinase to phosphorylate 
PheH.147 Phillip and Kaufman measured the rates of phosphorylation of PheH in 
the presence cAMP-dependent protein kinase, cAMP, and [γ-32P]ATP with either 
L-Phe or BH4. In the absence of either substrate or coenzyme, the reaction was 
complete in <30 minutes. However, in the presence of 8.6 µM BH4 the rate of 
phosphorylation was 25% of the rate without BH4. This effect was not seen when 
using either 6-MPH4 or 6,7-DMPH4. These findings were corroborated by another 
study that found at 30 µM BH4, the rate of phosphorylation was approximately 
half the rate without BH4 .36 However, the inhibition of the rate of 
phosphorylation could be overcome by incubation of L-Phe under aerobic 
conditions (i.e. conditions necessary for catalytic turnover). This study found the 
L-Phe alone only exhibited a modest (but reproducible increase) in the rate of 
phosphorylation. However, another study found the incubation with 0.5 mM L-
Phe doubled the rate of phosphorylation.36 The ability of L-Phe and BH4 to 
modulate the rate of phosphorylation and dephosphorylation suggest that these 
 




compounds may also modulate accessibility of S16 or the peptide recognition 
sequence to cAMP-dependent kinase.  Incubation with L-Phe makes this region 
more accessible and BH4 makes this region less accessible. Because the 
modulation was not seen in either 6-MPH4 or 6,7-DMPH4,36 this interaction 
involves likely the erythro tail BH4 with the N-terminal region of PheH 
containing S16. 
Effects of phosphorylation on the kinetics of PheH 
In contrast to many other enzymes, phosphorylation does not directly induce 
an activated state. Both unphosphorylated and phosphorylated PheH co-purify 
using the standard hydrophobic affinity purification which requires both T→R 
and R→T transition to occur.2 Therefor, phosphorylated PheH still undergoes a 
similar increase in hydrophobicity that unphosphorylated PheH does upon the 
T→R transition. Additionally, phosphorylated PheH still only has 4% of the 
activity of the enzyme that had been allosterically activated4 similar to 
unphosphorylated PheH. Accordingly, crystal structures of unphosphorylated 
and phosphorylated PheH1-429[ ] show high structural similarity(RMSD of 0.57 
Å).7 This observation suggests phosphorylation is not equivalent to allosteric 
activation by L-Phe. 
 




One of the first effects of phosphorylation that was discovered was the ability 
to increase the specific activity of activated PheH.163 An early study 
demonstrated a 2-3-fold increase in Vmax when 0.7 [32P] per subunit had been 
incorporated into partially phosphorylated PheH isolated from rat liver. The 
increase in Vmax  was observed when using BH4 but not 7,8-DMPH4.163 While the 
Vmax increased, the Km for both L-Phe and BH4 remained the same. However, it 
should be noted that the activity assay used in the study initiated the reaction by 
the addition of unactivated PheH. Therefore, the resulting activity is confounded 
by the inhibitory role of BH4 as a negative allosteric effector i.e. the increase in 
apparent specific activity could have been a result of a quicker T→R transition.  
However, a later study demonstrated an increase in activity when using 6-MPH4, 
which does not act as an allosteric effector (Table 1.10), demonstrating that the 
increase in Vmax is not unique to BH4.4  Therefore, the increase in activity could 
not solely attributed to the role of BH4 as a negative allosteric effector.   
 





In addition to the increase in activity, phosphorylation also increase the rate 
of the T→R conversion4,132 and the concentration of L-Phe need to effect the T→R 
                Table 1.10 Kinetic parameters for the effect of phosphorylation of the AAAHs 


















PheH BH4 23263 200 75 60   
 6-MPH4 6125 17025  6.2, 
(nmol/min) 
0.17 
       
S16P-
PhEH 
BH4   38 
(1.08±0.17) 
  
 6-MPH4    10.6, 
(nmol/min) 
0.38 
TyrH       
TyrH BH4 25±4171   53±2 min-1 -- 






S31P BH4 30 µM174 
(1.19±0.01) 





S40P BH4 13±3171   59±2 min-1 -- 
TrpH       
TrpH-1  -- --  --  
S58P-
TrpH-1 
 -- --  --  
   --    










                             Values in parentheses represent phosphates per subunit 
 
 




transition.52 Shiman et al. initially demonstrated that the T→R conversion occurs 
at a greater rate for  partially phosphorylated PheH (0.24±0.05 phosphate per 
subunit, 0.17 min-1) compared to stoichiometrically phosphorylated PheH 
(1.08±0.17 phosphates per subunit, 0.38 min-1).4 This study measured the rate of 
conversion by comparing rates of catalysis for activity assays that had either been 
preincubated or un-preincubated with L-Phe.4 A latter study using E270K (a 
mutant unable to bind L-Phe in the active site), also reported an increase in the 
rate of the T→R transition by examining the change in fluorescence that occurs 
upon the T→R transition. One interpretation of the increased rate of activation is 
that phosphorylation decreases the energetic barrier for the T→R conversion to 
occur. The increased rate of activation might allow for PheH to respond more 
quickly to large increases in physiological L-Phe concentration. Phosphorylation 
also reduces concentration of L-Phe required to induce the R-state.52 One study 
showed, that phosphorylated PheH was 50% activated at 38 µM but 
unphosphorylated PheH is 50% activated at 60 µM. Both the increase in rate of 
activation and the lowering of the concentration of L-Phe needed reach half-
maximal activation may be involved in the role of PheH as a clearance enzyme. 
Both these features would allow for PheH to respond quickly to rapid increases 
in physiological L-Phe concentrations. 
 




The structural basis for the effect of phosphorylation is not yet understood, 
however it is thought that phosphorylation disrupts the regulatory binding site 
of BH4.36,147 However, it is not yet known how the Kd changes upon 
phosphorylation. There is only one structure of phosphorylated PheH (PheH19-
429)7 and like all other structures there is no electron density for S16Pi because of 
the highly disordered nature of this autoregulatory domain. Additionally, 1H-1H 
TOCSY NMR study on unphosphorylated and phosphorylated PheH1-428 
demonstrated that both constructs behaved similarly when activated by L-Phe.23f 
However, as the authors note the effects of phosphorylation might be too subtle 
to detect under these limits of 1H-1H TOCSY NMR. The origin of the role of 
phosphorylation seems to be related to the negative charged at S16 induced by 
phosphorylation. A mutagenesis study by Kowlessur et al. replaced S16 with 
either a glutamate, aspartate, lysine, glutamine, asparagine, or alanine. Of these, 
S16E and S16D had a 2-4 fold increase in activity.164 The authors interpreted these 
results to mean that introduction of a negative charge displaces the 
autoinhibitory region of PheH. When plotting the ratio of the activity of BH4/6-
MPH4 ( a measurement of the extent of activation) vs volume of the amino acid, 
 
f This study added L-Phe to a concentration of 200 mM. However, this concentration is beyond the 
solubility of L-Phe in aqueous media at neutral pH. 
 




all the S16 mutant fell on a line.164 One interpretation of this observation is that 
these mutation destabilize the BH4 regulatory site enough to prevent allosteric 
inhibition by BH4.  
Relationship to TyrH and TrpH 
TyrH 
TyrH can be phosphorylated at multiple phosphorylation sites (S8, S19, S31, 
and S40) and phosphorylation of each of these residues affects the activity of 
TyrH in different ways. Early studies suggested, the primary role of 
phosphorylation appears to be to raise the KI for catecholamines (which are 
commonly found in the brain) for the ferric iron165 and also decrease the Km for 
pterin coenzyme. An early study demonstrated cAMP could stimulate TyrH 
activity in vivo suggesting that TyrH could be phosphorylated.166. In this study, 
when striatal homogenate was assayed for TyrH in the presence of 10 µM cAMP, 
the Km for 6,7-DMPH4 decreased from 62 µM to 8 µM and the Km for L-Tyr 
decreased from 53.6 to 22.3 µM.166 Importantly, the KI for the inhibitor dopamine 
increased from 9 µM to 64 µM.166 Since cAMP can activate protein kinases it was 
proposed that increase in TyrH activity was caused by phosphorylation of TyrH. 
The effects of phosphorylation were later probed using crude bovine striatal 
homogenate.156 This study measured the kinetic parameters for both 
unphosphorylated and phosphorylated TyrH for a range of pterin analogs. For 
 




unphosphorylated TyrH, all the coenzymes had a Km ranging from 0.3 mM to 
greater than 5 mM. However, upon phosphorylation, the Km range from 0.6-14 
µM suggesting that phosphorylation was somehow involved in altering the 
affinity of TyrH for the coenzyme. 
Phosphorylation of S40 appears to be the dominant means of acutely 
regulating TyrH activity in vivo. S40 can be phosphorylated by cAMP-PK167,CaM-
PK II,168cGMP-dependant protein kinase,169 and Protein Kinase C.170 
Phosphorylation of TyrH by PKA causes one phosphate per subunit to be 
incorporated at S40. Daubner et al reported phosphorylation of S40 decreased the 
Km for BH4 from 19 to 8.3 µM (Table 1.10).171 The Vmax remained relatively 
unaltered upon treatment with protein kinase 109% of the control reaction 
without protein kinase. However, in this study the Vmax for S40A treated with 
protein kinase was 111% the Vmax for untreated S40A. Importantly, 
phosphorylation both increased the Vmax and decreased the Km for BH4 for the 
dopamine bound TyrH. When S31 was phosphorylated to 0.6 phosphates per 
subunit.172 In contrast to phosphorylation of S16 in PheH, phosphorylation S40 in 
TyrH does appear to cause a conformational change.  
 




Phosphorylation of S31 and S19 have also been shown to alter the kinetics of 
TyrH. Phosphorylation of S31 marginally increases the activity of TyrH 1.2-2 
fold.173,174  In contrast to phosphorylation of S40, phosphorylation of S31 does not 
affect the ability of dopamine to bind to TyrH.172 However, one study reported a 
decrease in the Km( 50 µM to 30 µM) upon maximal phosphorylation of S31. The 
modest effects of phosphorylation of S31 on the kinetics of TyrH suggest that 
phosphorylation of S31 might not have a physiologically relevant role. 
Phosphorylation of S19 by PRAK to ~ 1 mol/subunit had no effect on the Km for 
BH4 or the Vmax.175 However, phosphorylation at S19 caused the rate of 
phosphorylation of S40 to increase three-fold.175 For these reasons TyrH has been 
proposed to follow a hierarchical phosphorylation regulation mechanism. 
TrpH 
Both TrpH-1 and TrpH-2 can be phosphorylated. TrpH-1 can be 
phosphorylated at S58 49,176,177 and S26049 by Ca2+/ Calmodulin dependent protein 
kinase II or protein kinase A.49 While S58 and S260 were identified as 
phosphorylation sites, their effects on the kinetics of TrpH-1 have not yet been 
determined. 
 TrpH-2 is phosphorylated at both S19 and S104 by a protein kinase A (PKA), 
however Ca2+/ Calmodulin dependent protein kinase II only introduced 0.2 
 




phosphate/subunit .178 Phosphorylation of both S19 and S104 resulted in slightly 
lower Vmax for wtTrpH and a Km for L-Trp (55.4±8.5 µM for non-phosphorylated 
and 44.9±9.0 µM for phosphorylated).179 However the Km for BH4 increased upon 
phosphorylation (42.3± 2.2 µM for phosphorylated vs 35.1±4.5 µM for 
unphosphorylated).179 Phosphorylation of TrpH-2 approximately doubles the 
activity178, however the reported activity is still ~100-fold less than that of PheH.25  
Other activation methods 
PheH can be activated in a number of other methods including treatment 
with detergents.146,180 alkylation of C237,119 increasing pH,146 removal of the N-
terminal regulatory domain.76 While none of these methods are likely 
physiologically relevant, they are nonetheless informative of our understanding 
of the allosteric activation process. Of these, increasing the pH, alkylation of 
C237, and treatment with detergents all share the same property of favoring the 
formation dimer of PheH over the tetramer (vide infra). Many reports seeing an 
increase in activity when using BH4 but not 6-MPH4 with these alternate 
activators. The increase in activity likely arises from the alleviation of the 
inhibitory effects of BH4 that are not present when using 6-MPH4. Additionally, 
many of these methods while showing an increase in activity of PheH also 
 




appear demonstrate substrate inhibition by L-Phe when using BH4 as a 
coenzyme but not 6-MPH4. 
Treatment with lysolecithin 
Treatment with lysolecithin was one of the first methods shown to 
stimulate the activity of PheH aside from preincubation with L-Phe. Fischer and 
Kaufman reported treatment with 1 mM lysolecithin decreases the Km,L-Phe (0.2 mM 
without lysolecithin to 0.09 mM with lysolecithin) and increases the Vmax  20-50 
fold76,180 depending on the order of addition of substrates. Treatment with 
lysolecithin also increases the substrate scope of PheH. Lysolecithin treated PheH 
can oxidize L-Trp, DL-Methionine, and L-norleucine.37 However, the substrates 
vary with the degree of coupling (moles of product formed/ moles of pterin 
oxidized). While lysolecithin activated PheH still retained a tight coupling when 
using L-Methionine (~NADH oxidized/methionine sulfoxide formed), when using 
L-norleucine, the coupling was ~2 NADH oxidized/methionine formed). In 
contrast, the coupling of hydroxylation of tryptophan by PheH was unaltered 
when incubated with lysolecithin (2.5 NADH oxidized per product formed when 
using the NADH coupled assay).76 Another study found the relative velocity of 
hydroxylation reaction was 1.3 times faster for the reaction preincubated with 
lysolecithin compared to one incubated at L-Phe at 13°C using 60 µM 6-MPH4 and 
 




1 mM L-Phe for both reactions.52 Therefore, like incubation with L-Phe, lysolecithin 
similarly increases the activity of PheH. However, the expanded substrate scope 
suggest alteration that are not present by allosteric activation by L-Phe. 
In addition to the increase in activity, there are several other features that 
suggest some structural similarity to the R-state. Treatment with lysolecithin 
increases the ability of PheH to absorb to a phenyl-Sepharose resin,52 induces a 
shift in fluorescence peak maximum to a longer wavelength identical to that of R-
state PheH.107 These observations have led some to suggest that treatment with 
lysolecithin brings PheH to a functionally identical state to that of the R-state.52 
Also, incubation with lysolecithin leads to an increase in accessibility of a buried 
sulfhydryl group.76 The ionization of a sulfhydryl group has also been associated 
with the T→R transition.181 While allosteric activation and treatment with 
lysolecithin bring about these mutual features, the relationship of these features to 
the increase in activity is not yet known. 
Even though treatment with lysolecithin and allosteric activation by L-
Phe share several similar properties, there are some important distinctions. One 
study reported lysolecithin activated PheH experiences substrate inhibition at 0.3 
mM, similar to that of PheHNEM, when using BH4 as a coenzyme. However, when 
 




using 6-MPH4 as a coenzyme, only slight substrate inhibition was observed at 5 
mM.25  This discrepancy could be attributed to differences in the coenzyme used 
in the assay. Studies that reported L-Phe inhibition for lysolecithin treated PheH 
used BH4 while those that reported no substrate inhibition used 6-MPH4. While a 
mechanistic explanation for the substrate inhibition is not yet known, it should be 
noted that both TyrH, TrpH-1, and Trph-2 have been reported to experience 
substrate inhibition by their respective amino acid substrates when using BH4, but 
little to no substrate inhibition when using other coenzymes (6-MPH4 or 7,8-
DMPH4). While initial reports suggested lysolecithin did not alter the molecular 
weight of native wtPheH,116 later studies by the same lab120 and ours143 confirmed 
lysolecithin causes the dissociation of wtPheH into dimers. 
The mechanism by lysolecithin activates PheH is poorly understood. 
The activity of PheH has a sigmoidal dependence on lysolecithin concentration 
with maximal activity reached  at ~0.2 mM lysolecithin.180 Despite the sigmoidal 
relation between activity and lysolecithin concentration, lysolecithin likely does 
not bind to the allosteric site of PheH because the structural dissimilarity with L-
Phe. Instead, the ability of lysolecithin to activate PheH is likely related to its 
detergent properties of lysolecithin because of the ability of sodium dodecyl 
sulfate (SDS) to also activate PheH. Although SDS, can also stimulate PheH 
 




activity, Fischer and Kaufman reported concentration of SDS greater than 0.5 
mM inactivated (and likely denatured) PheH.180 Because of propensity of SDS to 
denature PheH, lysolecithin has been the primary detergent used to stimulate 
PheH activity. Interestingly, 1% Tween 80, another detergent, can elute off PheH 
adhered to a Phe-Sepharose resin by lysolecithin suggesting the detergent does 
not have the same activating effects as lysolecithin does. BH4 appears to inhibit 
the ability for lysolecithin to activate PheH.52 
Modification of C237 
Modification of C237 by alkylation120,143 or mutagenesis to an acidic 
residue153,182  has also been shown to increase the BH4 dependent activity of 
PheH. Upon alkylation of C237, the activity was greatly increased (20-30 fold) 
over wtPheH, however there was pronounced substrate inhibition at 
concentration greater than 300 µM,119 similar to what was reported with other 
activators(detergents and removal of the N-terminal regulatory domain). This 
activating property appears to only be associated with alkylating reagents that 
incorporate bulky groups ( e.g. N-ethylmaleimide (NEM) or 5-
(iodoacetamido)fluorescein (5-IF).183  Smaller alkylating reagents (e.g. 
iodoacetamide and iodoacetic acid) do not cause an increase in activity.119  
Therefore, steric effects might play a role in explaining the activating effects of 
 




alkylation of C237. In addition to steric effects, the ionization of C237 was 
examined by mutagenesis to aspartate residue. While there was a 3-fold higher 
activity compared to L-Phe activated PheH, the increase in activity was much 
more modest compared to treatment with NEM. Additionally, C237D did not 
show any substrate inhibition past 500 µM L-Phe (the highest concentration 
tested) when using 75 µM BH4,182 in contrast to PheHNEM which exhibited L-Phe 
inhibition at concentrations > 300 µM.119 The difference in substrate inhibition 
behavior suggest that introduction of a bulky neutral group at C237 does not 
bring about the same structural changes that ionization does. Within one dimer 
of PheH, C237 on one subunit is pointed towards the interface between the 
regulatory and catalytic domain of another PheH subunit within the same dimer 
(Figure 1.24). C237D might allow for a salt bridge to form with R68 on another 
subunit. Whereas introduction of a bulky group might cause disruptive 
interaction between the catalytic and regulatory domains of an adjacent subunit. 
However, a mechanistic explanation for the differential abilities of alkylation of 
C237 and C237D to activate PheH remains elusive. 
Little is known about the structural changes that occur upon alkylation of 
C237 or the structural comparison of C237D to wtPheH. The fluorescence 
spectrum for wtPheHNEM is qualitatively similar to that of wtPheHR both having 
 




fluorescence peak maxima at 339 nm.124 Additionally, the fluorescence emission 
peak maximum for C237D (347 nm)153 is red shifted to that of wtPheHR. 
However, the λmax is longer than what is generally reported for wtPheHR 
suggesting that C237D and alkylation by NEM may not bring about the same 
structural changes of PheH. Alkylation of C237 also appears to affect the 
oligomeric state of PheH. An early study using sucrose density gradient 
centrifugation suggested alkylation of C237 by NEM does not affect the 
molecular weight of PheH.119  However, it is generally agreed that PheHNEM exist 
as a dimer.120,143 In contrast, C237D was shown by size exclusion chromatography 
to exist as primarily a tetramer at pH 7.0.153 However, there was no indication of 
the concentration of PheH used. Since the dimer tetramer equilibrium is 
concentration dependent, the inability to detect a change in the dimer-tetramer 
equilibrium might be a result of using a high enough concentration where the 
dimer-tetramer shift was unaffected. This shift in the dimer-tetramer equilibrium 
towards to dimer is likewise seen in other activating methods such as treatment 
with lysolecithin and raising the pH >8.5. This observation suggests that PheH 
dimers and tetramers may behave fundamentally differently. 
 





Figure 1.24: Orientation of C237 (circled) using tetrameric full-length PheH crystal 
structure (5DEN.pdb). C237 of one subunit is orientated between the regulatory and 
catalytic domain of another subunit within the same dimer. The regulatory domain is 
shown in green, the catalytic in blue, and the tetramerization domain in red. 
 




Alkylation of PheH by NEM appears to also affect the ability of PheH to 
bind L-Phe. Dose response curves measuring the activity of PheHNEM as a 
function of L-Phe show hyperbolic curves as opposed to the sigmoidal curves 
seen in wtPheH.119 Additionally, one study suggested that PheHNEM can only bind 
one molecule of L-Phe/subunit.119 These results suggest that the allosteric site 
might not form in PheHNEM. While the findings of this study should be 
confirmed, such an observation suggest that the allosteric site might not be 
present in PheHNEM. While there are several structural changes to both the 
tertiary and quaternary structure of PheH upon alkylation of C237 and mutation 
of C237 to an aspartate residue how these changes relate to the increase in 
activity of PheH remains elusive. 
Alkaline pH 
Increasing pH (>8.0) also appears to activate PheH52,108, however it is the 
least characterized of the different activating methods. One study demonstrated 
that, while increasing the pH did not activate PheH, it caused the T→R transition 
to occur more quickly( 0.17 min-1 at pH of 6.8 vs 0.43 at pH of 8.0).52 An increase 
in PheH also increases the rate or the T→R conversion even when PheH is 
phosphorylated ( 0.38 min-1 at pH 6.8 vs 1.4 min-1 at a pH of 8.0).4 These rates 
were determined by comparing rates of PheH activity when it had been 
 




preincubated with at various L-Phe concentration compared assays with no 
preincubation. Additionally, the S0.5 of L-Phe that gave half-maximal velocity 
decreased from 300 µM at pH 6.8 to 80 µM at pH 9.0 while the Km for 6,7-DMPH4 
(~800 µM) was invariant across pH ~6.5-9.108 However, it should be noted that 
this study used an coupled-assay that involved initiating the reaction with 
unactivated PheH and coupled the reduction of q-BH2 to the oxidation of NADH 
using dihydropteridine reductase.108 Therefore, the resulting pH dependence of 
PheH is a combination of the pH dependence of the catalytic step, the T→R 
conversion, and the dehydration of c4a-hydroxypterin to q-BH2 (or q-6,7-
DMPH2). An ionizable group with a pKa ~8.152 (corresponding to sulfhydryl 
group) has been proposed to be responsible for this behavior. 
The increase in activity upon increasing pH is accompanied by several 
other changes in PheH. The most prominent change is the shift in the oligomeric 
distribution. Increasing the pH is linked to formation of the dimer.25 The same 
shift in fluorescence peak maximum that occurs upon allosteric activation occurs 
upon increasing the pH to 9.5.108Size exclusion gel-filtration studies 
demonstrated that when 4 µM PheH is injected onto a size exclusion column two 
peaks are observed—one corresponding to a dimeric form and the other 
corresponding to a tetrameric form.25 Increasing the pH shift caused an increase 
 




in the population of the dimer. The observation of two peaks suggest that the 
dimer-tetramer equilibrium occurs slowly on the time course of the experiment. 
A later study again observed two distinct peaks for PheH when eluted through a 
size exclusion column at pH 7.0.111 The authors were able to re-chromatograph 
PheH that eluted out in either the tetrameric and dimeric peaks and recover the 
respective oligomer with 80-86% recovery for the tetramer and 90-95% recovery 
for the dimer.111 These results suggest the dimer-tetramer equilibrium is slow on 
the time scale of these experiments. In addition to the change in oligomeric 
distribution, there is a shift in fluorescence peak maxima and increase in 
absorbance at 238 nm is consistent with an ionizable sulfhydryl group.184 Both of 
these features are also observed upon allosteric activation107,181  
Removal of the regulatory domain 
The first reports showing that truncation of the N-terminal domain 
activates PheH were performed using α-chymotrypsin treated PheH.116 Removal 
of the N-terminus presumably removes the autoregulatory region of PheH. 
Treatment of PheH with α-chymotrypsin stimulated activity 20-fold when BH4 
was used as a coenzyme. However, when DMPH4 was used, no stimulatory 
effect of α-chymotrypsin was observed.116 These studies are consistent with the 
erythro tail of BH4 making important contacts with the N-terminal regulatory 
 




domain. Later studies where the N-terminal regulatory domain was removed by 
mutagenesis, showed no lag in activity when L-Phe was added as the last 
component to an activity assay.144,185 The observation of an increase in activity 
only when using BH4,but not 6-MPH4 is a result of using a fixed time assay 
where the small but observable lag is masked in the assay. Similar to the R-state 
of PheH, PheH lacking the regulatory domain has a fluorescence emission 
spectrum similar to that of R-state of PheH.39 α-chymotrypsin treated PheH also 
has been reported to experience substrate inhibition at L-Phe concentration > 300 
µM when using BH4.116 However, studies on PheH118-452 by our lab showed no 
substrate inhibition > 300 µM L-Phe and a study by Daubner et al. reported also 
no substrate inhibition either when using 6-MPH4.6 Given that BH4 is thought to 
interact with N-terminal autoregulatory domain, it is interesting that L-Phe 
inhibition is observed when using BH4 but not 6-MPH4 as the α-chymotrypsin 
treated PheH would lack the N-terminal autoregulatory region. Therefore, the 
origin of the observed L-Phe inhibition are a result of the interaction of the 
erythro tail of BH4 with the N-terminal autoregulatory region is not yet fully 
understood. 
 




Mutual properties of the alternate activation methods 
In addition to stimulating the activity of PheH, the known alternate 
activators bring about several unique properties of PheH. The most well studied 
of these properties is the shift in the dimer-tetramer equilibrium to favor the 
dimer. This observation is seen for PheHlysolecithin, PheHNEM, and wtPheH (pH > 
8.0). However, this feature is not observed for PheH118-452 which favors the 
tetramer. Additionally, the specific activity of the PheH decreases with 
increasing PheH concentration at an alkaline pH (pH 8.0)186, treatment with 
lysolecithin (pH 6.8) 76, or modification by NEM.119 In contrast, at pH of 6.8 there 
is a positive linear increase of activity as a function of wtPheH concentration i.e. 
the specific activity is not dependent on PheH concentration.119 The origin of the 
decrease in specific activity appear to be associated with a decreased affinity for 
BH4,150 which is also observed upon allosteric activation.31Additionally, the 
various activation methods share the ability to stimulate PheH activity only 
when using BH4, but not other synthetic coenzymes 6-MPH4 and DMPH4. The 
origin of the discrepancy is not yet fully understood. It appears to be rooted in 
the ability of BH4 to inhibit the allosteric activation process. Since BH4, is a 
negative allosteric effector and these methods of activation bring PheH into a 
state like that of the R-state it is consistent with the observation that 6-MPH4 and 
 




6,7-DMPH4 show no stimulatory effect. However, how these apparent properties 
that these alternate activators relate to their activating properties is not 
understood. The fact that they only exhibit their activating effects with BH4 (an 
allosteric inhibitor) but 6-MPH4 suggest that the dimer might interact with BH4 
differently than the tetramer. This observation would also be consistent with the 
observation that PheH118-452, which although exists as a tetramer, lacks the N-
terminal regulatory domain that is believed interact with the erythro tail of BH4. 
While the activating methods bring about similar properties in terms of 
fold increase in activation, changes in oligomeric state, fluorescence emission 
peak maximum, and ability to adhere to a Phenyl-Sepharose resin, these 
methods are not necessarily equivalent.  Incubation of PheHNEM with lysolecithin 
can further increase the activity of PheH to greater extent than what is observed 
for either of these treatments independently.119  Stopped-flow fluorescence 
studies suggest 6-MPH4 reduces Fe3+PheHNEM twelve times faster than wtPheH.143 
However, the twelve-fold rate enhancement of reduction is likely not solely due 
to formation of dimers as increasing the pH to 8.0 (which also induces formation 
of dimers) had no effect on the rate of reduction. Therefore, while both methods 
induce the formation of dimers, there are subtle differences in the properties of 
the two constructs. Also, unlike PheHLysolecithin or PheHNEM, PheH118-452 can be 
 




purified using the same Phenyl-Sepharose purification procedure as wtPheH 
(unpublished observation) suggesting that it also undergoes an increase in 
hydrophobicity as wtPheH. However, both PheHLysolecithin and PheHNEM will 
adhere to a phenyl-Sepharose resin in the absence of L-Phe binding. This 
observation is consistent with PheH118-452 behaving differently from the other 
activating methods. 
Relationship to TyrH and TrpH 
Tyrosine Hydroxylase 
 While phosphorylation is thought to be the predominant physiological 
method for activating TyrH (see Phosphorylation section), TyrH can also be 
activated by polyanions (e.g. heparin), detergents, and limited proteolysis by 
either increasing the specific activity or lowering the Km for the pterin coenzyme. 
An early report from Kuczenski and Mandell showed the activity of TyrH 
increased as a function of ionic strength using either (NH4)2(SO4),NH4Cl, and 
KCl.187 Of these, ammonium sulfate had the greatest activating properties 
increasing the specific activity two-fold at an ionic strength of 1 M. Heparin at a 
concentration of 0.0286 mg/mL decreased the Km for 6,7-DMPH4 from 77 µM to 
10.5 µM. Later Katz et al. showed the chondroitin sulfate, phosphatidylserine, 
polyacrylic acid, polyvinyl sulfuric acid, and polyglutamate could increase the 
activity of TyrH.188 Of these poly-L-glutamic acid had the largest activating 
 




properties increasing the activity 5-fold. 188 Raese et al. later confirmed the 
activating properties of phosphatidylserine.189 Additionally, Katz et al. showed 
TyrH could be activated when bound to a heparin substituted Sepharose.  
 RNA and DNA can also stimulate the activity of TyrH.190 Addition of 
either 100 µg/mL  RNA or DNA decreased the Km for BH4 by approximately 10 
and 20-fold respectively. However, the Vmax, BH4 decreased by half and the Vmax, L-
Tyr increased four-fold. The activating properties appeared to be associated with a 
conformational change. When using 8-anilino-1-naphthalenesulphonic acid (1,8-
ANS) as a fluorescence reporter, the authors found that the fluorescence 
decreases upon the addition of either DNA or heparin. The decrease in 
fluorescence was accompanied by an increase in TyrH activity. These results 
suggest that the presence of DNA or heparin induce a conformational change in 
TyrH the compounds are structurally dissimilar but share the same polyanionic 
property. While the mechanism of activation by polyanions has not yet been 
elucidated, one possibility is increase in ionic strength and introduction 
polyanions changes the oligomeric state of TyrH disrupting electrostatic 
interaction between subunits. The mechanism of the increase in activity by 
polyanions remains controversial because of conflicting reports of the extent of 
activation. These conflicting reports could be a result of differences in purity of 
 




the enzyme where the activating properties were only seen in samples of low 
purity.191 
 In addition to polyanions, detergents (e.g. lysolecithin) have also been 
shown to activate TyrH.189 The presence of  200 µg/mL of lysolecithin decreased 
the Km of TyrH for 6-MPH4 from 200 µM to 65 µM.189 However, other detergents 
(phosphatidylserine, phosphatidylinositol, phosphatidylcholine and 
phosphatidylethanolamine) were not able to activate TyrH.191  The increase in 
activity was attributed to an increase in affinity for the pterin coenzyme. 
However, these studies were performed on TyrH purified from rat brains where 
there could have been inhibited by catecholamines that co-purified with TyrH. 
Therefore, it would be interesting to see if treatment with lysolecithin, like 
phosphorylation, removes the inhibitory effects of catecholamines. 
 Proteolysis and removal of the regulatory domain decrease the Km for 
either 6-MPH4 or BH4.192 However, the Km for L-Tyr when using either 6-MPH4  
(~40% reduction) or BH4 (5% reduction) remains relatively unaltered. When rat 
tyrosine was subjected to limited proteolysis by trypsin, the molecular weight (as 
determined by sucrose density gradient centrifugation) decreased from ~200,000 
indicative of a tetramer to 49,600±400 Da indicative of a monomer.193 This tryptic 
 




digest likely removed both the regulatory and tetramerization domain. In 
contrast to removal of just the regulatory domain, this monomeric species had a 
reduced Km for both L-Tyr and DMPH4. However, the addition of heparin, 
appeared to increase the Km for L-Tyr and had no effect on the Km for DMPH4.193 
One study examined of series of N-terminal deletions to probe the role of the N-
terminus on dopamine binding.194 6-(S)-BH4 was more easily able to out compete 
dopamine binding when the first 38 residues were removed compared to the first 
35. This observation led the authors to suggest residues 36-38 are important 
residues in dopamine binding.194  
 It should be noted that assays for both TyrH and TrpH include the 
addition of ferrous ammonium sulfate to “stimulate” their activity.  However, 
there may not be complete metalation of TyrH under these conditions (see 
Activity Assay section). Therefore, some of the reported activators might be 
related to an ability to incorporate iron more easily into the active site compared 
to “unactivated” forms of TyrH and TrpH. 
Tryptophan Hydroxylase, 
 Many of the activators reported to stimulate TyrH (detergents and limited 
proteolysis) have also been reported to stimulate TrpH. However, these 
activating properties are less characterized for TrpH compared to TyrH.  One 
 




study demonstrated that TrpH can be activated by a wider array of 
phospholipids (phosphatidylserine, phosphatidylethanolamine and 
lysophosphatidylcholine) than either PheH or TyrH.195 Phosphatidylinositol or 
phosphatidylserine were also shown to activate TrpH isolated from the brain 
stem by approximated 2.5-fold, however prolonged incubation decreased the 
activity of TrpH196 However, another study found that lecithin, lysolecithin, 
phosphatidylethanolamine, lysophosphatidylethanolamine, phosphatidylserine, 
lysophosphatidylserine, and sphingomyelin was not able to stimulate the activity 
of TrpH when using 6-MPH4.159 The latter study used a more purified version of 
TrpH from hindbrain while the former used a less purified TrpH isolated from 
the brainstem suggesting that the observed differences might be associated with 
variations in purity. The increase in activity for impure TrpH could result from 
different distribution of TrpH-1 and TrpH-2 isoform where one isoform can be 
stimulated by phospholipids and another cannot. Like TyrH, the addition of 
phospholipids decreases the affinity of TrpH for 6-MPH4 ~2-fold depending on 
the phospholipid used. However, the addition 0.01% SDS  decreases the Km for 
both tryptophan (234±14 µM without and 110±5 with) and 6-MPH4(202±17µM 
without and 102±11 with).195  
 




 Limited proteolysis also decreases the Km for both tryptophan and 6-
MPH4. One study demonstrated that Δ1-44TrpH-2 had a 3-4 fold increase in 
activity and the Km for L-Trp when using 6-MPH4 dropped by ~50% when 
compared to TrpH-2 .197 However the Km for L-Trp when using BH4 as a 
coenzyme remained relatively unchanged (77±25 µM for TrpH-2 and 71±5 µ for 
Δ44TrpH-2).197 Removal of both N and C terminal domain increase the Vmax 
approximately 10 fold.198 Others showed that treatment of TyrH with trypsin or 
chymotrypsin increases the catalytic activity while decreasing both he Km for 
substrate and coenzyme 
While both TyrH and TrpH are reported to predominantly form 
tetramers191,199,200, it would be interesting to see how the various activators affect 
the oligomerization of these enzyme. One study found that when TrpH from rat 
brain stem is treated with L-α-phosphatidylinositol or L-α-phosphatidylserine 
that active TrpH eluted in the void volume when using a Ultrogel AcA 22 
column. 196  In contrast, untreated TrpH eluted in the fraction consistent with its 
molecular weight.196 The Ultrogel AcA 22 column has a fractional range of 10-
130,000 Da and an exclusion limit of 200,000 Da. Therefore, the addition of L-α-
phosphatidylinositol or L-α-phosphatidylserine could either causes aggregation, 
the formation of vesicles, or a shift in the dimer-tetramer equilibrium to favor the 
 




tetramer. Truncation the regulatory and tetramerization domain of TrpH appears 
to increase stability.201 However, truncation of the regulatory domain of TyrH 
appears to decrease the Vmax  by about half.6. Like PheH, phospholipids appear to 
increase the activity of both TyrH189 and TrpH.195 In the case of TyrH, lysolecithin 
caused a ~ 2.5-fold increase in activity with a 3-4-fold decrease in Km for the 6-
MPH4. However, the activating extent of phospholipids remains controversial.191 
Given that this study used TyrH purified from mouse striata, it would be 
interesting to see if the increase in activity was a result of alleviation of inhibitory 
effects of catecholamines similar to the activating effects of phosphorylation. The 
same study concluded that the dimer-tetramer equilibrium was unaltered given 
identical sedimentation behavior for TyrH in the absence and presence of 
lysolecithin. Similarly, TrpH showed an increase in affinity for 6-MPH4 upon 
treatment with various phospholipds195 and SDS when using 6-MPH4 as a 
coenzyme.202  
Prospectus 
 The goal of this dissertation is to characterize the changes in the active site 
of PheH and relate these changes to understanding the increase in catalysis that 
occurs upon allosteric activation. This goal was accomplished by using a 
combination of biophysical and biochemical techniques. In Chapter 2, NO was 
 




used to form a paramagnetic {FeNO}7 center.  1H-HYSCORE was then applied 
characterize the water coordination across the different mechanistic states of 
PheH and select mutants. Chapter 2 used 2H-ESEEM and 2H labelled 5-deaza-6-
MPH4 to examine how binding of L-Phe and allosteric activation change the 
positioning of the pterin coenzyme within the active site. In Chapter 3, 2H-
ESEEM and site-specifically 2H-labelled L-Phe substrates (ortho, meta, and para) 
were used to examine how L-Phe binding changes upon allosteric activation and 
binding of pterin coenzyme. Lastly, Chapter 5 examined how the allosteric 
activation affects the rate of pterin oxidation by O2
 









Nature uses many different mechanisms to control enzymatic activity 
including production of isoenzymes, covalent modification (e.g. phosphorylation 
and ubiquitylation), and allosteric activation.  These regulatory mechanisms 
allow for organism to properly respond to external stimuli. Of these, provides an 
acute and immediate mechanism to respond to changes the cellular environment. 
Allosteric activation involves the binding of an effector molecule to a site distinct 
from the active site. Binding of an allosteric effector alters the equilibrium 
between a structurally distinct low activity T-state and a high activity R-state 
(using MWC nomenclature). An important goal in understanding allosteric 
enzymes is developing a structure function relationship explaining the increase 
in activity upon transition to the R-state. The difference in activity can be 
explained by changes in substrate affinity, increased accessibility to the active 
site, and repositioning of substrate within the active site.  
 Phenylalanine hydroxylase (E.C. 1.14.16.1, PheH) is an allosteric enzyme 
that catalyzes the conversion of L-Phe to L-Tyr and is essential for maintaining 
 




physiological L-Phe concentrations. In order for catalysis to occur, PheH uses 
dioxygen, a tetrahydrobiopterin cofactor (which can act as a negative allosteric 
effector125), and a single non-heme iron (Figure 2.1)85. Inability to convert L-Phe 
to L-Tyr leads to hyperphenylalaninemia (HPA) and in more severe cases 
Phenylketonuria (PKU), one the most common inborn metabolic disorder related 
to amino acid metabolism. This disease affects more than 1 in 15,000 infants in 
the United States and is characterized by irreversible mental retardation.203   
The activity of PheH is tightly controlled by its allosteric effector L-Phe. 
Pulse-chase studies using 14C phenylalanine demonstrated that the location of the 
allosteric effector site is distinct from the catalytic site1,117. The binding of L-Phe to 
the allosteric site and the corresponding T→R transition is highly cooperative 
(Hill coefficient~2.310,25). Additionally, the affinity of the allosteric site for L-Phe 
Figure 2.1 Reaction catalyzed by PheH 
 




(Kd ~800 µM) is less than the affinity of the active site for L-Phe (Kd~ 110 µM). 
This regulatory aspect of allosteric activation in PheH is consistent with its role 
as a clearance enzyme. Under high levels of L-Phe, PheH converts to the highly 
active R-State to rapidly clear the body of L-Phe. As the L-Phe concentration 
lowers, L-Phe is released from the allosteric site and PheH converts to a low 
activity T-state as to not completely deplete the body of L-Phe. However, despite 
several decades of research, the chemical basis for the increase in catalysis upon 
the T→R transition in not yet fully understood.  
A detailed structure-function relationship for the T→R transition has been 
hindered by a lack of relevant crystal structures. Currently, there are only three 
full-length crystal structures9–11, none of which are of the allosterically activated 
R-state of PheH. The remaining crystal structures are of truncated variants 
lacking either the regulatory domain, tetramerization domain, or both. Therefore, 
it is not known if the changes seen upon L-Phe analog (noradrenaline and 
thienylalanine) and tetrahydrobiopterin binding are a true representation of 
binding of coenzyme or a result of structural plasticity arising from truncation of 
the enzyme. In contrast, biochemical and biophysical methods have been able to 
characterize structural changes that occur upon allosteric activation of full-length 
PheH. In addition to an increase in activity, the T→R conversion is characterized 
 




an increase in hydrophobicity2, shift in fluorescence emission peak 
maximum25,109, increase in hydrodynamic radius25 and an elongation to form a 
more ellipsoid shape.143 However, it is difficult to relate these structural changes 
to the increase in activity upon the T→R conversion.  
While biophysical and biochemical studies have characterized the global 
structural changes upon the T→R transition, less is known about the changes in 
the active site upon allosteric activation. To this end, the properties of the active 
site were probed using a series of spectroscopic studies to examine the roles of 
substrate, cofactor, and allosteric activation on the electronic and geometric 
properties of the iron center. MCD/XAS studies show that the iron coordination 
environment remains six-coordinate until both L-Phe and pterin are present in 
the active site and PheH is allosterically activated whereupon the iron center 
adopts a five-coordinate square pyramidal geometry upon loss of a water 
ligand12–14. This six → five coordination change is a common motif seen in non-
heme iron enzymes60. The MCD spectra for wtPheHT[L-Phe] (10Dq ~10,025 cm-1, 
∆5Eg 1,450 cm-1) wtPheHR[L-Phe] (10Dq ~10,000 cm-1, ∆5Eg 1,450 cm-1) were 
essentially equivalent indicating allosteric activation alone has minimal effects on 
the electronic structure of the iron center. Therefore, allosteric activation likely 
 




serves to reorient the protein structure surrounding the active site to form an 
activated complex. 
In this chapter, the Electron Spin Echo Envelope Modulation (ESEEM) 
technique of Electron Paramagnetic Resonance (EPR) spectroscopy was used to 
probe the structure of the catalytic site of PheH and changes that result from the 
binding of substrate L-Phe to the PheH[pterin] complex. Specifically, this study 
sought to examine how the pterin position changes upon addition of substrate L-
Phe. Our measurements made use of nitric oxide, NO, as a substitute for 
molecular oxygen for the purpose of converting the catalytically relevant, but 
EPR-silent, ferrous ion to an EPR-active, S = 3/2, {FeNO}7 paramagnetic center.   
This approach to structural studies of ferrous ion centers in biological systems 
was developed over 40 years ago.204–206 More recently, it has served as the 
foundation for structural studies of several non-heme monooxygenases such as 
Taurine Dioxygenase(TauD)207,208, SyrB2209, Naphthalene dioxygenase210, and 
Soybean lipoxygenase211 using orientation-selective, ENDOR and ESEEM 
methods. Because the hyperfine couplings measured using these techniques can 
be directly related to the Fe-NO bond axis, and samples can be prepared as 
frozen solutions with catalytically relevant substrate and cofactor, the orientation 
of substrate and cofactor at various mechanistic states of PheH can be 
 




measured.212,213 In addition to examining wtPheH, our study also examined 
PheH118-452, a truncated form of the enzyme that lacks the regulatory domain. 
PheH118-452 behaves as though it is allosterically active, lacking the requirement of 
pre-incubation with L-Phe to become catalytically active, and it provides a 
foundation for the detailed interpretation of our ESEEM results. Taken together, 
this chapter provides insight into the role of the regulatory domain and the 
allosteric activation process as it relates to the commitment to catalysis step in the 
phenylalanine hydroxylating system. 
Materials and Methods 
Materials 
  All commercial reagents were of the highest available grade and were used 
without further purification. Glycerol, L-Phe, 4-morpholinepropanesulfonic acid 
(MOPS), KCl, sodium dithionite, sodium ascorbate, sodium nitrite, ferrous 
ammonium sulfate, boric acid, ammonium molybdate, potassium iodide, and 
PtO2 were purchased from Sigma (St. Louis, MO). D2 gas was purchased from 
Cambridge Isotopes. Phenyl Sepharose resin was purchased from either 
Pharmacia or Fischer Scientific. DEA-NONOate was purchased from Caymen 
Chemical (Ann Arbor, MI). All electronic absorption spectroscopy (UV/Vis) was 
performed on an HP-8453 diode array spectrophotometer (Palo Alto, CA). All 
 




anaerobic work was performed in a Labconco inert box that was maintained at 4 
°C in a walk-in cold room (Kansas City, MO).    
Synthesis of 5-deaza-6-methyltetrahydropterin 
   The 5-deaza-6-methylpterin cofactor was synthesized following literature 
precedure214 except that D2 gas and d3-trifluoroacetic acid were used in the 
reduction step for the synthesis of the deuterated cofactor. Site specific 
deuterium incorporation levels at the 5, 6 and 7 positions of the reduced cofactor 
were determined by integration of spectra recorded on an Agilent 500 MHz 
VNMRS spectrometer.  
Overexpression of wtPheH and PheH mutants 
Enzymes were over-expressed in E.coli BL21(DE3) cells using previously 
described protocols13,25, except no iron was added to the PheH118-452 cultures. The 
cells were grown in a 10 L New Brunswick Instrument fermenter at 37°C to an 
Abs550=1.8 of modified 2xYT media, containing 16 g/L of Bacto-tryptone, 10 g/L of 
yeast extract, 85 mM NaCl,  0.4% v/v of glycerol, 0.5 g ampicillin, 2mM MgSO4, 
100 μM CaCl2, 8 μM H3BO3, 0.16 μM (NH4)6Mo7O24·4H2O, and 0.6 μM KI with 
Antifoam A concentrate, then induced with 0.4 mM of IPTG for 5-6 hr at 30°C.25 
For wtPheH, 70 μM FeCl3, prepared fresh in 5 mM HCl, was added, while 
PheH118-452 was over-expressed in the absence of iron as an apo-enzyme. Cells 
 




were pelleted at 8000 rpm for 10 min at 4°C. The wtPheH cell pellets were re-
suspended in an equal volume of lysis buffer (20 mM Tris-HCl, 200 mM KCl, 80 
mM L-Phe, pH 7.2 at 4 °C) and PheH118-452 cell pellets were re-suspended in a 5-
fold excess volume (with respect to the weight of cells) of lysis buffer (50 mM 
Tris-HCl, 100 μM EDTA, pH 7.2 at 4 °C) and frozen in liquid nitrogen. Cells were 
stored at -80°C until protein purification. 
Isolation of full-length constructs of PheH and PheH118-452 
All purification and reconstitution steps were performed at 4 °C unless 
otherwise noted. Amicon Ultra (30K) and Centricon (30K) microconcentrators 
(Millipore) were used to concentrate enzyme or for buffer exchange. wtPheH 
was purified using a variation of the hydrophobic affinity method2, as previously 
described9. PheH118-452 was purified using a method adapted from Daubner et al. 
185, and the purification was scaled-up with the following modifications; a final 
concentration of 0.1 μM PMSF was added to the cells before sonication. Nucleic 
acids were precipitated with either 0.25% PEI or 2% streptomycin sulfate (w/v). 
PheH118-452 was isolated between 8 and 28% (w/v) ammonium sulfate. The pellet 
was suspended in lysis buffer (50 mM Tris-HCl, 100 μM EDTA, pH 7.2 at 4°C) to 
a ratio of 1:8 (w/v) and applied to a 5.5. cm x 14.5 cm DEAE cellulose anion 
exchange column, pre-equilibrated with the lysis buffer, at a flow rate of 4 
 




mL/min using a Pharmacia LKB FPLC. The desired enzyme, PheH118-452, does not 
bind to DEAE column under these conditions, but a majority of unwanted 
protein impurities bind to the DEAE resin and are removed from PheH. The 
effluent was then concentrated to 0.25 mM and approximately 50 mg of apo- 
PheH118-452 were applied to a Superdex 200 20/60 column (Pharmacia) and eluted 
with 50 mM MOPS, 300 mM KCl, 5% glycerol buffer (pH 7.2), using a Pharmacia 
LKB FPLC. The Superdex 200 26/60 column was calibrated using a standard 
protein cocktail. A molecular weight of 155 kDa was calculated for the PheH118-452, 
which corresponds well to the molecular weight of 154.9 kDa for a tetramer 
obtained from amino acid analysis215. 
Iron (Fe2+) Reconstitution of apo-PheH118-452 
Removal of glycerol prior to reconstitution was essential to facilitate iron 
incorporation. To do so, apo-PheH118-452 (1 mM) was applied to a PD-10 (1.5 cm x 
5 cm) desalting gravity column (GE Healthcare) with glycerol-free 50 mM MOPS, 
0.3 M KCl buffer at pH 7.2. The enzyme was concentrated back to1 mM (40- 50 
mg/mL), snap-frozen in liquid nitrogen, and transferred to an inert atmosphere 
box for reconstitution. All anaerobic solutions were thoroughly degassed by 
three freeze-pump-thaw cycles on a vacuum line using N2 as the inert 
atmosphere. Protein samples were diluted to 0.05 mM using deoxygenated 
 




buffer (50 mM MOPS, 0.3 M KCl, pH 7.2). Ferrous ammonium sulfate (10 mM 
stock dissolved in 5 mM HCl) was added to a final concentration of 1:1 Fe2+: 
enzyme and incubated for 15 minutes for reconstitution. The reconstituted 
enzyme was then removed from the inert atmosphere box and let oxidized by air 
for one hour with gentle stirring and concentrated on a YM30 membrane in a 50 
mL Amicon concentrator (Millipore Corporation) to a final concentration of 1 
mM (40- 50 mg/mL). To get rid of exogenous iron, the protein solutions were 
passed through a Chelex 100 column pre-equilibrated with 50 mM MOPS, 300 
mM KCl buffer at pH 7.2. Iron content was routinely quantified by atomic 
absorption spectrometry before and after purification and reconstitution steps. 
The apo- and holo-enzyme contained 0-0.1 Fe/subunit and 0.8-1.0 Fe/subunit, 
respectively. 
Protein concentration 
Total amino acid analysis was performed by the Core Center, Beth Israel 
Hospital (Boston, MA)215 and the extinction coefficients for apo-PheH118-452 and 
holo-wtPheH were calculated as ε280=50,300 M-1 cm-1 215 and 58,000 M-1cm-1, 25 
respectively. The presence or absence of Fe had no discernable effect on the 
calculated results. 
 




Protein Purity  
Enzyme samples were electrophoresed on SDS-containing polyacrylamide 
gels, 12% acrylamide, according to Laemmli216. The gels were either stained with 
Coomassie brilliant blue217 or with Silver Stain Plus, following the manufacturer’s 
instructions (Bio-Rad). Since nitric oxide reacts with heme containing proteins 
rapidly and even residual amount of impurities result in a large chromophore 
formation in the visible range that can interfere with nitric oxide experiments 
that are discussed in this paper, all purified batches were also stained with 
TMBZ for heme detection, using previously described methods 218 with the 
following modifications. SDS-containing polyacrylamide gels, 15% acrylamide 
with 1.5 mm thickness, were used and immediately stained after electrophoresis. 
TMBZ and dilute H2O2 solutions were prepared fresh prior to staining. Hemin 
(from Sigma) were dissolved in a few drops of 0.1 M NaOH and diluted to 1 mM 
concentration with 50 mM MOPS buffer, pH 7.2. Dilutions of hemin sample (25- 
500 pm/gel) were applied to gels to determine the sensitivity of the stain. 
Specific activity assays 
Activity of wtPheH and PheH118-452 were assayed using the standard 
protocol,52 in which the formation of tyrosine was monitored at 275 nm.2 
 




Total iron content 
Total iron content of apo- and holo- enzymes were also routinely 
quantified using a Varian AA280 atomic absorption spectrometry, with Zeeman 
GTA120Z graphite furnace attachment or an AA240Z atomic absorption 
spectrometer, at 248.3 nm. Standard solutions of iron (concentrations ranging 
from 4-12 parts per billion (ppb) for when using the graphite furnace attachment 
and 0.125-1 ppm when using AA240Z spectrometer) were used to acquire a 
standard calibration curve. The enzyme samples were digested with 2% HNO3, 
centrifuged for 10 minutes to remove any precipitates and diluted to 
approximately 155 pmol enzyme concentration (corresponding to 6-8 pmol Fe 
concentration) or 6 µM with distilled water.  
EPR Sample Preparation  
 All protein samples were prepared in an inert glove box at 4 °C unless 
otherwise stated. Two chemical donors were used to generate the enzyme 
nitrosyl-adducts—reduction of nitrite219 and decomposition of an DEA-
NONOate.220 The resulting NO concentration was measured by a Clark-type NO 
electrode that was developed using a method adapted from Stetter et al.221 In 
general, the samples prepared with DEA/NONOate resulted in better signal-to-
noise ratios. 
 




Fe2+wtPheHT [ ]-NO  
 wtPheH was concentrated to ~3 mM, snap frozen in N2(l) and taken into 
the N2 atmosphere inert glovebox. It was then diluted to ~ 0.1 mM in degassed 
buffer (100 mM MOPS, 300 mM KCl, pH 7.2 at 4 °C). The enzyme was reduced 
with stoichiometric amounts of either 6-MPH4 (0.5 equivalents of iron) or 
dithionite (1 equivalent of iron). The minimum amount of pterin was used to 
reduce the iron to prevent unwanted side reactions with reduced pterin and NO. 
Furthermore, the minimum amount of pterin prevents saturating the pterin 
binding site as quinonoid-6-MPH2 has a very low affinity (no inhibition was 
observed up to 0.4 mM) for the active site.29,222 The addition of both 6-MPH4 and 
dithionite result in similar EPR spectra. Saturated NO buffer solutions were 
prepared by dissolving DEA/NONOate in 4 mL of buffer (100 mM MOPS, 300 
mM KCl, pH 7.2 at 4 °C) to a final 2-2.5 mM concentration.  The solution was 
placed in a 4 mL Wheaton vial with a butyl-rubber stopper, crimped with an 
aluminum seal and left to incubate for one hour with frequent stirring. This 
sample volume was used to minimize the amount of void volume present 
between the top of the solution and the bottom of the stopper of the vial. After a 
one-hour incubation, the NO concentration reached approximately 2.5-2.7 mM, 
determined with Clark-type NO electrode. The maximum saturation of NO at 4 
 




°C is reported as 3.2 mM 223. Once the buffer was saturated with NO, it was then 
added to wtPheH sample. After 5 minutes of incubation in a vial sealed under N2 
atmosphere, the resulting intense yellow colored solution (wtPheHT [ ]-NO) was 
transferred to Centricon (30K) microconcentrator (Millipore) and concentrated to 
a final concentration of 2.0-2.5 mM Fe/subunit. Approximately 200 μL of the 
reaction mixture was quickly transferred to a quartz EPR tube (4 mm OD, 707-
SQ-250M, Wilmad, Buena, NJ) and immediately frozen in N2(l). 
wtPheHT [ 5-deaza-6-MPH4]-NO  
 The sample was prepared the same as the protocol described above, 
except that 5-deaza-6-MPH4 (in 15-fold excess to the iron content) was added to 
the enzyme sample after reduction with 6-MPH4, in order to ensure the pterin 
binding site is saturated with 5-deaza-6-MPH4 and no competition occurs 
between the two cofactors. 5-deaza-6-MPH4 is a non-redox active structural 
analogue of the pterin cofactor and was used to effectively induce possible active 
site structure changes associated with cofactor binding, while preventing the 
possibility of side-reactions of the redox active cofactor, 6-MPH4, and NO. The 
saturated NO solution was also prepared identical to the protocol described 
above, except that 10 mM 5-deaza-6-MPH4 was present in the buffer solution. 
The presence of 5-deaza-6-MPH4 did not affect the NO release (~2.5 mM) from 
 




the DEA/NONOate donor, as detected by Clark-type NO electrode. The final 
concentrations of the samples were approximately 2.0-2.5 mM Fe/subunit. 
wtPheHR [L-Phe, 5-deaza-6-MPH4]-NO 
 The sample was prepared similarly to wtPheHT [ ], except that the protein 
sample was allosterically activated by incubation with 2 mM L-Phe for 10 
minutes at 25 °C prior to concentration and before being taken into the N2 inert 
glovebox. The final concentration of 10 mM 5-deaza-6-MPH4 was added to the 
enzyme solution after reduction with 6-MPH4. Additionally, 10 mM 5-deaza-6-
MPH4 and 15 mM L-Phe were present in the saturated NO buffers. The presence 
of substrate and cofactor did not affect the NO release (~ 2.5 mM) from 
DEA/NONOate donor. The final concentration of the samples was 
approximately 2.0-2.5 mM Fe/subunit. 
PheH118-452[ ]-NO 
 PheH118-452 were reconstituted as previously described before preparation 
of the enzyme-nitrosyl adduct. PheH118-452 was concentrated to ~ 4 mM final iron 
concentration, snap frozen in N2(l), and taken into the N2 inert glovebox. The 
enzyme was then diluted to ~0.1 mM in degassed buffer (100 mM MOPS, 0.3 M 
KCl, pH 7.2 at 4 °C). Similar to wtPheH, PheH118-452 
 




 was reduced with the minimum amount of 6-MPH4 (0.5 equivalents of iron) that 
is necessary for reduction29,222 in order to prevent any side reactions of 6-MPH4 
and the possibility of saturating the pterin binding site. Saturated NO buffer 
solutions were prepared as described previously and added to PheH118-452. After 5 
minutes of incubation in a vial sealed under N2 atmosphere the resulting intense 
yellow colored solution (PheH118-452[ ]-NO) was transferred to a Centricon (30K) 
microconcentrator (Millipore) and concentrated to 2.5-3.0 mM. 
PheH118-452[ 5-deaza-6-MPH4]-NO 
The sample was prepared similar to PheH118-452[ ]-NO sample described 
above, except that 5-deaza-6-MPH4 (in 15-fold excess to the iron content) was 
added to the enzyme sample after reduction with 6-MPH4, to make sure that the 
pterin binding site is saturated with 5-deaza-6-MPH4 and no competition occurs 
between the two cofactors. Parallel samples were also prepared by dithionite 
reduction and no difference was observed in the ESEEM spectra. The saturated 
NO solution was also prepared identical to the protocol described above, except 
that 10 mM 5-deaza-6-MPH4 was present in buffer solutions. The presence of 5-
deaza-6-MPH4 did not affect the NO release (~2.5 mM) from DEA/NONOate 
donor. 
 




PheH 118-452[L-Phe, 5-deaza-6-MPH4]-NO  
The sample was prepared similar to the PheH118-452[L-Phe]-NO sample 
described above, except that a final concentration of 10 mM 5-deaza-6-MPH4 and 
15 mM L-Phe was added to the enzyme solution after reduction with 6-MPH4. 
Additionally, 10 mM 5-deaza-6-MPH4 and 15 mM L-Phe were present in the 
saturated NO buffers. The presence of substrate and cofactor did not affect the 
NO release (~ 2.5 mM) from DEA/NONOate donor, as detected by Clark-type 
NO electrode. 
wtPheHT [180 uM L-Phe, 5-deaza-6-MPH4]-NO  
 PD-10 columns were used to exchange wtPheH into the cofactor 
containing buffer (50 mM MOPS, 0.3 M KCl,10 mM 5-deaza-6-MPH4) following 
manufacturer’s procedure. The eluent was then concentrated to ~ 200 µL (~ 2 mM 
wtPheH) and taken into an inert atmosphere glovebox at 4 °C. The enzyme 
solution was brought to 10 mM dithionite and incubated for 10 minutes. The 
solution was then added to 10 mg of DEA/NONOate and incubated for 10 
minutes upon which an intense yellow color indicative of the Fe-NO adduct was 
observed. The solution was then brought to 180 µM L-Phe using a 20 mM L-Phe 
stock and immediately loaded into an EPR tube and flash frozen in N2(l). L-Phe 
was added last to prevent allosteric activation of the sample. 
 




wtPheHT [400 uM L-Phe, 5-deaza-6-MPH4]-NO  
 The sample was made identically to wtPheHT[180 uM L-Phe, 5-deaza-6-
MPH4]-NO except that the sample was brought to 400 µM L-Phe immediately 
before being loaded into an EPR tube and frozen in N2(l). 
wtPheHT [600 uM L-Phe, 5-deaza-6-MPH4]-NO  
 The sample was made identically to wtPheHT[180 uM L-Phe, 5-deaza-6-
MPH4]-NO except that the sample was brought to 600 µM L-Phe immediately 
before being loaded into an EPR tube and frozen in N2(l). 
Physical Methods 
  EPR measurements were made at X-band on a Bruker E-680X spectrometer 
using a 5mm dielectric resonator (ER4118X-MD5-W1). Samples were poised at 4 
K using an Oxford CF-935 liquid helium cryostat and an ITC-503 temperature 
controller. ESEEM measurements made use of the standard 3-pulse (90° - τ – 90° 
- T -90°) stimulated echo sequence and the 4-pulse HYSCORE sequence (90° - τ – 
90° - t1 – 180° - t2 – 90°). All pulse widths were set to 16 ns FWHM with the 180° 
pulse having a peak power 6 dB higher than its 90° counterparts.224 Four – step 
phase cycles were used for both pulse schemes.225 HYSCORE data were collected 
using 128 points in each time dimension and a 16 ns time increment. Data were 
processed by using a 2nd degree polynomial to remove the background decay in 
both dimensions followed by application of a Hamming window, zero-filling to 
 




256 points and 2D-FFT. 2H-ESEEM data were obtained by dividing normalized 
time-domain data sets obtained for samples prepared with 5,6,7-2H-5-deaza-6-
methyltetrahydropterin (2H-5-deaza-6-MPH4) with corresponding data obtained 
from samples prepared with protonated 2H-5-deaza-6-MPH4.226 Spectral 
simulations were done using EasySpin 5.2 running in the MATLAB 2019b (The 
Mathworks) environment.227,228 Cw-EPR and 1 dimensional 2H-ESEEM spectra 
were fit using the global optimization routine, “fminsearch,” resident in 
MATLAB.  
Results and Discussion 
cw-EPR  
Continuous-wave EPR spectra of the {FeNO}7 complexes of PheH showed 
resonances at g = 4.0 and g = 2.0 that are typical of S = 3/2 paramagnetic centers 
characterized by large zero-field splitting (Figure 2.2). A full spectrum obtained 
for PheHT[5-deaza-6-MPH4] is shown in the upper right panel of Figure 2.3. 
Because the g = 2.0 region of these spectra often contained contributions from 
free NO, spectra were analyzed by fitting the g = 4 region of the data using a spin 
Hamiltonian consisting of zero-field splitting (ZFS) and isotropic electronic 
Zeeman interactions (Eq. 1). D in Eq. 1 is the ZFS  
(1) 
 




constant and has been estimated for {FeNO}7 complexes of this type to be on the 
order of 10 cm-1.229–232 E/D is the deviation of the interaction from axial symmetry, 
go is the electron spin-only g-value, and B, the applied magnetic field vector. 
Because D is much greater than the microwave energy of an X-band EPR 
spectrometer, our EPR spectra are only sensitive to the ratio, |E|/D, go, the strain 
in the ZFS parameters, and intrinsic linewidths.  
  
 





 The g = 4 region of the cw-EPR spectra collected for wtPheHT[5-deaza-
6MPH4], PheH118-452[5d-6MPH4], wtPheHT[L-Phe, 5d-6MPH4]and PheH118-452[L-
Phe, 5d-6MPH4] are shown in Figure 2.2. The two adducts prepared with just 
Figure 2.2: Cw-EPR spectra (black traces) and simulations (red traces) for (a) 
wtPheHT[5-deaza-6-MPH4] and PheH118-452[5-deaza-6-MPH4] (b) wtPheHR[L-Phe, 5-
deaza-6-MPH4] and PheH118-452[L-Phe, 5-deaza-6-MPH4]. Data were acquired under 
the following conditions: microwave frequency, 9.68 GHz, microwave power, 6.3 
µW; field modulation amplitude, 0.8 mT; field modulation frequency, 10 kHz and 
sample temperature, 4.0 K. Simulations were done using the pepper module of 
EasySpin with the Hamiltonian parameters listed in Table 2.1.   
 




pterin coenzyme, Figure 2.2a, are dominated by a species with |E|/D = 0.021, 
while the spectra obtained for enzyme loaded with an activating concentration of 
substrate L-Phe and pterin, Figure 2.2b, show a nearly equimolar mixture of 
species with |E|/D = 0.064 and |E|/D = 0.024. The red traces shown in the figure 
are spectral simulations done using the above spin Hamiltonian and the 
parameters provided in Table 2.1. Mixtures of paramagnetic centers, like those 
observed here, have been observed in previous studies of non-heme Fe(II) 
centers in enzymes poised in S = 3/2 forms by the addition of NO.48,233 Theoretical 
studies of these experimental results have suggested that small differences in 
|E|/D, consistent with those measured here, can arise from the presence of 
different NO rotamers as opposed to the binding of NO to different coordination 
positions at the metal site. 234 Our experimental results, detailed below, are 
consistent with the two species originating from different NO rotamers. In 
contrast, only on species is observed for wtPheHT[ ]. One explaination for why a 
mixture of rotomers is observed for the binary and ternary states, but not 
wtPheHT[ ], is that binding of the pterin coenzyme introduces rigidity to the 
active stie constricting rotation of the NO. 
 





  1H-HYSCORE analysis was applied to probe the coordination environment of 
the {FeNO}7 and to aid in the analysis of the 2H-ESEEM spectra.  ESEEM 
spectroscopy was applied to the samples studied in Figure 2.2 to probe structural 
changes at the active site that accompany allosteric activation of the enzyme. 
Previous ESEEM studies of {FeNO}7 adducts of non-heme Fe hydroxylases have 
shown congested spectra with contributions from the 14N nuclei of coordinated 
histidine residues and NO, and from the coupled protons of protein-based ligands, 
coordinated water molecules and the pterin cofactor. At X-band, these 
contributions are overlapped to the extent that both isotopic substitution and the 
two-dimensional 4-pulse HYSCORE methods of ESEEM are needed to resolve 
them. 48,207,233  Figure 2.3 shows the proton region of 4-pulse HYSCORE spectra 
collected for the PheHT[5-deaza-6MPH4] sample at 20 mT field intervals from 220 
mT to 300 mT. A parallel set of 1H-HYSCORE spectra collected for the truncated 
enzyme, PheH118-452[5-deaza-6-MPH4], provided nearly identical spectra to those 
shown in Figure 2.3 and Figure 2.4. Because the x-ray crystal structure of PheH103-
427 [BH4] (PDB: 1J8U) shows the coordination sphere of Fe(II) completed by 3 bound 
oxygen atoms, presumably from water molecules28, these spectra are expected to 
show cross peaks from water protons characterized by large anisotropic hyperfine 
 




couplings.235 Such couplings are easily identified in HYSCORE as their cross peaks 
are shifted to the high frequency side of the proton anti-diagonal and they move 
along an arc- or ridge-like trajectory as the magnetic field is varied from g⊥ to 
g||.224,236,237  In Figure 2.3, the proton anti-diagonal is depicted with a heavy red line, 
perpendicular to the frequency diagonal and intersecting it at the proton Larmor 
frequency for the specific magnetic field value used for the experiment. At 280 mT, 
there are cross peaks resolved at (10.3,18.3) MHz and (10.3, 16.6) MHz that arise 
from protons with dipolar couplings characteristic of water ligands. These cross 
peaks appear in pairs located on either side of the frequency diagonal, but in our 
description, each pair will be referenced using the coordinates of the cross peak 
with the higher f2 value. As the field moves to 300 mT, towards g = 2, these cross 
peaks shift towards the anti-diagonal and are resolved at (10.3, 17.3) MHz and 
(10.7, 16.1) MHz, respectively. As one moves to lower field, towards g⊥, the 
molecular orientations selected in the HYSCORE experiment increase in their 
projection onto a plane perpendicular to the axis of the Fe-NO bond, and the cross 
peaks due to these protons begin to become more diffuse, or cover a larger spread 
in frequencies. At 220 mT, the proton cross peaks are dominated by combination 
frequencies (να,νβ ± να), (να ± νβ, νβ),etc., that arise because multiple protons are 
coupled to the {FeNO}7 center. 238 
 








Figure 2.3 1H-HYSCORE spectra collected for PheH[5-deaza-6MPH4} at five 
magnetic field positions along with the full cw-EPR spectrum for reference. The 
heavy red line plotted on the HYSCORE spectra is the proton anti-diagonal. Data 
were collected at a microwave frequency of 9.703 GHz and sample temperature 4.0K. 
HYSCORE spectra were acquired using a 128 x 128 grid of time points using a 
repetition rate of 1 kHz. 
 





Figure 2.4 1H-HYSCORE spectra of PheH118-452[5-deaza-6MPH4] collected at 5 magnetic 
field positions across the EPR spectrum. Data were collected under conditions similar to 












Table 2.1:  Spin Hamiltonian Parameters for Simulation of cw-EPR Spectra 
Sample Fractional 
contribution 






























Parameters common to simulations: D = 300000 MHz, go = 2.02 
 To analyze these data, a systematic approach was developed to account for the 
magnetic parameters needed to describe the proton hyperfine coupling of water 
ligands bound cis- to the Fe-NO bond. Briefly, the electron spin system was 
described as an S = 3/2 paramagnet with the D, E/D and go values determined by 
analysis of the cw-EPR spectra (Table 2.1) being used to account for the 
orientations selected at each field position. The spin Hamiltonian used to model 
water proton hyperfine couplings consisted of nuclear Larmor and electron-
nuclear hyperfine coupling terms and is given in Eq. 2. γp in Eq. 2 is the  
 




    (2) 
proton gyromagnetic ratio,  and  are the nuclear and electron spin operators, 
respectively, B is the magnetic field vector and  is the hyperfine coupling tensor. 
Previous work on {FeNO}7 model complexes showed that the proton hyperfine 
coupling of water ligands can be modeled with an axial coupling tensor with 
principal values (Aiso -T, Aiso - T, Aiso + 2T) with Aiso @ 0  and T well-approximated 
by the point dipole-dipole interaction (Eq. 3), where r is the distance between Fe 











 Previous 2H-ENDOR studies on {FeNO}7 derivatives of ACCO oxidase have 
shown that reasonable dipolar distances from Fe can be estimated by setting the 
unpaired spin density on the metal, ρFe , at 0.9.213 For HYSCORE simulations, an 
elementary picture of water ligation was used. Specifically, the ligand was 
considered to show sp3 hybridization about oxygen and to be coordinated to Fe 
through one of its lone electron pairs. This places the ligand protons on the base 
of a cone whose symmetry axis is the Fe–O bond axis. Taking the principal axis of 
the spin Hamiltonian (Eq. 1) to lie along the Fe-NO bond212 and the principal axes 
 




of water protons to lie along an imaginary line connecting them to Fe, simple 
geometric relationships could be used to determine the angle arguments for the 
function “AFrame” which is used in EasySpin to transform the diagonal hyperfine 
tensor defined above into the axis system of the ZFS interaction. Because the 
hyperfine tensor is of axial symmetry, “AFrame” requires only two angle 
arguments, ahf, a rotation about the Fe-NO bond to position the y’ axis of the ZFS 
frame so it is perpendicular to the Fe-proton vector, and bhf, a rotation about y’ to 
align the Fe-NO bond axes with the Fe-proton vector. For a water ligand, two 
proton hyperfine tensors must be transformed, and expressions for the angle 
arguments are given in Eqs. 4-7.  
ahf 1 =fbond - Tan
-1(base*sin(brot ) / height) (4) 
bhf 1 =qbond - Tan
-1(base*cos(brot ) / height) (5) 
ahf 2 =fbond - Tan
-1(base*sin(brot + Db) / height) (6) 
bhf 2 =qbond - Tan
-1(base*cos(brot + Db) / height) (7) 
In these expressions, the location of each water proton is determined by specifying 
the orientation of the Fe-O bond in the ZFS axis system, Θbond and Φbond, and two 
rotation angles, βrot and Δβ, that describe the positions of the protons about the Fe-
 




O bond axis. The variables “base” and “height” in Eqs. 4-7 refer to the radius of the 
water cone base and its height, respectively, and are calculated from the value 
entered for the dipolar coupling, T. These parameters and their relationship to the 
Fe-NO bond are illustrated with the example shown in Figure 2.5.  
 
 
Figure 2.5 Elementary picture of water coordination used to set the angle arguments for 
the 1H-HYSCORE simulations of PheH[5-deaza-6MPH4] and PheH118-452 [5-deaza-
6MPH4] samples. a) T is calculated from the Fe – H distance using eq. 3 in the text. The 
orientations of the protons in the principal axis system of the ZFS are determined by 
specifying the orientation of the Fe-O bond, (Θbond, Φbond), and the angles βrot and Δβ. b) 
view looking down the Fe-O bond axis at the orientation of the water protons on the 
base of a cone. 
 
 Analysis of the HYSCORE data shown in Figure 2.6 was undertaken using the 
above model and the saffron module of EasySpin. As stated above, the crystal 
 




structure of PheH103-427[BH4] (1J8U.pdb) shows the three open positions on the Fe 
coordination sphere occupied by oxygen atoms presumably from water ligands. 
Given that one of these positions is occupied by NO, there should then be two 
water ligands described by (Θbond, Φbond) of approximately (90°,0°) and (90°, 90°). 
Starting with the spectrum collected at 280 mT, this simple model using Fe-O bond 
lengths of 2.0 Å and a corresponding dipolar coupling of 4.9 MHz, it was quickly 
evident that the cross peak spaced farthest from the proton anti-diagonal at (10.3, 
18.3) MHz required a larger dipolar coupling. Figure 2.6 shows a comparison of 
1H-HYSCORE simulations (red) and data for four field positions in the center of 
the cw-EPR spectrum. The model used for these calculations consisted of three 
protons: one with a stronger coupling, described by (Θbond, Φbond) = (90°, 0°), βrot = 
52°, Aiso = -0.8 MHz and T = 6.4 MHz; and two others belonging to a water molecule 
described by (Θbond, Φbond) = (90°, 90°), (βrot, Δβ) = (26°, 115°), Aiso = -0.6 MHz, and T 
= 4.8 MHz. While this model does a good job of accounting for the 1H cross peaks 
that arise from stronger dipolar couplings, it should be a viewed as a minimal 
model to account for the data. The two protons attributed to water have a dipolar 
coupling commensurate with a dipole-dipole distance of 2.5 Å and an Fe – O bond 
length of 2.0 Å. The odd proton corresponds to a dipolar distance of 2.3 Å and 
could arise from a hydroxide ligand, or a water molecule that has simply been 
 




pulled out of position by a hydrogen bonding interaction. There is a set of cross 
peaks in the 1H-HYSCORE spectrum collected at 240 mT (Figure 2.6) that are not 
accounted for by our model and these could arise from the second proton of this 
odd ligand.  
 





Figure 2.6 Simulations of 1H-HYSCORE spectra (red) superimposed on four of the data 
sets shown in Figure 2.3. The simulations were done using the saffron module of 
EasySpin and considered contributions from 3 coupled protons with the coupling 
parameters given in the text. 
 The addition of substrate L-Phe in sufficient amount to reach the allosterically 
activated PheHR[L-Phe, 5d-6MPH4], has a dramatic effect on the 1H-HYSCORE 
spectrum as shown in Figure 2.7. The cross peaks assigned to water ligands for T-
 




state PheH [5-deaza-6MPH4] are absent from these data and replaced by a single 
cross peak that arises from a coupled proton with sufficient dipolar coupling to 
shift it to the high field side of the anti-diagonal. This cross peak also follows an 
arc trajectory going from (10.5, 16.9) MHz at 300 mT where it shows an oval shape, 
to (6.1, 15.1) MHz at 220 mT, where the contour has a ridge shape. The absence of 
combination peaks, especially at low field, indicates that these data arise from a 
single proton with a strong dipolar coupling. The absence of these cross peaks for 
samples prepared with 5,6,7-2H-5-deaza-6MPH4 (Figure 2.8) allow for their 
assignment to the deaza-pterin cofactor. Analysis of these data were done using 
the saffron module of EasySpin and considered the HYSCORE to arise from an 
equimolar mixture of paramagnetic centers described by |E|/D values of 0.064 and 
0.025.  Figure 2.9 shows representative simulations as red contours superimposed 
on the spectra collected at 200, 260 and 300 mT, respectively. These simulations 
used a through-space axial proton hyperfine coupling described by Aiso = 0.0 MHz 
and T = 4.0 MHz and two sets of orientations, (17°, 66°, 0°) and (70°, 66°, 0°) that 
relate the orientation of the coupled proton to the Fe-NO bond axis for the two 
discrete paramagnetic centers revealed by cw-EPR. The difference in the first angle 
for these orientations, ahf, describes different rotations about the Fe-NO bond that 
are made to position the y’ axis for the subsequent rotation of 66° to transpose the 
 




hyperfine tensor. This difference was important for the simulations of HYSCORE 
spectra closer to g = 4, 200 and 220 mT, as it allowed for the spread of cross peak 
intensity along the observed proton ridges.  
  
 
Figure 2.7 1H-HYSCORE spectra collected for PheHR[L-Phe, 5d-6MPH4] at five 
magnetic field positions across the EPR spectrum.  
 





 As stated above, parallel 1H-HYSCORE experiments on truncated enzyme, 
PheH118-452, showed nearly identical cross peak patterns to those of PheHT[5d-
6MPH4] and PheHR[L-Phe,5-deaza-6MPH4]. Specifically, 1H-HYSCORE spectra of 
PheH118-452[5-deaza-6MPH4] were consistent with two water ligands coordinated 
cis- to the Fe-NO bond, one in a “canted” or strained orientation that gave rise to 
a proton with a larger dipolar coupling (Figure 2.10). Upon addition of L-Phe to 
Figure 2.8 HYSCORE spectra collected for PheHR[L-Phe, 5,6,7-2H-5d-6MPH4] (top) 
and PheHR[L-Phe, 5d-6MPH4] (bottom), along with the structure of the deuterated 
deaza-pterin. These data were collected at 280 mT under identical conditions to those 
described for Figure 2.7. The cross-peak set circled in red are assigned to the closest 
C-5 proton of the deaza-pterin. 
 
 




give the PheH118-452 [L-Phe, 5-deaza-6MPH4] adduct, all of the cross peaks due 
these bound water ligands were replaced by a single 1H cross peak with the same 
coupling parameters as described above for PheHR[L-Phe, 5d-6MPH4] (Figure 
2.11). X-ray crystal structures of PheH103-427 [BH4] (1J8U.pdb) and PheH103-427[L-
THA,BH4] (1MMK.pdb) soaked with slow substrate L-thienylalanine (L-THA) 
show that the addition of THA induces a conformational change at the active site 
that expels the water ligands and draws the BH4 cofactor closer to Fe.28,38 Using 
these results as a foundation together with the results of HYSCORE studies of 
PheHR[L-Phe,2H-5-deaza-6MPH4] (Figure 2.8), we can assign the strong-coupled 
coupled proton that appears in the 1H-HYSCORE spectra of PheHR{L-Phe, 5d-








Figure 2.9 Simulations of 1H-HYSCORE spectra (red) for PheHR[L-Phe, 5-deaza-6MPH4] 
superimposed on three of the experimental spectra shown in figure 6. Simulations 
considered a single coupled proton characterized by a dipolar coupling of 4.0 MHz and 
an orientation with respect to the Fe-NO bond of bhf = 66º 
 





Figure 2.10 1H-HYSCORE spectra of PheH118-452[5-deaza-6MPH4] collected at 5 magnetic 
field positions across the EPR spectrum. Data were collected under conditions similar to 








2H – ESEEM 
 2H-ESEEM can be used to characterize the distance and orientation of 
deuterium on 2H-5-deaza-6-MPH4 coenzyme relative to the {FeNO}7 in PheH. 
These results can then be used in the context of the 1MMK.pdb (PheH103-427[L-THA, 
BH4] structure to better understand the binding orientation of the pterin coenzyme 
in the PheH active site.  Figure 2.12 shows orientation-selected 2H-ESEEM spectra 
for activated enzyme, wtPheHR[L-Phe,2H-5d-6MPH4] (black traces), versus 
wtPheHT[2H-5d-6MPH4] (green traces).  Qualitatively, these data show that the 
Figure 2.11 1H-HYSCORE spectra of PheH118-452[L-Phe, 5-deazz-6MPH4] collected 
at 5 magnetic field positions across the EPR spectrum of this adduct (inset). These 
data were collected under similar conditions to those of Figure 2.3. 
 




binding of substrate L-Phe at concentrations sufficient to achieve allosteric 
activation greatly enhances the 2H-ESEEM amplitude by strengthening the 2H – 
hyperfine coupling to the {FeNO}7 paramagnetic center. This result is similar to 
that reported previously for tyrosine hydroxylase (TyrH) where the binding of 
substrate tyrosine resulted in a reduction of the distance between the {FeNO}7 
center and 6,7–2H-6MPH4 and allowed for the detection of a weak 2H - hyperfine 
coupling.48  The use of 5-deaza-6MPH4 in these studies allowed for deuteration of 
the 5-position on the pterin and the subsequent measurement of a substantially 
stronger 2H-hyperfine coupling. The ESEEM results of Figure 2.12 were analyzed 
using a spin Hamiltonian for deuterium that consisted of nuclear Zeeman, 
hyperfine and nuclear quadrupole interactions and is given in Eq. 8.  
(8) 
 Following the analysis scheme used previously for TyrH, the hyperfine 
interaction was modeled with a through-space dipolar coupling so that 
 in its principal axis system and the nuclear quadrupole interaction 
was taken as axial, so in its principal axis system,  . For 
the C-5 deuteron that shows the strongest hyperfine interaction, the dipolar 
coupling, T, and angles needed to transform its hyperfine tensor could be taken 
 




from our analysis of the 1H-HYSCORE for the PheHR{L-Phe, 5d-6MPH4} sample.  
Using these values, T = 0.62 MHz, ahf = 17° and bhf = 66°, an attempt at simulating 
the data of Figure 2.12 was made by varying the three parameters needed to 
describe the nuclear quadrupole interaction, e2qQ/h and the two angles required 
to transform the quadrupole coupling tensor into the ZFS axis system. These 
simulations were done with a blended value of |E|/D = 0.044 being used to 
describe the cw-EPR spectrum. Fitting procedures considered all six spectra, or 
magnetic field positions, shown in Figure 2.12 and were judged by a reduced cn
2  






















In Eq. 9, i is the index for the discrete spectrum considered, j is the index for the 
data points considered for each ESEEM spectrum from jmin = 0.5 MHz to jmax = 4.5 
MHz, npts is the total number of points considered for all six spectra and L is the 
number of adjustable parameters. Measures of the standard deviation for each 
ESEEM spectrum, σi, were estimated from the noise level between 5 – 10 MHz. 
ESEEM spectra were calculated using the saffron module of EasySpin and the time 
domain output was normalized and processed using the same procedure used to 
 




process the experimental data allowing for direct comparison of experimental, 
yij
exp t , and calculated, saffron module of EasySpin, amplitudes. To achieve cn
2  
values less than 13 using the strong deuterium hyperfine coupling derived from 
the 1H-HYSCORE data (see above), it was necessary to include a contribution from 
a weaker 2H coupling due to the minority population of 5,6,7-2H-5-deaza-6-MPH4 
molecules deuterated at the “axial”, or weaker-coupled, C-5 position. Because the 
labeled cofactor molecules are only deuterated at a single C-5 position, the ESEEM 
spectrum for each enantiomer was simulated separately and combined with a 
weighting factor determined by their speciation prior to comparison with the data.  
  
 





 The best set of simulations (red traces) obtained for the PheHR[saffron module 
of EasySpin, 2H-5-deaza-6-MPH4] samples is displayed along with the 
experimental spectra (black traces) in Figure 2.13. These simulations yielded a cn
2  
of 1.2 and were accomplished by systematically fitting the twelve adjustable 
parameters summarized in     . T1 and T2 in the table are the 2H dipolar couplings 
for the strong-coupled, or “equatorial”, deuteron and the weak-coupled, or “axial” 
Figure 2.12: 2H-ESEEM spectra collected for PheH{5,6,7-2H-5d-6MPH4} (green) and 
PheHR{L-Phe, 5,6,7-2H-5d-6MPH4} (black). Spectra are for 6 different field positions 
across the cw-EPR spectrum of each adduct. For each spectrum, time domain ESEEM 
data for deuterated and protonated samples were normalized by dividing out their 
background decays and then dividing the two normalized data sets by one another 








deuteron, respectively. The Euler angles that described the structural relationship 
between the Fe-NO bond, the principal axis of the ZFS, and each of these coupled 
deuterons are given by (ahf1, bhf1) and (ahf2, bhf2), respectively. A uniform value was 
used for the deuterium quadrupole coupling constant, e2qQ/h, and four Euler 
angles, (aq1,bq1) and (aq2, bq2), were needed to describe the transformations required 
for the two  tensors. In the table, these angles are expressed in terms of their use 
in the EasySpin functions AFrame and QFrame where the transformation is 
described as going from the ZFS frame to the principal axis system of the hyperfine 
or quadrupole tensors, respectively. The last parameter listed in     , was used to 
weight the contributions of the strong(equatorial)- vs. weak(axial)-coupled 2H-
ESEEM spectra to the simulation. Errors in these fit parameters were estimated 
using two methods. The first approach used standard deviations derived from the 
covariance matrix calculated from the best-fit set of parameters and then 
multiplied by a factor of 6.3 to yield 90% confidence limits. The second approach 
used plots of cn
2  vs. individual parameter values and estimated errors from the 
range of parameter values that allowed for a 25% increase in cn
2 . The errors 
estimated using these two approaches were comparable as long as the variation in 
χ2 about a given optimized parameter value was parabolic. However, for the 
initial rotation of the hyperfine and quadrupole tensors, ahf1, ahf2, aq1 and aq2, the χ2 
 




surfaces are shallow and often edge-like, making the fitting relatively insensitive 
to these values. This is reasonable given that the ZFS interaction is nearly axial.  
 
  
Figure 2.13 2H-ESEEM simulations (red traces) of ESEEM spectra collected for 
PheHR{L-Phe, 2H-5d-6MPH4} (black traces). ESEEM simulations were performed 
using the saffron module of EasySpin and the spin Hamiltonian parameters given 
in Table 2.3. 
 




 The 2H-dipolar couplings, T1 and T2, and their respective orientation angles, 
bhf1 and bhf2, can be interpreted structurally using the crystal structure obtained for 
truncated PheH103-427 treated with tetrahydrobiopterin, BH4, and soaked with the 
slow substrate THA (PDB: 1MMK).38 Figure 2.14 shows the active site of this 
structure edited with PYMOL so that the N-5 of the pterin cofactor is substituted 
with carbon. The distances between Fe and the two C-5 deuterons can be estimated 
using the dipolar couplings derived from our measurements and Eq. 3. For the 
equatorial deuteron, T1 = 0.64 MHz, and this translates into a dipolar distance of 
2.6 ± 0.1 Å. Furthermore, the angle that describes the orientation of this deuteron 
with respect to the Fe-NO bond is 65 ± 4º. For the weaker coupled deuteron, the 
0.25 MHZ coupling corresponds to a dipolar distance of 3.5 Å and it is positioned 
     
Hamiltonian 
parameters 




from χ2 plots 
T1 0.645 MHz ± 0.023 ± 0.05 MHz 
ahf1 11º ± 1º (± 52º) * 
bhf1 65º ± 1º ± 4º 
aq1 22º ± 4º (± 63º) * 
b-q1 77º ± 3º ± 17º 
e2qQ/h 0.227 MHz ± 0.04 MHz ± 0.08 MHz 
T2 0.256 MHz ± 0.06 MHz ± 0.07 MHz 
ahf2 60º ±10º * 
bhf2 75º ± 13º ± 13º 
a-q2 -14º ± 66º * 
b-q2 -84º ± 66º ± 34º 
Equatorial 
Fraction 
0.57 ±0.12 ± 0.07 
* χ 2 vs. parameter plots were too shallow for error estimation. 
 
Table 2.2: Spin Hamiltonian parameters from fitting the 2H-ESEEM data from wt-
PheHR{L- Phe, 2H-5-deaza-6MPH4} shown in Figure 2.13. 
 




at an angle of 75 ± 13º with respect to the Fe-NO bond. The structure shown in 
Figure 2.14a was constructed assuming that the NO coordinates to Fe opposite to 
the axial histidine ligand pointing towards substrate THA. If NO were in this 
position, the distances from Fe and the orientation angles with respect to the Fe-
NO bond for the two C-5 deuterons would be (3.6 Å, 55º) and (3.1 Å, 85º). Figure 
2.14b shows these orientations assuming that the NO coordinates at a position 
opposite one of the chelated oxygen atoms from the bidentate glutamate sidechain. 
For this case, the deuteron closest to Fe is at (3.1Å, 66º) and the weaker coupled 
nucleus is positioned at (3.6Å, 73º). Our data clearly favor the geometry shown in 
Figure 2.14b, where the NO binds to a position favoring the pterin. Our 
measurements also show that the dipolar distances from Fe to the two C-5 
deuterons differ from those of the 1mmk structure. While the distance derived 
from the weaker coupling matches that reported for the “axial” deuteron in the 
modified 1MMK structure, the stronger coupling measured with both 1H-
HYSCORE and 2H-ESEEM yields a dipolar distance that is 0.5 Å shorter.  
 





Figure 2.14: Structural interpretation of the 2H-ESEEM data using the 1mmk 
structure from the PDB as a foundation. Stick drawings and angle measurements 
were made with PYMOL. 
 




 The possibility that this shorter dipolar distance was a consequence of using 
the point dipole-dipole approximation with the modification recommended by 
Tierney, et al. (Eq. 3),213 was examined using the approach described by Martinie, 
et al.209 Briefly, the {FeNO}7 paramagnetic center is described as consisting of an 
S=5/2 Fe(III) antiferromagnetically coupled to an S = 1 NO-.231,234Using this model, 
the structural data obtained in our measurements (    ), an Fe-N bond length of 
1.75Å, an NO bond length of 1.15Å and an Fe-N-O bond angle of 160º, we 
calculated proton dipolar couplings for the full range of NO rotamers. If the 
coupled proton is placed 2.7Å from Fe at an angle of 66º with respect to the Fe-NO 
bond, the calculated dipolar coupling ranges from 3.9 to 4.2 MHz. Taken together, 
our analysis shows that in allosterically activated PheH, the pterin is closer to Fe 
than what is depicted in the 1MMK structure and oriented so that the two dipolar 
distances differ by nearly 1 Å. This is not surprising given that our experiments 
were done with 5-deaza-6-methylpterin and the 1MMK structure features 
tetrahydrobiopterin at the active site.   
 2H-ESEEM spectra were also collected for truncated PheH samples 
PheH118-452[5,6,7-2H-5-deaza-6MPH4] and PheH118-452[L-Phe, 5,6,7-2H-5-deaza-
6MPH4] and showed nearly identical results (Figure 2.15). The spin Hamiltonian 
parameters given in Error! Reference source not found. provide an excellent fit 
 




to the 2H-ESEEM spectra collected for the PheH118-452[L-Phe, 5,6,7-2H-5-deaza-
6MPH4] sample yielding a cn
2  value of 1.1 (Figure 2.16), slightly better than the 
best value obtained for full length enzyme. PheH118-452 lacks the regulatory 
domain believed to be involved in the formation of the allosteric site. Therefore, 
the movement of the pterin is a result of L-Phe binding to the active site (not 
allosteric site) in the PheH118-452 construct. 
 
Figure 2.15 2H-ESEEM spectra collected for PheH118-452[5,6,7-2H-5-deaza-6MPH4] 
(black traces) and PheH118-452[L-Phe, 5,6,7-2H-5-deaza-6MPH4] (red traces) at 
magnetic field positions across the EPR spectrum. The two low field data sets are 
from different field values as noted in the figure. Contributions from 1H and 14N 
common to the ESEEM spectra of these samples were removed using the ratio 
procedure as described in the text. Measurement conditions were similar to those 
described for Figure 2.12 
 





Figure 2.16 Computer simulations (red traces) of the 2H-ESEEM spectra (black 
traces) collected for PheH118-452[L-Phe, 5,6,7-2H-5-deaza-6MPH4]. The simulations 
were done using the spin Hamiltonian parameters given in Error! Reference 
source not found. and fit the data with cn
2  = 1.1. 
 
 It is important to distinguish that allosteric activation is required for the 
re-orientation of the pterin and not just binding of L-Phe in the active site of 
wtPheH. To this end, we prepared parallel samples of PheHT[5-deaza-6MPH4] 
and PheHT[5,6,7-2H-5-deaza-6MPH4] using non-activating concentrations of L-
Phe for the purpose of probing pterin position with 2H-ESEEM. In preparing 
these samples, care was taken to prevent transition to the R-state by keeping the 
L-Phe concentration low and by quickly freezing the samples after L-Phe 
 




addition. Figure 2.17 shows the g = 4 region of cw-EPR spectra (black traces) 
collected for PheHT[5-deaza-6MPH4] samples prepared with (a) 180 µM of L-Phe, 
(b) 400 µM L-Phe and (c) 600 µM L-Phe added to a 2mM solution of PheHT[5-
deaza-6MPH4]. The predicted fraction of PheH bound with L-Phe is summarized 
in Table 2.3. The cw-EPR line shapes, Figure 2.17, provide evidence for at least 3 
unique paramagnetic centers distinguished by |E|/D values of 0.02, 0.04 and 
0.06. The red traces in Figure 2.17 are simulations based on the spin Hamiltonian 
given in Eq. 1 that considered these three species to be present for each sample. 
The speciation determined from these simulations is summarized in Error! 
Reference source not found. along with the results obtained from analysis of the 
EPR spectrum of PheHT[5-deaza-6MPH4]. These results show that as L-Phe is 
added to PheHT[5-deaza-6MPH4], the fraction of the |E|/D = 0.02 feature at g = 4 
is reduced from 0.92 (no L-Phe added) to 0.52 (600 uM L-Phe), while the fraction 
of the g = 4 signal with |E|/D = 0.06 increases from 0.08 (0 – 400 uM L-Phe) to 
0.21 (600 uM L-Phe). The species with |E|/D = 0.04, does not contribute to the 
EPR spectra of PheHT[5d-6MPH4] or PheHR[L-Phe, 5-deaza-6MPH4] (Table 2.1) 
and behaves like an intermediate species in the L-Phe binding process 
accounting for 41% of the g=4 signal obtained from the 400 uM L-Phe sample, but 
just 27% when a 600 uM L-Phe concentration was used. While it is not possible to 
 




assign these different paramagnetic species to specific structures, these data are 
consistent with L-Phe binding to the active site and a shift in the equilibrium, 
PheHT[2H-5-deaza-6MPH4] + L-Phe  PheHT[L-Phe,2H-5-deaza-6MPH4] (10) 
 To correlate possible changes in pterin binding, we collected 2H-ESEEM 
spectra for the PheHT[5,6,7-2H-5-deaza-6MPH4] samples treated with non-
activating concentrations of L-Phe. To interpret these data, it is important to 
briefly return to the 2H-ESEEM data presented for PheHT[2H-5-deaza-6MPH4] 
shown in Figure 2.12 (green trace).  While this figure demonstrates a pronounced 
difference in the amplitudes of the 2H-ESEEM spectra for PheHR[L-Phe,2H-5-
deaza-6MPH4] (black traces) versus PheHT[2H-5d-6MPH4](green traces), it also 
shows that the T-state adduct, PheHT[2H-5-deaza-6MPH4], has a finite 
concentration of active sites with pterin bound in a “close,” or catalytically 
competent position with respect to the {FeNO}7 center. Figure 2.18 shows a 
comparison of these two sets of 2H-ESEEM spectra with the PheHT[2H-5-deaza-
6MPH4] spectral amplitudes multiplied by factors ranging from 3 - 6 (blue 
traces). There is remarkable agreement in the 2H-ESEEM lineshapes at magnetic 
field positions across the EPR spectrum, indicating that an equilibrium exists 
between catalytic sites with pterin bound at “close,” C5-2H at 2.6Å, versus 
 




“distant,” C5-2H > 4.6Å, positions for both R- and T-state samples. 2H-ESEEM 
simulations were undertaken for the purpose of estimating the fraction of active 
sites that have “close” pterin binding for the PheHT[2H-5-deaza-6MPH4] species 
and values that averaged 22% across the EPR spectrum were found.  
 
 Figure 2.17 The g = 4 region of cw-EPR spectra (black traces) collected for samples of 
PheHT[2H-5d-6MPH4] prepared with (a) 180 µM L-Phe, (b) 400 µM L-Phe and (c) 600 µM 
L-Phe. Data were collected under conditions given for Fig. 2.2. The red traces are spectral 
simulations performed using the spin Hamiltonian given by Eq. 1 and the parameters 
given in Error! Reference source not found.. 
 





Figure 2.18 2H-ESEEM spectra collected for PheHR[L-Phe,2H-5d-6MPH4] (black) and 
PheHT[2H-5d-6MPH4] (green). The red traces were derived from the T-state, PheHT[2H-
5d-6MPH4] spectra and obtained by multiplying their amplitudes by factors that ranges 
from 3 – 6. The agreement between the 2H-ESEEM lineshapes provides evidence that 
even T-state enzyme, PheHT[2H-5d-6MPH4] has a population of 5d-6MPH4 at the active 










Table 2.3: Speciation wtPheH[5-deaza-6MPH4] with varying concentration of L-Phe.  
[L-Phe]0 [L-Phe] eq wtPheH[L-Phe,5-deaza-
6-MPH4] 
Fraction of PheH active 
site bound with L-Phe 
180 µM 10 µM 166 µM 0.08 
400 µM 25 µM 370 µM 0.18 
600 µM 42 µM 548 µM 0.27 
Calculated using Kd, active=110 µM, Kd, allosteric=800 µM, and a [wtPheH] of 2 mM 
 
Table 2.4 Analysis of EPR spectra collected for PheHT{pterin} titration with L-Phe 
 
Figure 2.20 shows 2H-ESEEM spectra collected at 220, 300 and 320 mT for 
the PheHT[2H-5-deaza-6MPH4] (green trace) and PheHT [600 uM L-Phe, 2H-5-
deaza-6MPH4] (blue trace) samples. Also shown with these data at each magnetic 
field position is a 2H-ESEEM simulation (red trace) that shows the predicted 
ESEEM response for a sample with 27% of the pterin molecules at the “close”, or 
catalytically active, position where the dipolar distance between the Fe center 
and the equatorial C5 deuteron is 2.6Å, and the remaining 73% is 2 Å further 
Sample |E|/D Fraction of total 
amplitude 



























removed from the metal. These data show that the 2H-ESEEM response for the 
two T-state samples, PheHT[2H-5-deaza-6MPH4] (green) and PheHT[600 uM L-
Phe, 2H-5-deaza-6MPH4] (blue) are nearly identical given the experimental 
signal-to-noise ratio. Comparison of the simulation with both data sets shows 
some agreement at 300 and 320 mT, and also for the PheHT[2H-5-deaza-6MPH4] 
sample at 220 mT. As stated above, an analysis of the competing equilibria 
associated with L-Phe binding to the active- and allosteric-sites shows that 27% 
of the active sites for the PheHT[600uM L-Phe, 2H-5-deaza-6MPH4] sample 
should contain bound L-Phe. It is important to note that these samples are 
prepared in such a way as to prevent allosteric activation. Because we do not 
observe a measurable change in the population of active sites with the pterin 
coenzyme in the “close” position, it is likely that the shift in the pterin binding 
equilibrium (close vs. distant) requires allosteric activation.  As a result, when a 
non-activating concentration of substrate L-Phe is added to the wild type 
enzyme, the specific catalytic activity remains low.  
  
 





Figure 2.19: 2H-ESEEM spectra collected for PheHT[600 uM L-Phe, 2H-5-deaza-6MPH4] 
(blue traces) and PheHT[2H-5-deaza-6MPH4] (green traces) using the division or ratio 
method. The read traces are simulations using the spin Hamiltonian parameters of 
Table 2 to describe 27% of the coupled C5 deuterons of pterin at the active site (“close” 
population). The remaining 73% of active sites were described by a model that 
positioned the pterin 2Å further away from the metal center so that the dipolar 
couplings for the C5 deuterons became T1 = 0.11 MHz and T2 = 0.07 MHz 
 
 





 One of the central goals of this study was to understand the chemical basis 
for the increase in activity seen upon the T→R conversion of PheH. Proper 
positioning of the pterin coenzyme was previously proposed to be important for 
coupling of pterin oxidation and product formation.95 It has also been proposed 
that allosteric activation alters the BH4 binding site.31 Using the simulation 
scheme detailed above, loss of 2H-ESEEM we observed for PheHT[5,6,7-2H-5-
deaza-6MPH4] and PheH118-452[5,6,7-2H-5-deaza-6MPH4] samples would require 
4.6 Å between the C5 protons on the pterin coenzyme and  the metal ion.  These 
results suggest allosteric activation of wtPheH induces a reorganization of the 
active site that causes the pterin coenzyme to move ~2 Å closer to the iron center. 
This repositioning of the pterin coenzyme could serve two purposes. i)  
Repositioning of BH4 increases the rate of reaction of BH4 with O2. The in-
solution rates of BH4 reacting with O2 (0.6 M-1 s-1)32 are not kinetically competent 
with catalytic turnover (10-20 s-1).143 Therefore, the repositioning of the BH4 could 
allow an enhanced rate of O2 reactivity by altering local environment of BH4 with 
regards to alteration in hydrogen bonding network and/or dipole fields. ii) The 
movement of the pterin coenzyme closer to the iron center allows for the 
formation of Fe-OO-BH2 adduct after formation of c4a-peroxy-BH2 species. In the 
 




T-state, BH4 is too far away to form the Fe-OO-BH2 adduct regardless of O2 
activation. However, upon allosteric activation BH4 is brought close enough to 
the iron center to form Fe-OO-BH2 adduct. 
Finally, ESEEM results of PheH118--452 were nearly identical to those of wild 
type enzyme, PheH. In the absence of substrate, the deuterons at the 5 position of 
5-deaza-6MPH4 are positioned more than 4.6 Å from the iron center. The PheH118-
-452 construct lakes the regulatory domain thought to be involved in the formation 
of the allosteric site. Therefore, it is substrate binding to the active site that moves 
the 5-deaza-6-MPH4 ~2 Å closer to the iron center. PheH118-452 behaves as though it 
is allosterically activated and has several similar properties as wtPheHR similar 
fluorescence emission spectrum,39equilibrium to favor a tetramer over the 
dimer,39 enhanced rates of NO binding39, and ability to adhere to a phenyl-
Sepharose resin. However, PheH118-452 does have some similarities with wtPheHT 
such as inability to adhere to a phenyl-Sepharose resin and slower rates of NO 
binding. Therefore, if PheH118-452 is indicative of the R-state of PheH, it would 
suggest that it is binding of L-Phe in the active site that induces the repositioning 
of the BH4 coenzyme. Perhaps allosteric activation of PheH by L-Phe binding to 
the allosteric site simply places the enzyme into a state where this L-Phe induced 
active-site reorganization can occur.  
 




A similar study used 2H-ESEEM to examine the pterin coenzyme position 
in TyrH, another member of the AAAHs family.48  Unlike, PheH, TyrH has not 
been shown to be allosterically regulated by its substrate L-Tyr. Here, 2H-ESEEM 
was used to determine the orientation of 6,7-2H2-6-MPH4 with and without 
substrate L-Tyr. The pterin coenzyme used in the TyrH study differs from the 
one used in this study in two different ways: the first is that the TyrH study used 
a redox active 6-MPH4 having a nitrogen atom in the 5 position. In contrast, this 
current study used 5-deaza-6-MPH4, which has a carbon in the 5 position. The 
second difference is that the in the TyrH the deuterium are incorporated on the 6 
and 7 position whereas when using 5-deaza-6-MPH4, the deuterium are 
incorporated on the 5,6, and 7 position. It is important to note that, while both 6-
MPH4 and 5-deaza-6-MPH4 likely bind in similar if not identical orientations, our 
study detected changes in the orientation of the 5 position, the TyrH study 
detected changes in the 6 position.  
In TyrH, in the absence of substrate L-Tyr, the deuterium on 6,7-2H2-6-
MPH4 were outside the detection limit of the technique (>5.9 Å). However, upon 
the addition of substrate, the deuterium label at the 6 position shows an effective 
dipole-dipole distance to the {FeNO}7 of 4.4±0.2 Å and a βhf of 66±5°. Like, 5-
deaza-6-MPH4, the synthesis used to generate 6,7-2H2-6-MPH4 results in a 
 




distribution of axial and equatorial deuteria at 6 position. However, the 2H-
ESEEM spectra in the TyrH were simulated to a single deuterium. Therefore, a 
direct comparison in terms of the exact pterin position are difficult to make. 
However, these results are consistent with a reorganization of the active site that 
occurs upon substrate binding to the active site of TyrH akin what is seen in 
PheH118-452. 
Conclusion:  
 The studies presented in this chapter suggest that allosteric activation by 
L-Phe allows for a substrate induced reorganization of the active site that places 
the pterin coenzyme closer to the iron center. Our comparative study of wtPheH 
and truncated enzyme, PheH118-452 in which the regulatory domain (and therefore 
allosteric site) was removed, suggest that a similar reorganization of the active 
site occurs when L-Phe binds to the active site of PheH118-452. This re-positioning 
of the pterin coenzyme facilitates its reaction with O2 to form the Fe-OO-adduct 
in the proposed catalytic mechanism of PheH. With a better understanding of a 
chemical basis for the enhanced catalytic activity upon allosteric activation, we 
may be able to understand the decrease in activity in some PKU mutants. In 
particular, two PKU mutants—R158Q and E280K—are thought to result in a 
misalignment of the BH4. These mutants exhibit a decrease in coupling of pterin 
 




oxidation and product formation. Therefore, an obvious extension of these 
studies would be to examine how the pterin coenzyme binds in these mutants 
compared to wtPheH.  
  
 




Chapter 3 Pulsed-EPR analysis on the role of allosteric activation and 
coenzyme binding on the orientation of L-Phe in PheH 
Introduction: 
 PheH catalyzes the conversion of L-Phe to L-Tyr using BH4 and O2 and is 
allosterically regulated by its substrate L-Phe.85 All three substrates must bind in 
the correct orientation in the active site for coupled catalysis to occur. Therefore, 
an important goal in understanding both the regulatory and mechanistic 
properties of PheH is to understand how these substrates bind in the PheH active 
site and how these substrates interact with each other and the non-heme iron 
center.  
 Despite the importance of understanding how L-Phe interacts in the active 
site, a lack of relevant crystal structures has hindered the understanding of these 
properties. Currently, there are no crystal structures of PheH containing L-Phe in 
the active or allosteric site. Attempts to soaking L-Phe into PheH103-427[BH4] 
resulted in the crystal cracking and disintegrating.  Instead, L-Phe analogs (L-
Thienylalanine and norleucine) have been used to generate a ternary crystal 
structures of the catalytic domain of PheH (residues 103-427).34,38 Therefore it is 
unclear if the crystal structures containing L-THA or norleucine are reflective of 
L-Phe binding to PheH. Additionally, the allosteric site, would not be present 
because these crystals lacked both the regulatory and tetramerization domain. 
 




Therefore, any changes between these ternary crystal structures and the binary 
PheH103-427[BH4] structures would be a result of substrate analog binding in the 
active site (excluding differences that occur as a result in differences in 
crystallization procedure). 
 While less is known about the structural effects the occur upon binding of 
L-Phe, spectroscopic studies have been able to examine the effects substrate 
binding has on the iron center. Previous MCD/XAS studies in the Caradonna lab 
have examined the effect of substrate binding on the properties of the active site 
iron using MCD/XAS.14 Both wtPheHT[ ] and wtPheHT[L-Phe] had MCD 
spectrum that were qualitatively similar. In these cases, both MCD spectra had 
two peaks centered around ~ 10,000 cm-1 separated by ~ 2,000 cm-1 characteristic a 
six-coordinate octahedral ferrous center. However, the wtPheHT[L-Phe] MCD 
spectrum had a slight increase ligand field strength (10Dq=10,000 cm-1, ∆5Eg=1450 
cm-1) compared to wtPheHT[ ] (10Dq=9400 cm-1, ∆5Eg=1800 cm-1).  The increase in 
ligand field strength was attributed to substrate binding near the iron center. 
Further, allosteric activation resulted in no change in the MCD spectrum 
(10Dq=10,000 cm-1, ∆5Eg=1450 cm-1) and is essentially identical to the MCD 
spectrum of wtPheHT[L-Phe].  
 




 Understanding of how L-Phe binds in the active site has important 
mechanistic implications on the catalytic mechanism of PheH. One important 
mechanistic marker in the PheH mechanism is the migration of the para-
substituent to the meta position known as an NIH shift (Figure 3.1).66 Several 
proposals have been used to explain the NIH that occurs upon O atom transfer 
from the iron-oxo to the phenyl ring.  One proposal suggest that a 3,4-epoxide 
occurs after O atom transfer from the iron-oxo.72 A second proposal suggest that 
the para position is directly hydroxylated by OH+.66 Others have proposed a 
direct coordination of L-Phe to the iron center via a bridging oxygen at the para-
position. Determination of the position of L-Phe in the active will aid in 
determination of how L-Phe might interact with the iron-oxo.  
 




 Previous studies by Gulbenk Anarat-Cappillino have suggested that the 
para-position is not the closest position to the iron center in the allosterically 
activated state.  In these experiments, the para-2H-L-Phe gave weak ESEEM 
signals. However, the per-2H-L-Phe gave much greater ESEEM signals. 
Therefore, the closest position to the iron center on the phenyl ring must be 
either the meta or ortho position. To determine the binding orientation of L-Phe 
more directly in the active site PheH, a series of site specifically deuterated L-Phe 
substrates were used to prepare the various mechanistic states of PheH. This will 




Figure 3.1: Proposed mechanism for the O atom transfer from the iron-oxo to the 
phenyl ring in the catalytic mechanism of PheH 
 
 




across the various mechanistic states of PheH. Specifically, this chapter aims to 
address how both allosteric activation and binding of the pterin coenzyme affect 
the position of L-Phe. 
Materials/Methods: 
Materials 
 Para-chloro-L-Phe was purchased from Chem-Impex International. meta-
dichloro-L-Phe was purchased from Acrotein Chembio. ortho-dichloro-DL-Phe 
from Amatek. 3,3-2H-L-Phe and per-d5-L-Phe were purchased from Cambridge 
Isotope. Diethylamine NONOate (DEA/NONOate) was purchased from Cayman 
Chemicals. d3-Hypophosphorous Acid was purchased from Sigma Aldrich. 
MOPS (morpholinepropanesulfonic acid), KCl, and dithionite were purchased 
from Fischer Scientific 
Growth/Purification 
All enzyme was grown and purified as previously described in Chapter 2. 
Preparation of deuterated substrates 
 meta-2H-L-Phe and ortho-2H-DL-Phe synthesized from 3,5-Cl-L-Phe were 
2,6-Cl-DL-Phe, respectively, using modified procedure.239 Briefly, the reaction 
mixture contained 250 mgs (1.07 mmol) of either meta-Cl2-L-Phe or ortho-Cl2-DL-
Phe, 443 mg (3.21 mmol) K2CO3, 30 mg 10 % Pd/C, and 6 mL D2O. To the reaction 
 




mixture, 2 mmol of D3PO2 dissolved in 4 mL of D2O was added dropwise over 
gentle heat. The solution was refluxed for 24 hr and then quenched with ~ 4 mL 
of 1 M HCl.  The Pd/C was removed by filtration. Unreacted D3PO2 was removed 
by extraction with diethyl ether. Saturated NaHCO3 was added to neutralize the 
aqueous layer. The aqueous layer was then evaporated to dryness in vacuo. 
Because of the residual KCl that remained after purification, solutions of 
deuterated L-Phe substrates were estimated using an ε260= 200 M-1cm-1. 
 
Physical Methods and Data Analysis 
 
The cw-EPR and ESEEM collection as well as data analysis has been described in 
Chapter 2. 
 
Preparation of EPR samples 
All samples were prepared in an inert atmosphere (N2) glovebox maintained in a 
4° walk-in cold room. 
wtPheHT [meta-d2-L-Phe] 
wtPheH (~30 mgs) was concentrated to 200 µL Centricon (30 K) 
microconcentrators (Millipore). The sample was then transferred into an inert 
atmosphere glovebox. Dithionite was then added to a final concentration of 20 
mM and incubated for 5 minutes upon which the solution turned clear. The 
 




solution was then added to 10 mgs of DEA/NONOate and incubated for 10 
minutes. Immediately upon addition to DEA/NONOate, the enzyme solution 
turned orange-yellow color. A 100 mM stock of meta-d2-L-Phe in 50 mM MOPS/ 
0.3 M KCl pH 7.2 was used to bring the final concentration to 20 mM L-Phe. The 
solution was then loaded into an EPR tube and frozen in N2(l) 
wtPheHR [meta-d2-L-Phe] 
 This sample was prepared in a similar way to wtPheHT [meta-d2-L-Phe] 
except that wtPheH (30 mgs) was initially diluted to ~ 2 mg/mL using 50 mM 
MOPS/0.3 M KCl. A 100 mM stock of meta-d2-L-Phe in 50 mM MOPS/ 0.3 M KCl 
pH 7.2 was used to bring the final concentration to 20 mM L-Phe. The sample 
was incubated for 10 minutes at 25 °C in a water bath. The sample was 
concentrated to 200 µL. The reduction PheH and generation of NO was the same 
as wtPheHT [meta-d2-L-Phe].  
wtPheHR [meta-d2-L-Phe, 5-deaza-6-MPH4] 
This sample was prepared in a similar way to wtPheHT [meta-d2-L-Phe] except 
that wtPheH (30 mgs) was initially diluted to 15 mL using 50 mM MOPS/0.3 M 
KCl/ 10 mM deaza-6-MPH4.  The solution was then concentrated to ~ 200 µL and 
the dilution-concentration cycle was repeated two more times.  Before the last 
concentration step, 100 mM stock of meta-d2-L-Phe in 50 mM MOPS/ 0.3 M KCl 
 




pH 7.2 was used to bring the final concentration to 20 mM L-Phe. The sample 
was incubated for 10 minutes at 25 °C in a water bath. The sample was 
concentrated to 200 µL. The reduction PheH and generation of NO was the same 
as wtPheHR [meta-d2-L-Phe] 
wtPheHT [2,6-d2-DL-Phe] 
This sample was prepared identically to wtPheHT [meta-d2-L-Phe] except that 
ortho-d2-DL-Phe was used in place of meta-d2-L-Phe. 
wtPheHR [ortho-d2-DL-Phe] 
This sample was prepared identically to wtPheHR [meta-d2-L-Phe] except that 
ortho-d2-DL-Phe was used in place of meta-d2-L-Phe. 
wtPheHR [ortho-d2-DL-Phe, 5-deaza-6-MPH4] 
This sample was prepared identically to wtPheHR [meta-d2-L-Phe, 5-deaza-6-
MPH4] except that ortho-d2-DL-Phe was used in place of meta-d2-L-Phe. 
wtPheHT [3,3-d2-L-Phe] 
This sample was prepared identically to wtPheHT [meta-d2-L-Phe] except that 
3,3-d2-DL-Phe was used in place of meta-d2-L-Phe. 
wtPheHR [3,3-d2-L-Phe] 
This sample was prepared identically to wtPheHR [meta-d2-L-Phe] except that 3,3-
d2-DL-Phe was used in place of meta-d2-L-Phe. 
 




wtPheHR [3,3-d2-L-Phe, 5-deaza-6-MPH4] 
This sample was prepared identically to wtPheHR [meta-d2-L-Phe, 5-deaza-6-
MPH4] except that 3,3-d2-DL-Phe was used in place of 3,5-d2-L-Phe. 
Results/Discussion  
Cw-EPR spectra  
 The cw-EPR spectra for the various PheH mechanistic states examined in 
this study are shown Figure 3.2. All spectra contain a highly axial spectrum with 
a feature at g=4. The addition of L-Phe, but not pterin, appears to increase the 
rhombicity of the iron center. The observation of a change EPR spectrum upon 
addition of L-Phe (but not allosteric activation) suggest that L-Phe can bind to the 
active site in the absence of allosteric activation. Allosteric activation by L-Phe 
further changes the cw-EPR spectrum. The cw-EPR spectrum for wtPheHR[L-Phe] 
is best simulated to three slightly rhombic species (Figure 3.2). Lastly, the addition 
to pterin to form PheHR[L-Phe,5-deaza-6-MPH4] further distorts the cw-EPR 
spectrum. This spectrum is best fit to two slightly rhombic species. 
 
 






Figure 3.2 cw-EPR spectra for the a)wtPheHT[ ]-NO b) wtPheHT[L-Phe] c) wtPheHR[L-
















 The EPR spectrum for the PheHT[L-Phe] sample was not similar to the 
analogous isotopically enriched samples. Therefore, the spectra for the 
deuterated samples could not be divided by the spectrum for wtPheHT[L-Phe] to 
examine the site-specific deuterium contributions. Therefore, the wtPheHT[per-
d5-L-Phe] spectrum was divided by either the PheHT[ortho-d2-L-Phe] or 
PheHT[meta-d2-L-Phe] to examine the deuterium contributions of the 
complementary ring positions. The 2H-ESEEM spectra corresponding to the 2H in 
the 3,4, and 5 positions and the 2,4, and 6 positions are shown in Figure 3.3. 
These spectra were obtained by division of the PheHT[per-d5-L-Phe] by the 
PheHT[ortho-d2-L-Phe] and PheHT[meta-d2-L-Phe] spectra, respectively. The 2H-
ESEEM spectrum for 3,4, and 5 deuterons was generated by division PheHT[per-
d5-L-Phe] by the PheHT[ortho-d2-L-Phe] envelope. Likewise, the 2H-ESEEM 
spectrum for 2,4, and 6 deuterons were generated by division of PheHT[per-d5-L-
Phe] by the PheHT[meta-d2-L-Phe] sample. There is a feature ~ 2 MHz that 
dominates each spectrum. Regardless, both spectra give shallow 2H-ESEEM 
signals that suggest that these deuterons are far away from the {FeNO}7.  
 






 The 2H-ESEEM spectra for PheHR[para-2H-L-Phe] is shown in Figure 3.4. 
There is a weak 2H-ESEEM interaction suggestive that the para-position in far 
from the {FeNO}7 center. Sample of PheHR[per-2H5-L-Phe] , PheHR[ortho-2H2-L-
Phe],  and PheHR[meta-2H2-L-Phe] did not give cw-EPR spectra that were similar 
to either the PheHR[para-2H-L-Phe] or PheHR[L-Phe].  Because the cw-EPR spectra 
did not match, the quotient ESEEM method could not be applied to these 
deuterated samples. 
Figure 3.3: 2H-ESEEM spectra for 3,4,5 deuterons (red) and the 2,4,6 deuteron (black) 
 





Figure 3.4: 2H-ESEEM spectra for PheHR[para-2H-L-Phe]. The Larmor frequency is marked 
by the red arrow 
 




PheHR [L-Phe, 5-deaza-6-MPH4] 
 The cw-EPR spectra for PheHR [L-Phe, 5-deaza-6-MPH4] prepared with all 
isotopically enriched substrates were similar enough to be used in this study.  
The ESEEM spectra for wtPheHR[per-d5-L-Phe, 5-deaza-6MPH4] is shown in 
Figure 3.5. In contrast to the previous spectra, there is a large 2H-ESEEM signal. 
The largest amplitude peak is found at g = 4 (lower field) and that indicates that 
the deuteron(s) giving rise to the interaction are approximately perpendicular to 
the Fe-NO bond. Since there are five potential deuterons that can interact with 
the iron center, simulation of this spectrum can be challenging. Therefore, site 
specifically deuterated (ortho, meta, and para) substrates where used to aid in the 
determination of the L-Phe position. The 2H ESEEM spectrum for wtPheHR[para-
2H-L-Phe, 5-deaza-6-MPH4] is shown in Figure 3.5. Surprisingly, the 2H ESEEM 
intensity for wtPheHR [para-2H-L-Phe, 5-deaza-6-MPH4] is small compared to that 
of wtPheHR [per-2H-L-Phe, 5-deaza-6-MPH4]. The low intensity 2 H-ESEEM 
signal suggests that the para-position (i.e. the site of hydroxylation) is not the 
closest deuteron to the iron center.  
  
 




 In order to further determine the orientation of L-Phe, both 
wtPheHR[ortho-2H-DL-Phe,5-deaza-6-MPH4] and wtPheHR[meta-2H-L-Phe,5-
deaza-6-MPH4] were generated to determine the orientation of the ortho and 
meta position with respect to the iron ring.  It should racemic mixture of ortho-
Cl2-DL-Phe was used for the preparation of ortho deuterated phenylalanine 
substrate. However, the D isomer of phenylalanine has a reduced affinity for the 
active and allosteric site of PheH. Previous studies by Sarah Soltau in the 
Caradonna group have demonstrated that D-Phe concentration 10 mM resulted 
in no change in the fluorescence emission spectrum.124  In contrast, binding of L-
Figure 3.5: 2H-ESEEM spectra for PheHR[per-2H5-L-Phe, 5-deaza-6-MPH4](red) and 
wtPheHR[para-2H2-L-Phe] (black). 
 




Phe to the active and/or allosteric causes shift in fluorescence peak maxima. The 
maximum shift occurs at ~ 1.5 mM. Because of the reduced affinity of D-Phe for 
the active and allosteric site, it is assumed that L-Phe out competes D-Phe in the 
active and allosteric site and that there is little to no D-Phe bound in either site. 
 The 2H ESEEM spectra for wtPheHR[ortho-DL-Phe,5-deaza-6-MPH4] and 
wtPheHR[meta-L-Phe,5-deaza-6-MPH4] are shown in Figure 3.6 and 3.7. The 
ortho and the meta position contribute approximately the same to the 2H-ESEEM 
spectra. These results suggest that both the meta and ortho positions are close to 
the {FeNO}7. 
Figure 3.6: 2H-ESEEM spectra for PheHR[per-d5-L-Phe, 5-deaza-6-MPH4]( red) and 
wtPheHR[meta-2H2-L-Phe] (black) 
 






 The goal of this study was to determine how the orientation of L-Phe in 
the active changes upon allosteric activation and binding of the pterin coenzyme. 
By understanding these changes, we can than relate the different orientations of 
L-Phe to our understanding of the allosteric activation process and the catalytic 
mechanism of PheH. This study was able to demonstrate that the meta and ortho 
position of the phenyl ring are the closest ring positions to the iron center in the 
fully activated PheHR[L-Phe,5-deaza-6-MPH4] state. It is important to note the 
Figure 3.7: 2H-ESEEM spectra for PheHR[per-d5-L-Phe, 5-deaza-6-MPH4](red) and 
wtPheHR[ortho-2H2-L-Phe] (black) 
 




our ESEEM measurements correspond to the distance between the deuterons on 
L-Phe and the iron center and not the ferryl oxygen—the atom that directly 
reacts with the L-Phe substrate.  
 The observation that the meta and ortho positions are similarly close to 
the iron center has important implications to our understanding of the O atom 
transfer step in the catalytic mechanism. There have been three main proposals 
for the O atom transfer reaction between the iron-oxo and L-Phe substrate. The 
first involves the addition of O across the 3,4 π bond to form a 3,4 epoxide.72 
Opening of the 3,4-epoxide would form phenol followed by subsequent 
migration of the para-substituent. The second proposed mechanism involves 
direct hydroxylation of the para-position by an OH+ with subsequent migration 
of the initial para-substituent. 66 A third proposed mechanism involved direct 
coordination of L-Phe to the iron center via a bridging O atom. The low 2H 
ESEEM signal for wtPheHR[para-2H-L-Phe, 5-deaza-6-MPH4] suggest that the 
para-position is too far away to directly react with the iron-oxo (Figure 3.1 top and 
bottom). Additionally, the observation that the meta and ortho position are closer 
to the iron center in the wtPheHR [L-Phe, 5-deaza-6-MPH4] than the para position 
favors an O atom transfer step involving the formation of an epoxide. In this 
 




proposal, the iron-oxo would add the O atom over the π cloud like an electric 
aromatic addition reaction.240 
 Another study had used 2H-ESEEM the binding orientation of L-Tyr in 
TyrH.48 Specifically, this study used 3,5-2H2-L-Tyr to determine how the binding 
of 6-MPH4 affects L-Tyr orientation. In this study demonstrated that the 
TyrH[3,5-2H2-L-Tyr] sample had βhf=26±5° and a reff=4.1±0.1 Å. Upon binding of 
6-MPH4 the reff increased to 4.7±0.2 Å and the βhf increased to 94±10°. The changes 
in βhf and reff were attributed to changes in the coordination of NO from an axial 
position in the TyrH[L-Tyr] to an equatorial position in TyrH [L-Tyr, 6-MPH4]. 
Therefore, the authors suggested that binding of 6-MPH4 did not alter the 
position of L-Tyr. TyrH and PheH appear to bind their respective substrates in 
different positions with respect to orientation of the site of hydroxylation to the 
iron center. These difference in binding modes might suggest that there are 
subtle differences in the respective catalytic mechanism of the AAAHs. This 
would be expected given that PheH catalyzes a reaction on an unactivated 
aromatic ring as opposed to TyrH which catalyzes the hydroxylation of an 
activated aromatic ring.  Therefore, in TyrH mechanism, the hydroxyl group 
adjacent to the site of hydroxylation might alter the O atom transfer step in the 
reaction compared to the PheH mechanism. 
 





In the absence of allosteric activation and pterin binding, L-Phe substrate appears 
to be position away > 5 Å from the {FeNO}7 center. However, in the PheHR[L-Phe, 
5-deaza-6-MPH4] state the L-Phe substrate is positioned much closer the iron 
center such that the ortho and meta position contribute equally to the 2H-ESEEM 
signal of PheHR[L-Phe, 5-deaza-6-MPH4]. This observation that the meta and 
ortho positions are closer to the Fe center support a mechanism where O atom 
transfer from the iron-oxo leads to the formation of an 3,4-epoxide on the phenyl 
ring of L-Phe.  
  
 




Chapter 4 HYSCORE Analysis of the Primary Iron Coordination Sphere of 
PheH 
Introduction 
Non-heme iron oxygenases are ubiquitous throughout nature having a wide 
range of functions including the metabolism amino acids85, degradation 
xenobiotics, and biosynthesis of natural products.241 These enzymes have a 
characteristic 2His-1Glu(Asp) motif in which the iron center adopts an 
octahedral geometry coordinated by two histidine residues, either a glutamate or 
aspartate, and three waters.26,60 However, there are variations of the 2His-1Glu 
motif that involve the iron being coordinated  3His-1Glu, 4His242 or a 2His-1Glu-
1Tyr (intradiol cleavage dioxygenase) with a Tyr residue displacing a water 
molecule and other motif are also known. The three open coordination sites 
provided by the bound waters allow for the binding of either substrate, cofactor, 
or dioxygen. Additionally, binding of either substrate or cofactor can trigger the 
dissociation of a water molecule to form a five-coordinate square pyramidal iron 
center. Therefore, the determination of their primary coordination sphere is 
important to understanding the catalytic mechanism of these enzymes.  
One member of the non-heme iron oxygenase enzymes is Phenylalanine 
Hydroxylase (PheH). PheH catalyzes the conversion of L-Phe to L-Tyr using 
tetrahydrobiopterin and O2. PheH has a six-coordinate octahedral geometry until 
 




both substrate and cofactor are bound in the active site and allosteric activation 
occurs, whereupon the iron center adopts a five-coordinate square pyramidal 
geometry with loss of water.12–14 While MCD/XAS has unambiguously 
determined the geometry of the iron center, other details of the primary 
coordination sphere are uncertain such as the identity of the ligands comprising 
the primary coordination sphere, the denticity of E330, and the number of 
coordinated waters. The currently available crystal structures provide an 
inconsistent depiction of the primary coordination sphere of the iron center. 
There are currently only three full-length crystal structures of PheH.9–11 The 
remaining crystal structures are of truncated constructs lacking either the 
regulatory domain, tetramerization domain, or both. Therefore, it is unclear 
whether the variations seen are a result of plasticity of the truncated constructs of 
if they are representative of the actual primary coordination sphere of the iron 
center. The binary (with coenzyme bound) and ternary complex (with substrate 
analog and coenzyme bound) show that neither substrate analog nor coenzyme 
coordinate directly to the iron center. These crystallographic results are 
consistent with MCD/XAS12–14 data and other studies31 that suggest that neither 
substrate or coenzyme bind to the iron center. 
 




Traditional methods for determining water coordination to metalloenzymes 
involve both CW-EPR243–245 and pulsed-EPR spectroscopies.213,246 The first method, 
compares the line-broadening in the CW-EPR spectra of H2O and 17O enriched 
H2O. The 17O broadens the signals in CW-EPR spectrum because of the weak 
hyperfine interaction between the 17O (I=5/2) and the Fe center that is not present 
for 16O (I=0) H2O. However, because of the weak hyperfine coupling interaction, 
the CW-EPR spectrum typically broadens by a few mT. Coordinated waters can 
be detected using and 17O and 2H enriched H2O and looking at the corresponding 
resonances using ENDOR.213 However, there can be significant overlap between 
17O resonance with non-exchangeable nitrogen features. Lastly, the ESEEM 
quotient method using D2O to examine exchangeable waters has also been used. 
However, there can been overlap with nearby exchangeable protons such as 
those found on coordinated histidines.246  
Because of the difficulties associated with determining waters coordinated to 
non-heme iron metal centers we sought to develop new method for counting 
these coordinated waters. We have previous carried out a study on model 
complexes that have a core facial N,N,O binding motif to an Fe(II) that vary in 
the number of carboxylates ligated to the iron.236 Varying the number of 
carboxylates in turn varies the number of labile ligand sites. HYSCORE 
 




spectroscopy was used to examine these model complexes. Because of the strong 
dipolar coupling associated with protons on water coordinated to the Fe (II), 
their signals are easily distinguishable on a HYSCORE spectrum. These model 
studies have allowed us to analyze the corresponding HYSCORE for non-heme 
iron enzymes. In this study, we extended the HYSCORE analysis from model 
systems to biological system (i.e. PheH). In this study, wtPheH and three select 
PheH mutant (PheH118-452, E286A, and E330A) were examined. PheH118-452 lacks 
the regulatory domain and behaves as though it is allosterically activated i.e. it 
does not require pre-incubation with L-Phe for full activity. Previous studies 
from the by Gulbenk Anarat-Cappillino have suggest that wtPheH and PheH118-
452 have different primary coordination spheres.39 Here, association rate constant 
for the formation NO binding to wtPheH were best fit to a single exponential. 
However, association rate constant for the formation NO binding to PheH118-452 
were best fit to a two- exponential. These results suggested that PheH118-452 has at 
least one more labile ligand site compared to wtPheH. E286 was the closest 
residue that could coordinate to an iron center. Therefore, E286A mutant was 
selected for further analysis in this study. E330 is a residue that was shown to 
bind to non-heme iron center. Therefore, the E330A mutant was chosen to probe 
 








 wtPheH and PheH1188-452 were grown and purified as previously described 
in Chapter 2. E286A and E330A were grown and purified in the same manner as 
wtPheH except FeCl3 not added during the growth. 
Reconstitution of PheH118-452, E286A, E330A 
 PheH118-452, E286A, and E330A were reconstituted with Fe using the 
reconstitution procedure in Chapter 2 
HYSCORE Sample Preparation 
wtPheHT [ ] 
wtPheHT [ ] sample was made as previously described in Chapter 2 
wtPheHT [ L-Phe] 
wtPheHT[L-Phe] was prepared as previously described in Chapter 2 
wtPheHR [ L-Phe] 
wtPheHR[L-Phe] was prepared as previously described in Chapter 2 
 




wtPheHR [L-Phe, pterin] 
wtPheHR [L-Phe, pterin] was made as previously described in Chapter 2 
PheH118-452 [] 
PheH118-452[] was made in an identical manner to wtPheHT[ ] 
PheH118-452 L-Phe] 
PheH118-452[ L-Phe] was made in an identical manner to wtPheHT [L-Phe] 
PheH118-452 [ L-Phe, pterin] 
PheH118-452 [ L-Phe, pterin] was made as previously described in Chapter 2 
E3286A [] 
E286A [] was prepared in an identical manner to wtPheHT [ ] 
E286A [L-Phe, pterin] 
E286A [L-Phe, pterin] was prepared in an identical manner to wtPheHT [ ] 
E330AT [] 
E330A [] was prepared in an identical manner to wtPheHT [ ] 
E330AT [ L-Phe] 
E330A [ L-Phe] was prepared in an identical manner to wtPheHR [ L-Phe] 
 




E330AR [L-Phe, pterin] 
E330AR [L-Phe, pterin] was prepared in an identical manner to wtPheHT [ ] 
Preparation of 17O enriched samples 
 wtPheHT [ ], PheH118-452 [ ], E286A [ ], and E330A [ ] were concentrated to 
500 uL and buffer exchanged into 50 mM MOPS/ 50 mM KCl pH 7.2 using a PD-
10 column following manufacturer’s protocol. The protein solution was then 
concentrated to 200 µL and frozen in N2(l). The protein sample was then 
lyophilized and brought into an inert atmosphere glove under N2(g). The 
solution was then resuspended in 200 µL of 70% 17O H2O. Powder KCl was 
added to achieve a final concentration of 300 mM. Dithionite was added to final 
concentration of 20 mM and incubated for 10 minutes.  DEA/NONOate (10 mgs) 
was added to the protein solution and incubated for 10 minutes. The solution 
was loaded into an EPR tube and immediately frozen in N2(l). 
PheH118-452[L-Phe, 5-deaza-6-MPH4] was made identically to wtPheHT[ ] except 
after the addition of KCl, powder L-Phe and 5-deaza-6-MPH4 was added to the 
protein sample to achieve a final concentration of 10 mM L-Phe and 10 mM 5-
deaza-6MPH4. 
EPR methods 
The EPR samples were analyzed in the same as Chapter 2. 
 





17O enriched water 
 Only wtPheHT[ ] (wtPheH with neither L-Phe or pterin bound) and 
PheH118-452[L-Phe, 5-deaza-6-MPH4] (PheH with the first 117 residues absent 
prepared with L-Phe and pterin) samples had similar enough CW-EPR to 
directly examine the line-broadening the occurs upon 17O enrichment. The 16O 
and 17O samples for wtPheHT[ ] are shown in Figure 4.1. There is clear line-
broadening in the 17O sample compared to the 16O sample. This line-broadening 
can be quantified in two ways—directly determination of the line-broadening or 
determination of the Aiso. The former was used by Han et al. in their study of 
cvPheH. Han et al. determined the line-broadening by simulating the 16O 
spectrum to determine spin Hamiltonian parameters, |E|/D, g-values, and E-
Strain. Then these same parameters were used to simulate the 17O spectrum, but 
the intrinsic linewidth was varied. Using this method, 103, 103, and 65 MHz 
linewidths were determined for the x, y, and z portion of the spectrum for 16O 
sample. For the 17O sample the linewidths were 126,126, and 92 MHz. The second 
method to determine line broadening involves determination of the Aiso. Like the 
first method, the parameters determined from the 16O spectrum were used to 
simulate the initial 17O spectrum. Then two bound waters (with an appropriate 
 




ligand hyperfine coupling) were added into the simulation to determine the 
isotropic hyperfine coupling. Using this method Aiso = - 8 ± 4 MHz was 
determined. A simulation of this data is shown in Figure 4.2. 
 




Figure 4.2: cw-EPR spectra for wtPheHT[ ]-NO prepared in 17O water (black) and the cw-
EPR spectrum simulated with two water ligands (red)Figure 4.1: Cw-EPR spectra for 
wtPheH[ ]-NO prepared in 16O (black) and 17O (red) water. 
 
 






 The 16O and 17O PheH118-452[L-Phe,5-deaza-6-MPH4] CW-EPR spectrum are 
shown in Figure 4.3. Unlike cw-EPR spectra for wtPheHT [ ], the 16O and 17O 
spectrum are nearly identical indicative of no bound waters to the {FeNO}7 
paramagnetic center. The 16O spectrum was a 50:50 of two paramagnetic centers. 
One with |E|/D = 0.026 (inner two peaks) and one with |E|/D = 0.065 (outer two 
peaks that are somewhat broader). The |E|/D = 0.065 for both 16O and 17O 
samples could be fit using the same linewidth parameters.  However, the |E|/D = 
Figure 4.2: cw-EPR spectra for wtPheHT[ ]-NO prepared in 17O water (black) and 
the cw-EPR spectrum simulated with two water ligands (red)  
 
 




0.026 species has smaller linewidths for the 17O sample compared to the 16O. The 




Figure 4.3: cw-EPR spectra for PheH118-452[L-Phe,5-deaza-6-MPH4]-NO 16O (black) and 
17O (red) water. There is little to no line-broadening the occurs upon 17O enrichment 
suggestive of no coordinated waters to the {FeNO}7 center 
 
 





 The cw-EPR spectra for E286AT[ ] (Figure 4.4), E330AT[ ] (Figure 4.5), and 
PheH118-452[ ] (Figure 4.6) samples prepared in 17O water did not have comparable 
spectra to those samples prepared in 16O water. The reason for large differences 
in spectrum is unclear but could be a result of different methods used to generate 
the {FeNO}7 adduct. While line broadening in cw-EPR spectrum could not be 
used to determine the number of coordinated waters, other methods that rely on 
the 17O nuclei such as ENDOR or 17O HYSCORE could be used to determine 
coordinated waters in these samples.  
 
Figure 4.4: Cw-EPR spectra for E286A[ ]-NO prepared in 16O (black) and 17O 
(red) water. 
 





Figure 4.5: Cw-EPR spectra for E330[ ]-NO prepared in 16O (black) and 17O (red) 
water. 
 






wtPheHT [ ] 
The HYSCORE spectrum for wtPheHT [ ] is shown in Figure 4.7. One set of cross 
peaks could be resolved at 260 and 280 mT. The cross peaks for water appear to 
be diffuse and of a low intensity at 240 and 300 mT.   The diffuse cross-peaks are 
likely a result of rotational dispersion of the water molecules. An increase in 
rotational dispersion broadens the cross-peak contours as there are more 
available orientation between 1H and the {FeNO}7.  
 
Figure 4.6: Cw-EPR spectrum of PheH118-452[ ]  prepared in 17O 
enriched water 
 







Figure 4.7: HYSCORE spectra for wtPheHT[ ]. Samples were prepared by Dr. Gulbenk 
Anarat-Cappillino. 
 





 The HYSCORE spectra for wtPheHT[L-Phe] is shown in Figure 4.8. In 
contrast to the HYSCORE spectra of wtPheHT [ ] show evidence for two waters at 
280 mT in the 16-19 MHz region. 
 
wtPheHR[L-Phe] 
 The HYSCORE spectra for wtPheHR[L-Phe] are shown in Figure 4.9.  At 
280 mT over the range from 15 – 20 MHz there is a clean spectral window for 
 
Figure 4.8 HYSCORE spectra for wtPheHT [L-Phe]. Samples were prepared by 
Gulbenk Anarat-Cappillino.  
 




defining 1H couplings from water molecules. The 1H-HYSCORE spectra are 
similar to wtPheHT[L-Phe] suggesting that there are two waters coordinated to 
the {FeNO}7 center.   
 
 
Figure 4.9 HYSCORE spectra for wtPheHR [L-Phe]. Samples were prepared by 
Gulbenk Anarat-Cappillino.  
 
 





 The HYSCORE spectra for PheH118-452[ ] (Figure 4.10) are generally poor 
(except for 260 mT) and show no cross-peaks associated with H2O.  The reason 
for lack of cross peaks could be a result of rotational dispersion similar to what is 
seen in wtPheHT [ ].  
  
 
Figure 4.10: 1H-HYSCORE spectra for PheH118-452[L-Phe]. Samples were 
prepared by Gulbenk Anarat-Cappillino 
 





 The PheH118-452[L-Phe] data are shown in Figure 4.11 and are very much 
like those collected for PheHT[L-Phe] and PheHR[L-Phe] (Figure 4.12).  The main 
difference is that the HYSCORE spectra for PheH118-452[L-Phe] show better cross 
peak intensities as you can now resolve 4 cross peaks for strongly coupled 
protons at 260 and 280 mT. These spectra are consistent with {FeNO}7 center 
coordinated with two waters.  
  








E286A [ ] 
 The HYSCORE Spectra for E286A[ ] is shown in Figure 4.13. While there 
are cross peaks consistent with bound waters, the intensity is weaker than what 
was observed in either wtPheHT[ ] or PheH118-452. The reason for the weaker 
intensity could be a result of fewer coordinated water to the {FeNO}7 center or 
because of a greater spread of conformational rotamers for the bound waters.  
  
Figure 4.12: 1H-HYSCORE spectra for PheH118-452[L-Phe](left), PheHT[L-Phe] 
(center), and wtPheHR[L-Phe](right) at 220 mT and 260 mT. The HYSCORE spectra 
for each of are qualitatively similar. 
 
 




E286A [L-Phe, 5-deaza-6-MPH4 ] 
 The HYSCORE spectra for E286A[L-Phe, 5-deaza-6-MPH4 ] is shown 
Figure 4.14. The HYSCORE spectra are very similar to the HYSCORE spectra for 
wtPheHR[L-Phe, 5-deaza-6-MPH4 ] (Figure 4.15) suggesting no bound waters in 
the ternary state for either enzyme. The data show 1H-cross peaks consistent with 
a single, strong dipolar coupling and are nearly identical to spectra observed for 
 
Figure 4.13: 1H-HYSCORE spectra for E286A[ ]. Samples were prepared by Breia 
Salsbury  
 




wtPheHR[L-Phe, 5-deaza-6MPH4]. This coupling arises from the C5 proton of the 
reduced pterin cofactor that comes closest to the {FeNO}7 paramagnetic center. 
The similarity in HYSCORE spectra suggest that the pterin coenzyme bind in 
identical manners in the ternary state of wtPheH and E286A.   
 
 
Figure 4.14: 1H-HYSCORE spectra for E286A[L-Phe, 5-deaza-6-MPH4]. The 
cw-EPR spectrum is shown in the bottom right hand corner 
 





E330A [ ] 
 The cw-EPR spectra for E330A[ ], E330A[ 5-deaza-6-MPH4], and E330A[L-
Phe, 5-deaza-6-MPH4 ] are shown in Figure 4.16. The spectra for these samples 
represent a single species have a modest rhombicity with |E|/D of about 0.02. 
The quaternary sample has a cw-EPR response similar to what has been 
observed for the quaternary samples of wtPheH and PheH118-452, a roughly 60/40 
mixture of paramagnetic centers with |E|/D = 0.02 and 0.05, respectively. The 
 
Figure 4.15: 1H-HYSCORE spectra for wtPheHR[L-Phe, 5-deaza-6-MPH4] (black) 
and E286A[ L-Phe, 5-deaza-6-MPH4] (red)  
 




HYSCORE spectra for E330A[ ] is shown in Figure 4.17. The data show cross 
peaks characterized by a stronger 1H-dipolar coupling that is best viewed at 240 
mT.  It appears that they first become visible at 220 mT and then actually move 
outward, away from the frequency diagonal as one goes to higher field.  These 
cross peaks are not resolved at 320 mT or 200 mT.   
 
Figure 4.16 cw-EPR spectra for E330A[ ] (top), E330A[ 5-deaza-6-MPH4] (middle), 
and E330A[L-Phe, 5-deaza-6-MPH4 ] (bottom). Samples were prepared by Breia 
Salsbury   
 




                                                                                                   
E330A[L-Phe] 
 The 1H-HYSCORE data collected for the E330A[L-Phe] sample (Figure 
4.18) are very similar to that shown above for the sample with no additions, 
E330A [ ]. The 1H-cross peaks that are split away from the anti-diagonal, 
Figure 4.17: 1H-HYSCORE for E330A [ ] 
 




indicating a stronger dipolar coupling, originate at 220 mT and move away from 
the frequency diagonal as you go to higher field.  
 
 
Figure 4.18 1H-HYSCORE spectra for E330A[L-Phe, 5-deaza-6-MPH4]. Samples 
were prepared by Breia  
 





 Finally, the 1H-HYSCORE collected for the quaternary sample of E330A[L-
Phe, 5-deaza-6-MPH4] (Figure 4.19) and is almost identical to wtPheHR[L-Phe, 5-
deaza-6-MPH4] (Figure 4.20). This coupling is due to the C5 proton of the 
reduced pterin that comes closest to the Fe-NO center when bound.   
Figure 4.19 1H-HYSCORE spectra for E330A[L-Phe, 5-deaza-6-MPH4]. 
Samples were prepared by Breia Salsbury   
 







Figure 4.20: 1H-HYSCORE spectra for E330A [L-Phe, 5-deaza-6MPH4] 
overlaid with E330A[L-Phe, 5-deaza-6-MPH4]. Samples were prepared 
by Breia Salsbury   
 





 The aim of this chapter was to use cw-EPR and 1H-HYSCORE 
spectroscopies to probe the primary coordination sphere of wtPheH and select 
PheH mutants for the purpose of determining the number of bound water 
ligands and gaining a measure of the active site flexibility.  
 For both wtPheHT[ ] and PheH118-452[ ], little to no cross-peak intensity for 
strongly coupled 1H, indicative of water coordination, was observed. In the 
wtPheHT [ ] 1H-HYSCORE spectra, there were low intensity cross-peaks 
corresponding to 1H from bound waters. We were only able to resolve one set of 
cross-peaks at 260 and 280 mT. At 240 mT, the cross peaks for water were diffuse 
and at 300 mT, there was no observable cross-peaks corresponding to bound 
waters. In contrast, the cw-EPR spectra for wtPheHT [ ] made in 17O enriched 
water suggested that there are two coordinated waters to the {FeNO}7 center.  
The reason why these cross peaks were not as intense as expected based on our 
17O experiments can be explained by high rotational freedom for the bound 
waters. An increase in the dispersion of water molecule orientation would lead to 
an increased range of dipolar couplings. The increased range of dipolar 
couplings would cause the cross-peaks to become more diffuse. The 1H-
HYSCORE spectra for PheH118-452[ ] had no evidence of 1H cross-peaks 
 




corresponding to coordinated waters. MCD studies suggest that the geometry of 
PheH118-452[ ] retains its six-coordinate octahedral geometry. Therefore, the lack of 
1H cross-peaks is likely a result of increased rotational dispersion compared to 
wtPheH rather than a change in iron geometry. 
 Both E286A [ ] and E330A[ ] do show evidence for at least one bound 
water. In E286A [ ], while there are cross-peaks consistent with one bound water, 
these cross-peaks are weaker than what was observed in wtPheHT[L-Phe], 
wtPheHR[L-Phe], or PheH118-452[L-Phe]. However, the spectra of E286A [ ] are 
different enough from those wtPheHT[L-Phe], wtPheHR[L-Phe], or PheH118-452[L-
Phe] that the reduced amplitudes might be a result of increased rotational 
dispersion.  In a crystal structure of fL-PheH (5DEN.pdb), E286 made hydrogen 
bond interactions with one of the waters coordinated to the iron center. As 
E286A cannot make this hydrogen bond interaction, the coordinated water 
would have a greater rotational freedom. Additionally, the decrease in amplitude 
might arise from NO binding in a different coordination site that would yield 
smaller dipolar couplings. In the E3330A 1H- HYSCORE spectra, cross-peaks 
associated with water protons move outward as the field strength is increased. 
This behavior is consistent with a model where the water protons are aligned 
with the Fe-NO bound. This type of behavior is opposite of what is seen in 
 




wtPheHT [ ], PheH118-452[ ], and E286A [ ]. These changes in behavior in both 
E286A and E330A HYSCORE spectra suggest that these mutants have altered 
behavior compared to either wtPheH or PheH118-452.  
 For wtPheH and PheH118-452 addition of either L-Phe or 5-deaza-6-MPH4 
(Chapter 2 and Chapter 3) to free enzyme appears to increase the cross-peaks 
intensity for 1H from coordinated waters. The cross-peak intensity is consistent 
with two coordinated waters. The binding of either L-Phe or 5-deaza-6-MPH4 
appears to impart some rigidity to the active site decreasing the rotational 
dispersion of the coordinated water molecules. In contrast, the E330A[L-Phe] 1H-
HYSCORE spectra had similar cross-peak intensities as the E330A [ ] spectra. 
Here, both E330A [ ] and E330A [L-Phe] had evidence for strong 1H couplings. 
These results suggest the waters coordinated to the {FeNO}7 center in E330A 
behave differently in terms of their rigidity or orientation with respect to NO 
compared to either wtPheH or PheH118-452 
 WtPheHR[L-Phe,5-deaza-6-MPH4] , PheH118-452[L-Phe,5-deaza-6-MPH4 ], 
E286A[ L-Phe, 5-deaza-6-MPH4], and  E330A[L-Phe,5-deaza-6-MPH4]  nearly 
identical 1H-HYSCORE spectra. These spectra show no evidence for coordinated 
waters. The primary 1H coupling arises from the C5 protons on the 5-deaza-6-
 




MPH4 coenzyme.  These results indicate that the ternary complex of all four 
PheH constructs have similar primary coordination spheres and that the pterin 
coenzyme binds in a similar orientation. E330 residue is expected to be bidentate 
in wtPheHR [L-Phe, 5-deaza-6-MPH4]. However, E330A is not able to coordinate 
to the iron center and lacks evidence for coordinated waters.  This observation 
raises the question of what ligands to are {FeNO}7 is in E330A [L-Phe, 5-deaza-6-
MPH4]. One possibility is that E286 adopts a bidentate conformation. E286 is the 
closest residue that can coordinate to the iron center. In the 1mmk.pdb structure 
of PheH103-427[L-THA, BH4] crystal structure oxygen of the carboxylate group is 
4.9 Å away from the iron center. E286A has also been implicated in pterin 
binding. 27,33,247–250 Despite this, the pterin coenzyme appaers to bind in a similar 
orientation compared to wtPheH. 
Conclusion 
The results of this study suggest that there are two the waters coordinated to the 
{FeNO}7 in wtPheH [ ]. These water molecules have a high degree of rotational 
dispersion reducing the intensity of their signal in the 1H HYSCORE spectra. 
However, addition of either L-Phe or pterin coenzyme impart some rigidity to 
the active site reducing the rotational dispersion of these water molecules. Lastly, 
the addition of both L-Phe and pterin coenzyme causes iron center to adopt a 
 




five-coordinate square pyramidal geometry with loss of two water molecules. 
The addition of L-Phe and pterin will cause PheH to adopt this geometry even 








Chapter 5 Interaction of pterin coenzyme and oxygen within the protein 
scaffold of Phenylalanine Hydroxylase 
Introduction 
 Dioxygen can serve as an oxygen source in a variety of enzymatic 
reactions. However, reactions between O2 (S=1) and organic compounds 
(typically S=0) are forbidden because of Wigner’s spin conservation rule. 
Consequently, Nature had developed several methods to activate O2. Non-heme 
iron monooxygenases are a class of enzymes that can activate O2 
 Non-heme iron monooxygenases are a class of enzymes that activate O2 
and do so using a variety of methods. One sub-class of enzymes in this family is 
the aromatic amino acid hydroxylases (AAAHs).85 These enzymes are involved 
in the metabolism  of the aromatic amino acids and biosynthesis of the 
neurotransmitters dopamine and serotonin. PheH, specifically, catalyzes the 
conversion of L-Phe to L-Tyr using dioxygen and a tetrahydropterin coenzyme in 
the rate-determining step biosynthesis of dopamine. However, how these 
enzymes active O2 remains controversial. 
 PheH is allosterically activated from a low activity T-state to a high 
activity R-state by its substrate L-Phe. The activity of PheH must be tightly 
controlled not only to control physiological level of L-Phe in the bloodstream, but 
 




also to unwanted activation of O2 and subsequent formation of H2O2 that occurs 
upon the uncoupling of the reaction. Activation of O2 results in the formation of a 
Fe-OO-pterin adduct. Heterolytic cleavage of the peroxy bond yields the iron-
oxo responsible for hydroxylating L-Phe and c4a-hydroxy-BH2. However, the 
intimate details of how the Fe-OO-adduct is formed remain elusive.  
 There have been multiple proposals for how PheH activates O2. Some 
have proposed that the iron center reacts with O2 to form an iron superoxide.56 
This proposal was supported by DFT studies using PheH118-424[BH2] to determine 
energetics of O2 reacting first with the iron center or with the pterin coenzyme. 
However, it is uncertain if the crystal structure used is representative of an 
activated form of PheH. Chapter 2 demonstrated that pterin coenzyme moves ~ 
1.8 Å closer to the iron center upon binding of substrate. Therefore, crystal 
structure lacking the substrate L-Phe may not be reflective of the change in pterin 
position. Additionally, the rate of oxidation of the ferrous center is slow ( 2.6 x 10-
4 s-1) regardless of the presence of substrate or a redox inactive coenzyme.39 If the 
iron center were responsible for the activation of O2 it would be expected that the 
rate of oxidation of the ferrous center by O2 were at least the same order of 
magnitude the observed rate of catalysis (10-20 s-1).251 Therefore, it is not likely 
the iron center is the initial site of activation of O2.  
 




 Pterins can react with O2 in solution (0.6 M-1s-1).32 However, the rate of 
reaction is not kinetically competent with turnover rate (10-20 s-1). However, 
flavin dependent monooxygenases which use a structurally related flavin 
cofactor, can modulate the reactivity of flavins in the active site.252–254. Therefore, 
PheH active could tune the reactivity of pterin coenzyme through possible 
alteration in dipole field or hydrogen bond network to increase the reactivity of 
the pterin coenzyme. In this study, the rate of pterin oxidation was examined in 
the absence of an iron center to probe how the rate of pterin oxidation changes 
within the protein scaffold of PheH.  
Materials and Methods 
 All chemical were purchased from commercial vendors except for 6-MPH4 
which was synthesized using established procedures.255 
Growth 
 Growth and purification of PheH and PheH118-452 were performed as 
detailed in Chapter 2. 
Preparation of apo-PheH 
 Apo-PheH was prepared using adaptions of literature procedures which 
use a reductant (DTT) and a ferrous chelator (o-phenanthroline) to remove the 
iron from the active site.129,143 Both wtPheH and PheH118-452 was diluted to 2-3 
 




mg/mL in 50 mM MOPS, 0.3 M KCl, 15% glycerol, pH 7.2. The addition of 
glycerol was necessary to prevent denaturation of the enzyme. O-phenanthroline 
was added to a final concentration of 15 mM from 300 mM stocks in isopropanol. 
Slow addition of o-phenanthroline to the enzyme solution was necessary to 
prevent precipitation of enzyme. Β-ME was added to final concentration of 15 
mM. The enzyme was then incubated at 4 °C for 60 minutes whereupon a red 
color associated with Fe(o-phenanthroline)32+ slowly formed. Fe(o-
phenanthroline)32+ and excess o-phenanthroline and β-ME (beta-
mercapatoethanol) were removed by either repeated concentration and dilution 
cycles using a Centricon spin column or by dialysis using 50 mM MOPS. 0.3 M 
KCl, 5% glycerol, pH 7.2. A persistent red color occurred following dialysis and 
dilution-concentration cycles. The red color could be removed by the addition of 
3 mM o-phenanthroline and 3 mM B-ME and further concentration and dilution 
cycles.  
Iron content measurements 
 The iron content was measured using an Agilent 4200 MP-AES. Both 
wtPheH and PheH118-452 samples were diluted to 0.3 mg/mL in 2% HNO3. The 
digested samples were briefly spun to pellet the denatured enzyme. A standard 
curve was generated using iron concentrations ranging from 0- 1 ppm Fe. The 
 




iron content of the 50 mM MOPS/0.3 M KCl pH 7.2 was also measured and 
subtracted from the iron measurement of the enzyme to account for trace 
amounts of iron in the buffer. 
UV-Vis measurements of pterin oxidation 
 The rates of 6-(R)-BH4 were measured using a Hewlett-Packard 8452 diode 
array spectrometer in kinetics mode. The cuvette cell holder was attached to 
water cooler set at 8 °C.  A completed assay mixture contained 0.1 M potassium 
phosphate pH 6.8, 3000 U/mL catalase, 5 µM enzyme, and 100 µM (6R)-BH4 or 6-
MPH4, and varying concentrations of L-Phe or D-Phe. For experiments where 
apo-wtPheH was incubated with L-Phe, apo-wtPheH was incubated with the 
indicated concentration of L-Phe or D-Phe at 25 °C for minutes and immediately 
placed on ice until measurements were taken. The absorbance was measured 
between 200-600 nm. Spectra were taken every 0.5 seconds for 60 seconds. The 
rates were measured using the slope over 30 seconds of the linear portion using 
Δε330=3500 M-1cm-1 for (6R)-BH4 and Δε334=3300 M-1cm-1 for 6-MPH4 
O2 consumption assay 
 A NeoFox Optical Oxygen sensor with stirring attachment was used to 
measure O2 concentration. The assay contained 0.1 M phosphate pH 6.8, 5 µM 
enzyme, 3000 U/mL catalase, +/- 1 mM L-Phe,100 µM (6R)-BH4. The assay was 
 




initiated by the addition of (6R)-BH4 to an otherwise complete reaction mixture. 
The rates of O2 consumption calculated by using the first 60 seconds of the linear 
region of O2 consumption.  Assays were performed at room temperature (~ 23 
°C). 
H2O2 measurements 
 H2O2 measurements were performed using a colorimetric Ti-PAR 
reagent.256 The Ti-PAR reagent is generated by mixing equimolar amounts of 
TiCl4 and 4-(2-pyridylazo)rescorcinol (PAR). TiCl4 was first diluted to 438 mM in 
4 M HCl then further diluted to 1 mM with deionized water. PAR was dissolved 
in 0.25 M NaOH to a concentration of 25 mM and further diluted to a 
concentration of 1 mM in deionized water. The final Ti-PAR reagent was made 
by combing 4 mL each of 1 mM stock and diluting with 2 mL of deionized water 
to make a 400 µM Ti-PAR solution. 
 Standard curves were generated from commercial grade 3% hydrogen 
peroxide that had been diluted to 1 mM in deionized water. Each standard 
solution was generated by diluting 400 µL of the Ti-PAR reagent with 0.1 M 
phosphate buffer pH 8.0 and adding 1 mM hydrogen peroxide to a final volume 
of 1000 µL. The solution was incubated at 42 °C for 5 min and the absorbance at 
508 nm was measured. Incubation at temperatures > 30 °C are necessary in order 
 




to remove the chromophore associated with the Ti-PAR reagent itself which has 
a broad absorbance around 530 nm. Under these conditions that molar extinction 
coefficient (32,000 M-1cm-1) agreed well with other reports at pH from 7.2-8.5 
(30,000-32,000 M-1cm-1).256,257 
 For measurements of H2O2, the assays contained 0.1 M potassium 
phosphate pH 8.0, 5 µM enzyme, 100 µM (6R)-BH4, and +/- 1 mM L-Phe. The 
assay was initiated by the addition of (6R)-BH4 and allowed to incubate room 
temperature for 3 minutes. Afterwards, 200 µL of the assay was added to 400 µL 
of 0.1 M potassium phosphate and 400 µL of Ti-PAR reagent. The reaction was 
then incubated at 42 °C for 5 minutes and the UV-Vis absorbance spectrum was 
immediately taken. 
Detection of Tyrosine by HPLC 
 Tyrosine formation was detected using an Hewlit-Packard 1100 HPLC 
with diode array detection with a Diamonsil 5µM C18(2) 250 x 4.6 mm column 
and a mobile phase of 5% Acetonitrile 95% water. Under these conditions, 
phenylalanine, tyrosine, meta-tyrosine, and ortho-tyrosine can be separated.  The 
amino acids were detected at 210 and 275 nm (Figure 5.1) 
 















































Figure 5.1: Separation L-Tyr, o-DL-Tyr, m-L-Tyr, and L-Phe using a C18 
column a mobile phase of 5% Acetonitrile at A) 210 nm and B) 275 nm. All 
standards made to a concentration of 10 µM. L-Phe does not have an 
appreciable absorbance at 275 nm at a concentration of 10 µM 
 




Results and Discussion 
 In order to examine how the protein scaffold of PheH influences the rate 
of pterin oxidation by O2, both the formation of oxidized pterin (q-6-MPH2) and 
consumption of O2 were measured using apo-wtPheH and apo-PheH118-452. The 
apo version of both wtPheH and PheH118-452 was used to prevent catalytic turnover 
and examine the initial O2 activation step. The iron center is removed from 
wtPheH and apo-PheH117-452 using the ferrous chelator o-phenanthroline and B-
ME as a reductant. This apo-preparation procedure yields enzyme containing 
<0.01 Fe/subunit. 
Absorption spectroscopy 
 The rate of oxidation of 6R-BH4 by O2 can be followed by measuring the 
absorbance at 330 nm—the  isosbestic point for the q-6BH2 to 7,8-dihydro-6-BH2 
(Figure 5.2). The immediate oxidation product for the uncoupled oxidation of 
6R-BH4 is q-6-BH2. Once the q-6-BH2 species forms, it can tautomerizes to the 7,8-
dihydro-6-BH2 in a solvent and buffer mediated process. Therefore, in order to 
minimizes the contribution of this tautomerization process, the rate of (6R)-BH4 
oxidation was measured at 330 nm.  
  
 














































Figure 5.2: A) UV-Vis for (6R)-BH4, q-BH2, and (6R)-BH2.B) UV-vis absorption spectra for 6-
(R)BH4(black) and tautomerization of q-BH2(red) to 7,8-dihydro-BH2(violet) in 0.1 M potassium 
phosphate pH 6.8. q-BH2 is formed by the mixing BH4 with two molar equivalents of potassium 
ferricyanide. Spectra for the q-BH2 to 7,8-dihydro-BH2 tautomerization were taken in one-minute 
intervals except for the last which was taken 10 minutes after the previous spectra. The spectra for 
the q-BH2 to 7,8-dihydro-BH2 tautormerization had the spectrum for 200 µM ferrocyanide subtracted 
from their spectrum. Isosbestic points for the q-BH2 to 7,8-dihydro-BH2 occur at 286, 330, and 350 
nm. Arrows points in direction of increasing time. 
 





















































Figure 5.3 Time dependent diode array UV-vis spectra for the oxidation of 100 µM (6R)-BH4 
with 5 µM apo-wtPheH (top) and 0.1 µM Fe2+wtPheH (bottom) activated by 1 mM L-Phe. Spectra 
are shown in five-second intervals for clarity. The increase at 275 nm corresponds to the 
formation of L-Tyr while the absorbance at 330 nm corresponds to the formation of q-BH2. 
 




 The spectrophotometric changes that occur upon the oxidation of BH4 in 
the presence of apo-PheHR[L-Phe] are qualitatively different from those that 
occur in the presence of Fe2+PheHR[L-Phe] (Figure 5.3). In the presence of 
Fe2+PheHR[L-Phe], the oxidation of BH4 is tightly coupled to the formation of L-
Tyr. In contrast, in the presence apo-PheHR[L-Phe], the peak at 330 nm (q-BH2 
formation) builds up faster relative to peak at 275 nm (L-Tyr formation) than in 
Fe2+PheH. These results qualitatively suggest that the oxidation of BH4 to q-BH2 
occurs without L-Tyr production with apo-PheHR[L-Phe] 
 In order to probe the effect of allosteric activation on the rate of BH4 
oxidation, the L-Phe dependent rate of BH4 oxidation were measured for both 
apo-wtPheHT [L-Phe, BH4] and apo-wtPheHR[L-Phe, BH4].  In order to minimize 
allosteric activation during measurements with apo-wtPheHT [L-Phe, BH4] both 
(6R)-BH4 and a decreased temperature were used in this experiment. The natural 
coenzyme (6R)-BH4 is a known allosteric inhibitor of PheH and slows the rate 
allosteric activation and thus prevents the T→R transition.125 A low temperature 
(8 °C) also significantly slows the rate of allosteric activation which has a strong 
temperature dependence.52 
 




  In the absence of allosteric activation, the rate of BH4 oxidation is slow  
but still exhibits an L-Phe dependent increase in BH4 oxidation (Figure 5.4). The 
L-Phe dependent increase in BH4 oxidation could be a change in active properties 
that occur when L-Phe binds to the active site or by a small of amount of apo-
wtPheH that has converted to the R-state. In contrast, in apo-wtPheH [L-Phe, 
BH4] exhibits a much greater L-Phe dependent manner increase in the rate of 
(6R)-BH4 oxidation. The kinetics of the L-Phe dependent enhancement in (6R)-
BH4 oxidation does not appear to follow either Michaelis-Menten or cooperative 
behavior. Instead, the there is a nearly linear increase in the rate of BH4 oxidation 
over 100-600 µM. When using 6-MPH4 which does act as an allosteric inhibitor, 
the rate L-Phe dependent 6-MPH4 oxidation (calculated using a ε334 =3,400 M-1cm-
1) is much greater than when using 6R-BH4. The increase in the rate BH4 
oxidation could not be reproduced when using D-Phe as a substrate/activator 
suggesting that the increase in oxidation is attributed to L-Phe binding to the 









The apo-PheH118-452 construct also exhibits an L-Phe dependent increase in 
(6R)-BH4 oxidation (Figure 5.5). The maximal rate of BH4 oxidation is similar to 
apo-wtPheH when using 6-MPH4(which does not act as an allosteric inhibitor125). 
PheH118-452 lacks the regulator domain and behaves as though it is allosterically 
activated; the truncated enzyme does not need preincubation with L-Phe to reach 
maximal activity as there is no identified allosteric change. PheH118-452 also lacks 
the N-terminal auto-regulatory region thought to interact with the BH4 
coenzyme. This interaction is proposed to be responsible for the inhibitory 
character of BH4 
Figure 5.4: Dose response curves for the PheH-dependent oxidation of BH4 and 6-MPH4. R-
state was achieved by incubating PheH with L-Phe for 10 minutes. All reactions were 










































  Both the apo-PheH and apo-PheH118-452 constructs appear to exhibit an 
increase in BH4 oxidation. However, removal of the iron center may cause 
structural changes that could influence the binding L-Phe or BH4 in the active 
site. Therefore, Zn2+ was used to probe the effects of a divalent cation binding in 
the active site. Zn2+ is both redox inert and isosteric with Fe2+. The PheH118-452 
construct is more readily metallated compared to the full-length wtPheH and so 
was used in this set of experiments. The presence of 5 equivalents of ZnCl2 (25 
µM) resulted in a modest decrease in the rate of BH4 oxidation compared the rate 



































Figure 5.5: L-Phe dose response curve for the PheH118-452 oxidation of BH4 with and without 
the presence of 25 uM ZnCl2. All reactions were initiated by the addition of BH4. 
 




O2 consumption   
 O2 is proposed to initially react with apo-wtPheHT [L-Phe, BH4] BH4 in the 
PheH mechanism. Therefore, to probe PheH-dependent oxidation of BH4, the 
rate of O2 consumption was measured across different mechanistic states of apo-
PheH and apo-PheH118-452 as an orthogonal method to measure the oxidation of 
BH4 by O2 within the protein scaffold. Consistent with the UV-Vis measurements 
of BH4 oxidation, upon the addition of L-Phe to either apo-PheH and apo-
PheH118-452, there is a dramatic increase in the rate of O2 consumption (Table 5.1). 
The rate of O2 consumption by PheH118-452 was unaffected by the presence of 500 
µM EDTA. The observation that EDTA had no effect on the rate of O2 suggest 
that the resulting increase in O2 observed in the presence of L-Phe was not 
attributed to trace amounts of iron incorporating into the PheH118-452 active site.  
Product determination 
 The high enzyme concentration (5 µM) used in these assays raises the 
possibility that the increase in BH4 oxidation was a result of small amounts of 
PheH still containing an iron center. This small amount of Fe3+PheH would result 
              Table 5.1: µmol of O2 consumed/min using conditions in the Experimental section 
(-)L-Phe (+)L-Phe 
wtPheH PheH118-452 wtPheH PheH118-452 
5.3±0.5 13.3±0.9 41±1 34±7 
 
 




in coupled turnover where L-Tyr is formed. In contrast, in uncoupled turn-over 
(what occurs in apo-PheH) the products are q-BH2 and H2O2.  Therefore, in order 
to examine if the PheH-dependent BH4 oxidation was a solely result of 
uncoupled turnover and not due to a small fraction of metallated holo-PheH, the 
amount of H2O2 and L-Tyr were measured. H2O2 was measured using a Ti-PAR 
reagent and L-Tyr was detected using HPLC and LCMS 
 The Ti-PAR-H2O2 species has a strong absorbance at 508 nm (Figure 5.6). 
The presence of apo-PheH[L-Phe] and apo-PheH118-452[L-Phe] decrease the 
amount of H2O2 (Table 5.2).  As Table 5.2 shows, BH4 will react with O2 to form 
H2O2 even in the absence of PheH. The decrease in the amount of H2O2 formed is 
likely a result of a greater amount of coupled turnover. A significant amount of 
coupled turnover was further supported by HPLC and LCMS results which 
suggest a large formation of L-Tyr under these assay conditions.  
 










































Figure 5.6 H2O2 determination using Ti-PAR reagent. H2O2 concentrations ranged from 0-
20 µM A) Diode array spectra for Ti-PAR-H2O2 adduct. Formation of the Ti-PAR-H2O2 
complex results in a chromophore with a λmax at 508 nm. B) Calibration curve for the Ti-
PAR-H2O2 assay. The absorbance at 508 nm has a linear concentration dependence from 0 
-20 µM. 
 






 A central theme of this thesis is examining how allosteric activation 
influences the active site properties of PheH. Previous studies from our lab have 
shown that allosteric activation results in a 25-fold increase (8.8 ±1.6 s-1 for 
wtPheHT[ ] vs 212 ±5 s-1) in the rate of NO binding to the iron center.39 These 
results suggest that allosteric activation may cause a formation of gas channel 
which contributes to the increased in activity observed upon allosteric activation. 
39 While NO is often used an analog for O2, oxidation of the ferrous PheH iron 
center by O2 is not kinetically competent with catalytic activity.39 Therefore, O2 
likely reacts with BH4 in the initial activation step of O2.  Chapter 2 demonstrated 
allosteric activation causes the pterin coenzyme to move ~ 1.8 Å closer to the iron 
center. While BH4 will react with O2 in solution32, the rate BH4 oxidation by O2 is 
not kinetically competent with catalytic turnover. To this end, this chapter 
 
(-) L-Phe (+)L-Phe 
wtPheH PheH118-452 Buffer wtPheH PheH118-452 Buffer 
17.9±0.8 18.8±0.9 25±3 11.3±0.6 2.9±0.6 21±2 
 
Table 5.2 : µmole of H2O2 formed during the PheH dependent oxidation of BH4. All 
assays contained 100 µM of BH4 using the conditions stated in the Experimental section 
 




focused on measuring the rate of BH4 oxidation by O2 within the protein scaffold 
of apo-PheH and apo-PheH118-452.   
 Using the apo-PheH and apo-PheH118-452 construct, the rate of pterin 
oxidation appeared to increase relative to the rate of BH4 oxidation (Figure 5.4) 
when compared to Fe3+PheH. These results suggest that enhanced BH4 oxidation 
occurs in the absence of a divalent metal center. However, even when using apo-
PheH and apo-PheH118-452 constructs with <0.01 Fe/subunit, there was still a 
significant amount of L-Tyr observed. The formation of L-Tyr suggests that part 
of the enhanced rate of BH4 oxidation can be attributed to catalytic turnover that 
arises from a small fraction of enzyme still containing an iron center. The small 
amount of Fe3+PheH could come from a small population of PheH which did not 
have the iron removed during the apo-preparation or from a PheH which was 
metallated with Fe during the assay. Trace iron sources (e.g. iron found salts and 
buffers used to prepare the assay) are likely Fe3+ and not labile to incorporation 
into the active site. Reduction of Fe3+ by BH4 in the assay would result in Fe2+ 
which is more labile. However, 500 µM EDTA did not affect the rate of O2 
 




consumption when using PheH118-452. Regardless, the formation of L-Tyr and lack 
of formation of H2O2 make determine the rate of reaction of BH4 and O2 difficult. 
 The rate of L-Phe dependent BH4 oxidation for apo-PheHR exhibited a 
nearly linear increase from 100-600 µM L-Phe. While these measurements should 
be repeated, the linear dependence on L-Phe concentration is analogous to the 
linear L-Phe dependence see when looking at the release of L-Phe from the 
allosteric site using SAW spectrometry.124 In this study, the linear dependence 
was attributed to kinetically trapping wtPheH in the R-state. The kinetic trapping 
occurs by of the R-state by L-Phe. In contrast, BH4 acts as an allosteric inhibitor 
by stabilizing the T-State. Therefore, the linear dependence over this region may 
be attributed to the hysteretic nature of the active, homotermeric PheH complex. 
Given the linear dependence of BH4 oxidation on L-Phe concentration, it might 
be expected that catalytic activity might also have a similar linear dependence on 
L-Phe concentration. However, there are surprisingly few studies which have 
examined the L-Phe dependence on the catalytic rate of PheH when using BH4 
and allosteric activated PheH. Most studies have either measured catalytic 
activity using 6-MPH4 or PheH that has not been allosterically activated. One 
study that did measure catalytic activity did find a sigmoidal dependence of 
specific activity on L-Phe concentration.258 However, they also reported 
 




significant substrate inhibition at [L-Phe] > 1mM an observation that has not been 
corroborated by other studies.  
 An analogous study performed on metal depleted monomeric cvPheH 
also demonstrated an L-Phe dependent increase in pterin oxidation when using 
DMPH4.55 Hyperbolic dose-response curves were observed for apo-cvPheH 
suggesting Michaelis-Menten type kinetics with a kcat of 0.96±0.30 s-1 and a Km of 
2.63±0.74 mM. The greater rate of pterin oxidation ( ~1 µmol min-1 mg-1 vs  0.35 
µmol min-1 mg-1) in cvPheH (using DMPH4) compared to apo-wtPheH (using 6-
MPH4) is likely attributed to differences in temperatures used and the greater 
mass of wtPheH (52 kDa) compared to cvPheH (32 kDa).  Interestingly, the Km 
for L-Phe in the substrate dependent DMPH4 oxidation in cvPheH (2.63±0.74 
mM)55 is much greater that what is reported under steady-state catalytic turnover 
conditions for Fe2+cvPheH (244 ± 41 µM).250 One possible explanation for the 
difference in Km is that binding of iron in the active site influences DMPH4 
 




binding or that q-DMPH2 (uncoupled turnover product) is released from the 
active more slowly than c4a-hydroxy-DMPH2 (coupled turnover product).  
Future direction 
 The goal of this chapter was to examine the role of the protein matrix on 
the oxidation of BH4 by O2. While there were qualitative differences 
spectrophotometrically in the BH4 oxidation when using apo-PheHR[L-Phe] 
compared to Fe2+PheHR[L-Phe], determination of the rate of BH4 by O2 in the 
PheH scaffold was confounded by apparent catalytic turnover by trace amounts 
of Fe3+PheH. In order to prevent binding of trace amounts of iron to the active 
site, H285L mutant could be used. H285 is a residue involved in binding the iron 
in the active site. H285L would prevent trace iron from binding in the active site. 
Additionally, to reduce the amount of metalation, buffer could be made using 
high purity chemicals with reduced iron content. Chelex resin could also be used 
to further remove trace amounts of iron.   
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